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Abstract
The role o f the gastrointestinal tra c t in drug metabolism was evaluated: 
(i) by measuring m ixed-function oxidase and UDP-glucuronyltransferase 
activ ities in microsomal preparations of live r, stomach, duodenum, jejunum, 
ileum and caecum/colon from  ra t and fe rre t; (ii) by measuring the 
pharmacokinetics of labetalol in ra t, fe rre t and dog; and (iii)  by determining the 
rate of labetalol metabolism by jn  situ perfused intestine preparations from ra t, 
fe rre t, and dog and in v itro  perfused live r preparations from ra t and fe rre t.
The activ ities  o f four m ixed-f unction oxidase enzymes, namely biphenyl
2-hydroxylase, biphenyl 4-hydroxylase, ethylmorphine N-demethylase and 
ethoxyresorufin O-deethylase, o f cytochrome c reductase, and o f  UDP- 
glucuronyltransferase towards three group- 1  substrates, namely 1 -naphthol,
4-nitrophenol, and 4-m ethylum belliferone, were determined in each tissue 
preparation. Comparison o f the specific enzyme activ ities in the various tissue 
preparations from  both species used in this study showed that these enzymes 
were more active in ra t than in fe rre t and that they were more active in the 
liver than in the gastrointestinal tra c t. Also, the specific ac tiv ities  of the 
enzyme systems studied indicated that detergent activated UDP- 
glucuronyltransferase were more active than the m ixed-function oxidases.
The greatest activ ities  of the m ixed-function oxidase enzymes along the 
gastrointestinal tra c t o f ra t and fe rre t occurred in the proximal section of the 
small intestine, and these progressively declined along the small intestine to the 
aboral end. The d istribution of UDP-glucuronyltransferases along the small 
intestine o f rat was sim ilar to that of the m ixed-function oxidases, but in the 
small intestine from fe rre t the greatest activ ities occurred in the ileum. The 
m ixed-function oxidase ac tiv ity  in the stomach and caecum/colon from  both 
species tended to be lower than that observed in the ileum, but glucuronylation
of some substrates by these tissues may be sim ilar to that occurring in the 
middle section of the small intestine.
A ll substrates used in this study were metabolised by the microsomal 
preparations of livers from both ra t and fe rre t. The various gastrointestinal 
preparations from ra t and fe rre t did not metabolise ethylmorphine, nor did the 
various gastrointestinal preparations from the fe rre t metabolise ethoxyresorufin. 
Although treatm ent of the fe rre t w ith  3-methylcholanthrene induced 
ethoxyresorufin O-deethylase in the small intestine, phenobarbitone treatm ent 
of ra t did not induce ethylmorphine N-demethylase in any section of the 
gastrointestinal trac t. Phenobarbitone was a poor inducer of m ixed-function 
oxidase, cytochrome c reductase and UDP-glucuronyltransferases in any o f the 
various tissues of the ra t. 3-Methylcholanthrene and Aroclor 1254 treatments of 
ra t greatly increased the activ ities of a ll these enzymes, except ethylmorphine 
N-demethylase, in most of the tissue preparations. Glucuronylation was less 
sensitive than m ixed-function oxidation to the inductive effects of these agents 
and the cytochrome P-448-related m ixed-function oxidases in the 
gastrointestinal tra c t were particu la rly  sensitive to induction by
3-methylcholanthrene and Arolor 1254. Treatment of ra t and fe rre t w ith  the 
inducing agents did not a lter the re la tive distribution of enzyme activ ities in the 
various tissues.
Three radioactive metabolites of labetalol, namely the N -, O-phenyl-, and
secondary alcohol glucuronides, were isolated from the urine of dogs, collected
afte r an oral dose of "^C -labeta lo l (20 mg/kg). The O-phenyl- and secondary
alcohol glucuronides were purified su ffic ien tly  for use as standards (the
N-glucuronide was lost during purification). A method of separating 
14C -labeta lo l and its radioactive metabolites by HPLC in the ion-pair mode, 
followed by measuring the rad ioactiv ity  in the HPLC eluate was investigated but
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the recovery of was poor (circa 50%), so this method of analysis could only 
be used on a sem i-quantitative basis.
The pharmacokinetics o f labetalol in ra t, fe rre t and dog was investigated. 
Oral doses o f ^ C - la b e ta lo l, to ra t 25 mg/kg, to fe rre t 25 mg/kg, and to 
dog 30 mg/kg, and intravenous doses of the drug (1 mg/kg) were given to each 
species. The concentrations of labetalol and its metabolites measured in the 
plasma samples from  ra t and fe rre t were unsuitable fo r s ta tis tica l analysis. In 
dog, the mean labetalol b ioava ilab ilityoraj was 0.82 which indicated tha t f irs t-  
pass metabolism by the gastrointestinal tra c t had occurred.
The in situ vascularly perfused intestines of ra t and fe rre t both absorbed
10% of a ^ C - la b e ta lo l dose (25 mg/kg and 22 mg/kg respectively) and
metabolised approximately 2% of the dose w ith in  3 h. The dog gut loop
preparation, however, absorbed 10% of a ^C - la b e ta lo l dose (4.7 mg/kg) and
metabolised 1.6% of the dose in 30 min. The in v itro  perfused livers from ra t
14and fe rre t were more e ffective  at metabolising C-labetalol; 12.4% and 8 .8%, 
respectively, o f the dose (7 or 7.5 mg, respectively, c irculating in the perfusion 
medium) were metabolised in 2 h.
The pattern o f radioactive labetalol metabolites detected, by HPLC in the 
ion-pair mode, in the urines and plasma samples from  ra t, fe rre t and dog 
d iffered. Also, the pattern of labetalol metabolites detected in the perfusate 
samples from the perfused organ preparations of ra t, fe rre t and dog d iffe red. 
Therefore, not only species differences in labetalol metabolism but also organ 
differences in labetalol metabolism occurred. Although five previously 
unidentified metabolites of labetalol were detected, insuffic ient concentrations 
of these metabolites occurred in the urine and plasma samples from  the species 
used in this study fo r isolation and characterisation.
On the basis of these observations and those from other workers i t  is 
concluded that the characteristics of the drug metabolising enzymes in the 
gastrointestinal tra c t are sim ilar to those of the liver, but that the mechanisms 
of regulating these enzymes in the live r and various sections of the 
gastrointestinal tra c t d iffe r. The enzyme capacity fo r drug metabolism in live r 
is much greater than the capacity o f the mucosal epithelia l cells o f the 
gastrointestinal tra c t from  both ra t and fe rre t. However, the specific a c tiv ity  
o f UDP-glucuronyltransferase towards group-1 substrates in the small intestine 
o f rats, and to a certain extent o f ferre ts, can account fo r significant first-pass 
metabolism o f drugs by this tissue. Also, tha t significant first-pass metabolism 
o f labetalol does occur in the intestine o f ra t, fe rre t, and dog. However, the 
first-pass metabolism and uptake of labetalol by the livers of ra t and fe rre t are 
more like ly to be the reasons for the necessity to give high oral doses of 
labetalol in order that the drug may exert its therapeutic e ffec t.
- v i i  -
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Section One: 
Safety Evaluation, Kinetics and Metabolism of Drugs
1. Safety Evaluation of Chemicals
Toxic ity  and Safety Evaluation
Drugs are se lective ly-toxic chemicals which have been found useful in the 
treatm ent of disease. However, these chemicals and/or the ir metabolite(s) can 
react w ith  non-target tissues and this may lead to the expression of adverse 
side-effects varying in degree of to x ic ity . Although some side-effects may not 
be quantifiable biochemically, they can seriously a ffec t the patient’s health: e.g. 
p-aminosalicyclic acid, an anti-tubercular drug, commonly produces anorexia, 
nausea, epigastric pain and vom iting as side-effects (Hawking et al., 1980). 
Biochemically quantifiable tox ic ities  may result from interference of the 
chemical or its metabolite(s) w ith  intermediary metabolism (Parke, 1982a). 
Chronic adm inistration of certain anti-convulsants to epileptics can reduce 
fo late concentrations in the body fluids (loannides and Parke, 1979), and 
laxatives which may inh ib it sodium and potassium ATPase a c tiv ity  (Banwell, 
1979; Heizer, 1979). Other toxic e ffects have been observed such as hepatic 
necrosis w ith phenacetin and acetaminophen (G ille tte , 1979% gastrointestinal 
inflammation which leading to the formation of ulcers as w ith  benoxaprofen, 
feprazone or phenylbutazone (Dodge et al., 1979; Weber, 1984), sclerosing 
periton itis  which has been closely associated w ith  practolo l (Marshall et al., 
1977; Thompson and Jackson, 1977), and teratogenic effects w ith drugs such as 
thalidomide or phenytoin (McBride, 1961; Lenz and Knapp, 1962; Parke, 1984) i f  
they are taken during foetal development. A variety of drugs have also been 
implicated in the development o f carcinomas in man (Tomatis et al., 1978): 
phenacetin (kidney), chloramphenicol (haemopoietic system), d ie thylstilbestro l 
(uterus and vagina), and phenytoin (lymphoreticular tissues).
In order to evaluate the safety of a drug i t  is essential to study its 
metabolism and kinetics in animals and man when given by d iffe ren t routes. The 
possibility of toxic effects must also be identified in animals prior to 
adm inistration of the drug to man. These studies indicate which is the most 
suitable animal to m im ic the metabolism of the drug in man. The use of 
k ine tica lly  equivalent dosages to allow for species -VcSfiqtion is also im portant in 
such investigations (Parke, 1980). A fte r general release of a drug i t  is considered 
prudent to monitor patients fo r serious adverse reactions. Less frequently 
prescribed drugs may provoke serious adverse reactions which are s ta tis tica lly  
insignificant, but i f  the drug were to become more widely prescribed the 
absolute number of serious adverse side-effects may need earnest consideration 
when evaluating its to x ic ity  (Weber, 1984).
Drug K inetics and Metabolism
The study of drug kinetics and metabolism serves two functions: (i) to
define the dose range which produces the required therapeutic e ffec t, and (ii) to 
evaluate the tox ic ity  of the drug. The therapeutic e ffec t and to x ic ity  o f a drug 
are often related to its concentration in the plasma which in turn is related to 
the chemical properties of the drug, the dose administered, and the pathways and 
rates of metabolism. Various mathematical models have been developed to 
describe drug kinetics and metabolism (Wagner, 1961; Colburn, 1979; I l le t t  and 
Davies, 1982; Renwick, 1982). These can be used in conjunction w ith 
experimental studies to determine drug e fficacy and the effects of tissue 
distribution and metabolism on the concentration of unchanged drug in the 
systemic c irculation. However the use of animal models in the prediction of drug 
tox ic ity  in man is d if f ic u lt because of species variation in drug kinetics and 
metabolism (Duggan et al. 1975; Dixon, 1976; Smith, 1978). For example, 
feprazone, a non-steroidal anti-in flam m atory drug, is metabolised by ra t and dog
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to free and conjugated hydroxylation products, whereas in man the major 
metabolite (30-40% dose) is the unusual C - 6 -glucuronide (Berry, 1982). The 
results of drug kinetic and metabolism studies in various animals and man can be 
used to iden tify  those species which have a sim ilar pattern of drug metabolism to 
that in man. These results can also be used to calculate fo r each species the 
k ine tica lly  equivalent dosage to man which can then be used in the toxicology 
studies to evaluate the potential to x ic ity  of a drug to man. This is im portant 
because the a c tiv ity  o f m ixed-function oxidases, the major drug metabolising 
enzymes, have been shown to vary inversely w ith log body weight (Walker, 1978). 
Consequently where m ixed-function oxidation is the primary drug metabolism 
pathway, the ra t w ill metabolise the drug at a much faster rate than man. The 
dependence of toxicology on drug metabolism and chemobiokinetics has recently 
been reviewed (Parke, 1980).
2. Drug Kinetics
Routes o f Drug Adm inistration
There are a variety of routes of administration available fo r drug therapy 
(Figure 1.1). Drugs may enter the systemic circulation d irectly  by intravenous or 
in tra -a rte ria l in jection, or ind irectly by the process of absorption. The la tte r 
may occur from  the mouth and gastrointestinal tra c t a fte r oral adm inistration, 
from the rectum a fte r recta l adm inistration, from the lungs a fte r inhalation, or 
through the skin a fte r topical adm inistration. Other routes of adm inistration 
such as subcutaneous, intramuscular, or intraperitoneal in jection also require 
absorption to take place before the drug enters the systemic circula tion. Once 
in the blood compartment, drugs may then be distributed to the tissues where 
penetration can take place. The m ajority of drugs, however, are given orally 
because this route gives a wide margin of safety and it  is convenient fo r the 
patient (George, 1981).
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Figure 1.1, Schematic representation o f pharmacokinetics
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Some routes of adm inistration may result in a drug being metabolised 
before i t  reaches the systemic circulation; this is known as first-pass 
metabolism (Jaquot et al., 1977). Drugs given orally (Figure 1.2) may undergo 
metabolism by the gastrointestinal mucosa, by the live r, the principal site of 
drug metabolism, or sometimes by the gastrointestinal m icroflora (Caldwell and 
Smith, 1977). Moreover, inhaled drugs may undergo metabolism by the lungs 
before they reach the systemic circulation. First-pass metabolism of 
isoprenaline by the gastrointestinal tra c t (George et al., 1974; George, 1982), of 
propranolol by the live r (Evans et al., 1973; George and Shand, 1982), and of 
rim ite ro l by the lungs (George, 1982) s ign ificantly reduces the drug dosage which 
is available in the systemic circula tion. Extensive first-pass metabolism reduces 
b ioavailab ility and e fficacy of a drug. For example in ra t, 9 3 % of an oral dose of 
clonazepam, an anticonvulsant, is metabolised by the intestine and live r (Colburn 
et al., 1980). A lternative  routes of adm inistration may be considered fo r drugs 
which undergo extensive first-pass metabolism a fte r oral adm inistration. A. 
drug absorbed from  the mouth (Gibaldi and Kanig, 1965) or per rectum, below the 
haemorrhoidal plexus, (Figure 1.2) is not exposed to metabolism by the liver, 
and/or intestine immediately a fte r adm inistration (Rowland and Tozer, 1980). 
These routes o f adm inistration delay metabolism, prolong b ioava ilab ility  and 
increase e fficacy o f the drug. The re lative merits of the various routes of drug 
administration have been reviewed (Jaquot et al., 1977).
Absorption
Absorption is the transfer o f a nutrient or xenobiotic from  the site o f 
administration to the systemic c irculation. It involves the transfer across a 
biological membrane and may occur at any of the body's external surfaces 
(namely the skin, lungs, mouth and gastrointestinal tract). Four mechanisms of 
transfer across membranes occur: (i) f iltra tio n , (ii) pinocytosis, ( iii)  active
- 7 -
Oral (enteral) 
administration
Sublingual
administration
Venous return from buccal cavityBuccal
cavity
Hepatic vein
Stomach
Bile duct
Liver
Intestine
Lymphatics
Portal vein
Venous return from rectumRectum
Vena cava
Rectal
administration
Figure 1.2. Passage o f drugs from the alim entary t r a r t  in to  
the bloodstream (Bowman and Rand, 1980).
transport, and (iv) passive diffusion. There is l it t le  evidence that drug absorption
occurs by filtra tio n , pinocytosis, and active transport; although analogues of
sugars and amino acids may be absorbed by active transport, e.g. methyldopa and
5-fluorouracil by the intestine or levodopa by the blood-brain barrier (Stenlake,
1979; Rowland and Tozer, 1980). The m ajority o f drugs are absorbed by passive
diffusion along a concentration gradient (Chhabra, 1979). The rate of diffusion
depends on the lip id so lub ility  and dissociation constant, pK , o f the drug also on
the pH of the environment and the localised blood flow . Neutral compounds have
absorption characteristics which closely resemble the ir lipid solubilities whereas
w ith  ionisable salts of weak acids or bases.pK is also an important fac to r ingrate
/  a k
o f absorption. The m ajority o f drugs are weak acids or weak bases and the 
• relationships between the ir diffusion rates across a membrane, the ir
C, £
concentration^and ionisation state^in the two physiological phases separated by a 
membrane, and the ir physico-chemical properties may be described by the 
pH -partition  hypothesis (Schanker, 1961). For example, aspirin, pKg = 3.6, is 
almost completely unionised in the acid conditions of the stomach and so i t  is 
readily absorbed. Once in the blood i t  becomes su ffic ien tly  ionised at the higher 
pH to prevent back diffusion. However, the greater surface area of the intestine 
compared to that o f the stomach ensures that extensive absorption o f aspirin 
occurs in the intestine despite the higher pH o f its luminal contents (Stenlake, 
1979). There are drugs which e lic it systemic effects (e.g. quaternary ammonium 
compounds) but the ir absorption cannot be explained by the pH -partition  
hypothesis because they are usually ionised at the pH range along the 
gastrointestinal tra c t. These drugs may be absorbed as ion-pairs as has been 
observed w ith tetracycline which can be transported across the gut wall in its 
positively charged state by combining w ith some non-specific anion (Perrin and 
Vallner, 1970).
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Absorption of the m ajority o f orally administered drugs is affected by a 
number of factors peculiar to the gastrointestinal tra c t. The aqueous so lub ility 
and form ulation of the drug are important because these factors govern the 
dissolution rate and the rate at which the drug goes into solution in the aqueous 
gastrointestinal lum inal contents (Jones, 1977). For example, the aqueous 
solubility and dissolution rate of d iffe ren t formulations of chloramphenicol have 
been related d irectly  to the rate of absorption of the drug by the gastrointestinal 
tra c t (Glazko et al., 1968). The aqueous solubility o f a drug may be increased i f  
formulated as a sodium or potassium salt, as in the case of phénobarbital 
(Rowland and Tozer, 1980), and the dissolution rate of the drug may be increased 
by altering its partic le  size (Fincher et al., 1968). The intake of food retards 
gastric emptying tim e, stimulates acid secretion in the stomach, and stimulates 
digestive juice secretion in the stomach and intestine. These factors may 
profoundly influence the dissolution and absorption rates of the drug. Other 
factors which may a ffec t the absorption of drugs by the gastrointestinal tra c t 
are: temperature, presence or absence of chelating agents, intestinal m o tility , 
gastrointestinal flora, nutritiona l status, status o f health, and age (Heizer, 1979; 
McElnay and D’Arcy, 1980). The absorption of drugs has recently been reviewed 
(Stenlake, 1979; Rowland and Tozer, 1980; Parke, 1982b).
Tissue D istribution
Drugs (and/or the ir metabolites) may be distributed to the tissues, 
including the target tissue, by the systemic circula tion. Drug penetration of 
internal tissue boundaries (such as the blood-brain barrier or placetal barrier) or 
tissues may occur by simple partition  of the non-ionised molecule from  the body 
fluids into the in tracellu lar lipids where they can be stored or can undergo 
metabolism. A dynamic equilibrium is set up between the tissues and the body
- 1 0  -
flu ids so there is a flux of concentration of drug between the various body 
compartments. This enables the drug to produce its therapeutic e ffec t at its 
target site. As the drug is elim inated from  the body, its . . concentration 
decreases in the blood. This allows further movement o f drug from the tissues to 
the blood and excretion can continue. Chemicals of high lip id -so lub ility , such as 
thiobarbiturates, tend to become concentrated in the adipose tissue (Parke, 
1982b). I f  such chemicals are not easily metabolised by mammals, as w ith 
halogenated compounds, they have long biological ha lf-lives and are 
progressively accumulated by the adipose tissue (Muhlebach and Bickel, 1981). 
Other drugs have high a ffin ities  fo r certain tissues e.g. te tracycline antibiotics 
become concentrated in ca lcify ing tissues (Parke, 1982b) and chlorpromazine, a 
tranquilliz ing drug, and/or its metabolites accumulate in the cerebral cortex and 
hippocampus (Cassano et al., 1965; Sjostrand et al. 1965). Drugs may also bind 
w ith  proteins of the blood and cells preventing the ir transfer across biological 
membranes. Where drugs bind to proteins at sites which are normally occupied 
by endogenous molecules the la tte r can become com petitive ly displaced from 
these sites and this may lead to a toxic e ffec t, e.g. salicylates, phenylbutazone, 
and indomethacin can displace b ilirub in  from plasma proteins causing kernicterus 
in children (G ille tte , 1973). Drug-protein binding may prevent a drug from  
exerting its toxic e ffec t and enable i t  to be used for its therapeutic properties. 
Carbenoxolone, an antiulcer drug, has a potent uncoupling action on oxidative 
phosphorylation in v itro  and its detergent properties would lead to extensive 
haemolysis of red blood cells. A t therapeutic plasma levels the drug is almost 
completely bound to plasma proteins in a number of species, including man 
(Parke, 1972). This drug-protein binding therefore restric ts the drug to the blood 
plasma compartment and liver where i t  is metabolised and excreted in the bile 
thus preventing the toxic effects of the drug being exerted.
- 11 -
Excretion
Excretion is the irreversible elim ination of drug (and/or its metabolites)
from  the body and is sim ilar to absorption in that i t  involves the transfer of a
molecule across a biological membrane. There are various routes of excretion
available in the mammal, including expiration in the air, by gastrointestinal and
genital secretions, or via sweat, saliva and m ilk, but the major routes of
excretion are by the bile or the urine. B ilia ry and urinary excretions are
complementary pathways of drug elim ination; for anions (Hirom et al., 1976) and
cations (Hughes et al., 1973a and 1973b) there are various molecular weight
thresholds above which the compounds are excreted in the bile and below which
the compounds are excreted in the urine. B ilia ry excretion occurs in the live r
and is e ffected by an active transport mechanism whereas urinary excretion
occurs in the kidney and is achieved by a combination of filtra tio n  (glomerulus)
and active secretion (into the distal tubule of the nephron). Most drugs are 
$
lipophilic molecules which need to undergo metabolism into polar molecules 
which are then readily excreted. Compounds which are excreted in the bile may 
be either elim inated from  the body in the faeces or a lternative ly reabsorbed 
from the gastrointestinal tra c t to be excreted la ter (Figure 1.2). This process is 
known as entero-hepatic recircu la tion (Smith, 1977; Parker e t al., 1980). For 
entero-hepatic recircu la tion of a compound to occur the compound may or may 
not undergo further metabolism in the gastrointestinal tra c t. Extensive reviews 
of the mechanisms o f excretion have recently been published (Stenlake, 1979; 
Rowland and Tozer, 1980; Parke, 1982b).
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3. Drug Metabolism
General Aspects
The metabolism o f drugs by mammals is catalysed by enzymes which also 
transform endogenous molecules (Hartiala, 1973; A itio  and Marniemi, 1980; 
Connelly and Bridges, 1980) and are classified into two types of reaction:
1. B iotransformation (Phase I reaction),
2. Conjugation (Phase II reaction).
Biotransformation and conjugation reactions form  products which are usually 
more hydrophilic than the ir precursors and are therefore more readily excretable 
(Chhabra, 1979; Dutton, 1980). These enzyme reactions may occur in seguence 
or in parallel (Figure 1.3) (Parke, 1982b) and may lead to:
a. detoxication of the chemical
b. metabolism of the chemical into its pharmacologically e ffective  
form, or to a change in pharmacological a c tiv ity  (Parke, 1978a),
c. activation of the chemical into a reactive intermediate which may 
bind to v ita l cell constituents and produce a tox ic e ffec t (G ille tte , 
1980; M ille r and M ille r, 1981; Reichert, 1981).
These reactions are found in a wide variety of mammalian tissues (Dutton, 1966; 
Chhabra, 1979; Connelly and Bridges, 1980), but the principal site of drug 
metabolism is the liver w ith  significant contributions made by the 
gastrointestinal trac t, kidney and skin (George, 1981; Parke and loannides, 
1981).
Biotransformation
Biotransformation reactions are catalysed in a variety o f tissues, p rim arily  
the live r, and can involve oxidation, reduction or hydrolysis. S im ilarly, the 
m icroflora of the gastrointestinal tra c t are also capable of metabolising these 
compounds by reduction or hydrolysis reactions (Scheline, 1968; Boxenbaum et
- 13 -
Xenobiotic Endogenous
compound compound
Phase I Metaboli sm
mixed-function oxidase, 
monoamine oxidase, 
epoxide hydrase, etc.
DNA
binding
reactive
intermediate
non-reactive
intermediate
Care i nogenes t s ^ -
enterohepatic
recircu la tionToxicity
Phase I I  Metabo1ism
sulphotransferase, UDP- 
glucuronyltransferase, 
acetyl a tton, methylati on,
amino acid transferase, etc,
f
Excretion
Figure 1.3. Metaboli c pathways available to xenobiotic compounds.
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al., 1979; Brewster, 1981). The m ixed-function oxidase fam ily  of enzymes, 
located in the endoplasmic reticu lum , has been found to catalyse a great many of 
these reactions, namely: aliphatic and aromatic oxidation, epoxidation,
oxidative deamination, N -dealkylation, O-dealkylation, 5-dealkylation, 
N -oxidation, N -hydroxylation, sulphoxidation, desulphuration, dehalogenation, 
n itro-reduction, azo-reduction, and hydrolysis of esters (Table 1.1). Other 
phase I oxidation reactions which are carried out in the cell may be catalysed by 
flavoprotein dependent oxidases (endoplasmic reticulum ), monoamine and 
diamine oxidases (endoplasmic reticulum ), alcohol and aldehyde dehydrogenases 
(cytosol), and epoxide hydrase (endoplasmic reticulum ). A great many drugs are 
substrates fo r m ixed-function oxidase reactions (Martin and Reid, 1981; 
Schenkman et al, 1981) and consequently this enzyme system plays an im portant 
role in drug metabolism.
Conjugations
Conjugation is a synthetic reaction which transfers a re la tive ly  small polar 
molecule (such as glucuronic acid, sulphate, acetic acid, amino acid, peptide or 
a lkyl group) from  an endogenous co-enzyme to the xenobiotic or its metabolite 
(Table 1.2). This type of reaction generally requires the expenditure o f energy, 
except when the molecule being transferred to the xenobiotic is glutathione 
which can react d irectly  w ith a su ffic ien tly  electrophylic partner (Reichert, 
1981). Conjugation reactions are catalysed by enzymes such as uridine 
diphosphate (UDP)-dependent glucuronyltransferases (endoplasmic reticu lum ) 
(Dutton, 1966; Dutton and Burchell, 1975), sulphotransferases (cytosol) (Jakob j 
et al., 1980; Powell and Roy, 1980), acetyl transferases (cytosol) (Weber and 
Glowinski, 1980; Weber et al., 1980), m ethyltransf erases (cytosol and 
endoplasmic reticulum ) (Sikic, 1980), aminotransferases (cytosol and 
mitochondria) (K illingberg and Webster, 1980), and glutathione transferases 
(cytosol) (Ja^û!>^v and Habig, 1980). The ava ilab ility  o f co-enzymes fo r these
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TABLE 1.1 DRUG METABOLISM BY PHASE I REACTIONS
(See also figures 1 .4 , 1.5 amd 1.7)
Reaction
1 . A liphatic  oxidation
Substrate
Hx  . L  / C2HJ ch2ch2ch3
N C Ç CH
„ ' cT s SCH-
H
Pentobarbitone 3
H
Metabolite
' /zH , g
( Ç CH CH 2 C H C H 3
O -'^ N -S  'tHl
H
Pentobarbitone alcohol
2. Aromatic Hydroxylation
HSCX X
NHCOCH,
Phenacetin3
H5C2OXX
NHCOCHj
OH
3. 0-Dealkylation
4. S-Oealkylation
Ethoxyresorufin"
N/XN
6-Methylthiopuri ne3
Resorufm
I T  \  > HCHO
6-Mercaptopurine
5. Desulphuration
y O C 2Hs 
S
Parathion3
NO,
OzN-
Paraoxon
NH,
0C2H.
ll^OCzH-
6. Nitroreduction
H0ÇH 0 I II 
H0CH2CHNHCCHC12
Chloramphenicol
HOJH OH 
H0CH2CHNHCCHfC12 
Reduction product
7. Azoreduction
8. Hydrolysis
SO,NH
Prontosil 3
NH,
NHz
S02NH2 
Sulphanilamide
NH,
NH;
NHz
Xs,
C O C H z C H z N ( C z H a ) :  II
0 \
Procaine
j - O H  + H O C H z C H z N ( C z H a ) :  
0
P-Amino-benzoic acid
a Martin and Reid, 1981 ; b Burke and Mayer, 1974.
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Enzyme Co-enzyme
UDP-glucuronyltransferase
Sulphotransferase
Acetyl transferase
Amino acid transferase
Glutathione S-transferase
Methyl transferase
3 Dauterman, 1980;  ^ Mead et
TABLE 1.2 CONJUGATION REACTIONS 
Co-enzyme Type of Conjugation Example
Substrate Metabolite
Uridine diphosphate 
glucuronic acid 
(UDPGA)
eth er, es te r, N- 
S-, and C- bonding
4-Nitrophenol
4-Nitrophenyl fr-0- 
glucuronide (ether)
3 1-Phosphoadenosine- 
S'-phosphosulphate 
(PAPS)
akyl and aryl 
sulphate, sulphamate
HO
Phenol'
HO 3 SC
Phenyl sulphate 
(arylsulphate)
Acetyl CoA
Isoniazid  
(see Figure 1.4)
Glycine, glutamine, 
o rn ith in e , taurine, 
and acyl CoA's
\ - c < COOH
H
+ glycine
OH
Coumarinic acid*3
H / E nHCHzCOOH
C=c(
H
OH
Cinnamoylgycine
Glutathione
(GSH)
Adenosylmethione
(AM)
0 - , N -, and
S- bonding
H00CH2CHN(0)CHCH2CSH2C
H 0 0 C ( N H z ) C H 2 C H 2 C ( 0 ) C H N
Benzyl chloride  
NHCH(CH3) 2
Ç»
CHOH
Isoprenaline
Benzylglutathione
NHCH(CH3) 2
OCH,
3-0-Methyl - 
isoprenaline
a l , 1958; George et a l , 1974.
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reactions is constrained by the requirements of intermediary metabolism and the 
pools of co-enzymes, such as activated sulphate O ’-phosphoadenosine 
5'-phosphosulphate), glutathione, amino acids, etc., which can often be depleted 
(Caldwell, 1984; Mulder et al., 1984). Because glucose is a universal food and 
source of energy and UDP-glucose and its dehydrogenase are widely available in 
the tissues there is a readily available supply of UDP-glucuronic acid, which can 
be conjugated w ith  a wide variety o f functional groups. For these reasons 
glucuronylation is one of the major conjugation reactions (Dutton, 1980).
M ultip le pathways of drug metabolism
Xenobiotics may undergo sequential metabolism by several enzymes or may 
be metabolised simultaneously by several enzymes. For example, isoniazid, an 
antitubercular drug, undergoes deamination, oxidative deamination and several 
conjugation reactions, but the major metabolic pathway is N -acety la tion  
(Figure 1.4). B ifluranol, an antiandrogen:
B iflu ra n o l
undergoes metabolism by several conjugation reactions to form  the 
mono-sulphate ester, mono-glucuronide, bi-sulphate ester, bi-glucuronide, 
mono-sulphate ester mono-glucuronide, and possibly a mono-phosphate and 
mono-phosphate mono-sulphate ester (Pope et al., 1981). Other drugs such as 
chlorpromazine, a tranquillizer, can be metabolised by many d iffe ren t enzymes 
to form a great many metabolites. Metabolic modifications of chlorpromazine 
include sulphoxidation (Posner et al., 1963), déméthylation (Ross et al., 1938; 
Fishman and Goldenberg, i960), ring hydroxylation and conjugation (Lin et al., 
1959; Fishman and Goldenberg, 1963 and 1965), and oxidation at the term inal 
nitrogen of the side chain (Fishman et al., 1962) (Figure 1.5).
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0
II
C-NHNH2
0
II
C-NHNHCOCHc
Ison tco ttnoy l - 
hydrozones o f 
glucose, pyruvtc 
ac id , or
« -k e to g lu ta tic  1 ISONIAZID
l-a ce ty la tio n
(a major pathway)
acid or ketone
0 0
Il II
C- NHNH-C
N
N ,N '-d iiso n ico tin o y l 
hydrazine
ox ida tive  deamination
deamination
C-OH
C-l
Isonicotinam ide
Is o n ic o ti n ic 
acid
conjugation
t
0
II
C-NHCH C0ÔH
Is o n ico tin o y lg lyc in e
Figure 1.4. Metabolic pathways o f iso n ia z id , an a n ti- tu b e rc u la r drug.
j B r e w e r j  i 9 7 7 )
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CH2CH2CH2N
/CHs
CH^CH^CH^N'
'CH.
Sulphoxidation Déméthylation
CH2CH2CH2N:
Chlorpromazine
rtng hydroxylation -o x id a tio n
/C H 3 
CHzCHzCHzN^ cu
0
4 /CH3 
CH2CH2CH2NX 
I CHs
Figure 1.5. Some o f the metabolic pathways o f chlorpromazine.
(Fishman e t al_, 1962; Fishman and Goldenberg, 1963, 1965)
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Factors a ffecting  drug metabolism
The factors which have been observed to a ffec t biotransformation and 
conjugation of drugs are: species (Hartiala, 1961; Heitanen and Vainio, 1973; 
Chhabra, 1979; Walker, 1980), age and sex (Hietanen, 1974; loannides et al., 
1977; Benford and Bridges, 1979; Chhabra, 1979), hormonal status (Dutton, 
1966; Fang and Strobel, 1981; Stohs and Wu, 1981), nu tritiona l status 
(Wattenberg, 1971; Pantuck, 1976a and 1976b; Joly and Hetu, 1980; Sitar and 
Gordon, 1980; Smith-Barbaro et al., 1981), disease state (Chojecki and Kern, 
1961; Rao and Breuer, 1980), and environmental chemicals (Parke, 1980). These 
factors contribute towards the homeostatic equilibrium which governs the rate 
o f drug metabolism.
Mixed-Function Oxidation
The cytochrome P-450 system
Mixed-function oxidase is a multi-component membrane bound enzyme 
system located in the endoplasmic reticulum  (Bentley and Oesch, 1979). The 
enzyme system consists of a haemoprotein term inal oxidase, cytochrome P-450 
(so called because o f its characteristic spectral absorption at 450 nm when its 
reduced form  is complexed w ith  CO), coupled by phosphatidylcholine to 
cytochrome P-450 reductase (a flavoprotein containing both flav in  adenine 
dinucleotide and flavin mononucleotide), cytochrome b^ and its reductase 
(Nebert et al., 1975; Estabrook, 1982). Cytochrome P-450 reductase is linked to 
a source of electrons (from NADPH). Cytochrome P-450 catalyses the 
activation and sp litting  of molecular oxygen to insert one atom into a substrate 
molecule while the other oxygen atom associates w ith  two protons, gains two 
electrons and forms a molecule of water (Figure 1.6) (White and Coon, 1980).
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Cytochrome P-450 Substrate
Fe+++
.+++ High
Spin
Substrate
+++ Low
Spin
SOH
Product
Fe+++ -S
Low Spin
++
Fe++ S
02 O2
Figure "1,6. The cytochrome P-450 cycle of m ixed-function ox ida tion .
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M ultip le forms o f cytochrome P-450
The isolation and purifica tion of d iffe rent forms of cytochrome P-450 and 
its reductase have revealed that these proteins exist as isoenzymes in more than 
one species (Botelho et al., 1979; Kohli et al., 1981; Thomas et al., 1981; Reik et 
al., 1982; Sakai et al., 1983). Nine d iffe ren t forms of cytochrome P-450 have 
been purified from  ra t live r, seven from  rabbit live r, four from  the livers of 
mice, and six from  human liver (Bentley and Oesch, 1979; Guengerich et al., 
1982; Guengerich, 1984). The d iffe ren t forms are d istinct gene products which 
have d iffe ren t amino acid sequences (Ryan et al., 1982) w ith  a sim ilar 
a rch itectura l design o f tigh tly  folding protein around the haem moiety and they 
present a common ca ta ly tic  site (Dus, 1982). Studies w ith  pure cytochrome 
P-450 have shown tha t its enzyme ac tiv ity  is dependent on the presence of 
negatively charged phospholipids, particu larly  phosphatidylcholine (Bosterling et 
al., 1981), which fa c ilita te  the form ation of a complex between the cytochrome 
and its reductase (Guengerich, 1984) and the electron transfer between the two 
proteins and may determine the conformation o f the cytochrome (Greinert et al,
1982). With some substrates the function of cytochrome P-450 reductase 
requires both its prosthetic groups (FAD and FMN) (Shawver et al., 1984). The 
d iffe ren t forms o f cytochrome P-450 have overlapping enzyme activ ities and can 
be classified into two groups (Guengerich et al., 1982). Some forms of 
cytochrome P-450 normally exist in tissue in the 'low-spin' state (six ligand 
complex of haem moiety), but a fte r substrate binding are converted to the 'high- 
spin* state (five ligand complex of haem moiety). This results in a conformational 
change in the enzyme and enables the oxygen to be activated prior to insertion 
into the substrate (Schenkman et al., 1981). Cytochrome P-448 (so called 
because the reduced cytochrome-CO complex has a spectral absorption at 
448 nm), however normally exists in the 'high-spin' state.
- 23 -
Reactive intermediates
Cytochrome P-450 is not only capable of activating oxygen but also is 
capable o f substrate activation which results in the production of reactive 
intermediates (Estabrook, 1982). A number of substrates (such as lipophylic 
amines, phosphines, carbenes, etc.) can be ca ta ly tica lly  transformed by 
cytochrome P-450 into reactive intermediates (Parke, 1979a) which may then 
bind to cytochrome P-450, RNA, DMA, or other cell macromolecules and cause 
tissue necrosis, particu larly  in the live r, and/or carcinogenesis (G ille tte , 1979; 
G ille tte  et al., 1984). Binding o f reactive intermediates to cytochrome P-450, 
such as the carbene complex postulated fo r safrole interaction, inhibits the 
m ixed-function oxidase a c tiv ity  (loannides et al., 1981). However, some 
inhibitors, like safrole, also act as potent inducers of cytochromes P-450 and 
P-448 which may lead to the production of more reactive intermediates resulting 
in degranulation of the endoplasmic reticu lum , lip id peroxidation and free radical 
form ation, necrosis and cell death (Parke, 1982a).
The major difference between cytochrome P-450 and cytochrome P-448 is 
that the la tte r is able to insert molecular oxygen into sterica lly hindered 
positions of substrate molecules, such as the so called ’bay region’ of polycyclic 
aromatic hydrocarbons (Parke and loannides, 1982). An example of this type of 
reaction is the metabolism of benzo(a)pyrene by cytochrome P-448 mediated 
m ixed-function oxidase and epoxide hydrase to its 7,8-d io l 9,10-oxide metabolite 
which is regarded as an u ltim ate carcinogen (Figure 1.7) (Guenther and Oesch,
1981). Extensive reviews of reactive intermediate involvement w ith  
carcinogenesis have been published (Austwick and Mattocks, 1979; Hathaway, 
1979; Guenther and Oesch, 1981; M ille r and M ille r, 1981).
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"bay reg ion"
cytochrome P-448 
mediated mixed-function 
oxidation _
Benzo(a)pyrene Benzo(a)pyrene 7 ,8-oxide
Epoxide
hydrolase
cytochrome P-448 
mediated mixed- 
function 0
oxidation ^
Benzo(a)pyrene 7 ,8 -d io l Benzo(a)pyrene 7 ,8 -d io l-9 ,8 -o x id e  
(u lt im ate  mutagen/carcinogen)
Figure 1.7. Activa tion  of benzo(a)pyrene.
(Guenther and Oesch, 1981 ; Parke and loannides, 1982)
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Induction
The effects of m ixed-function oxidase inducing agents on the enzyme 
activ ities  towards d iffe ren t substrates vary; however there are three main 
classes of inducers (Parke, 1979a; Toftgard et al., 1980):
1. Drugs (such as phenobarbitone): which increase the cytochrome
P-450 concentration, its related 
enzyme activ ities  (Scharf and 
U llrich , 1974), and its reductases 
(Kohli et al., 1980).
2. Carcinogenic polycyclic aromatic which increase the cytochrome
hydrocarbons (such as P-4ÿ8 concentration, its related
3-methylcholanthrene): enzyme activ ities  (Burke et a l.,
1977) but not its reductases.
3. Catatoxic steroids (such as which do not a ffe c t the
pregnenolone 16a-carbonitrile): cytochrome P-450 concentration,
increase enzyme activ ities , and 
increase reductase concentration.
Other compounds (such as the polyhalogenated biphenyls or safrole) may lead to
an increase in concentration of cytochrome P-450 and cytochrome P-448 w ith  a
consequent increase in enzyme activ ities related to both types of cytochrome
(L itte rs t and Van Loon, 1974; Kennedy et al., 1981; Kluwe and Hook, 1981). It
has been shown that pure polychlorinated biphenyl compounds induce enzyme
activ ities  which are sim ilar to those induced by either 3-methylcholanthrene or
phenobarbitone, according to the positions of halogen substituents (Parkinson et
al., 1980 and 1981). Five immunologically d istinct forms o f cytochrome P-450
have been purified from  the livers o f rats treated w ith  various enzyme inducing
agents (Botelho et al., 1979; Reik et al., 1982; Ryan et al., 1982; Sakai et al.,
1983). These are:
a. a minor haemoprotein present a fte r treating rats w ith  phenobarbitone or 3- 
methylcholanthrene,
b. the predominant form of haemoprotein a fte r treating rats w ith 
phenobarbitone,
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c. the major haemoprotein a fte r treating rats w ith 3-methylcholanthrene,
d. a major protein a fte r treating rats w ith isosafrole,
e. a minor haemoprotein a fte r treating rats w ith phenobarbitone.
These purified forms of cytochrome P-450 have overlapping substrate 
specific ities except w ith  ethoxyresorufin which is metabolised specifica lly by 
cytochrome P-448 (Guengerich et al., 1982; Phillipson et al. 1984). S im ilar 
results have been observed using other animal species (Graf et al., 1980; 
Guengerich et al., 1981). Other workers have shown that the treatm ent of rats 
w ith phenobarbitone results in de novo synthesis of cytochrome P-450 (Adesnik 
et al., 1981; Phillips et al., 1981), and the polysomes isolated from the livers of 
these animals synthesize the cytochrome at a greater rate than those isolated 
from untreated rats (Colbert et al., 1979).
M ixed-function oxidase induction is believed to result from  high 
concentrations of a substrate, particu la rly  i f  tha t substrate is slowly metabolised 
(as w ith  phénobarbital or the polycyclic aromatic hydrocarbons). Occupation of 
the active site of the enzyme by a substrate fo r long periods of tim e leads to 
reversible inhibition of the enzyme, genomal depression, increased enzyme 
protein synthesis, and an increase in enzyme a c tiv ity  (Parke, 1978b).
Inhibition
Inhibition of m ixed-function oxidase may be com petitive or 
non-com petitive. Four classes of compounds (namely: amphetamines, SKF 525A 
type, d ith ionite type and nitroso-compounds) have been observed to complex w ith  
cytochrome P-450 and this results in inhibition of m ixed-function oxidation 
(Franklin, 1977). Safrole inhibition, fo r instance, occurs as a result of a simple 
substrate competition, but prim arily by the formation of a safrole carbene 
complex w ith cytochrome P-450 (loannides et al., 1981). However, a fte r in itia l
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inhibition of m ixed-function oxidation, safrole also acts as a potent inducer of 
both cytochromes P-450 and P-448. The ligand binding between inh ib itor (e.g. 
thiocarbonyl and thiophosphonyl compounds) and cytochrome P-450 may lead to 
lip id peroxidation and destruction of cytochrome P-450 (Parke, 1979a); this 
occurs a fte r animal treatm ent w ith  disulphiram and parathion (Parke, 1979a), 
carbon disulphide (Obrebska et al., 1980), and carbon tetrachloride (Koivusaari et 
al., 1980).
UDP-Glucuronyltransferase A c tiv ity
Biochemical characteristics
UDP-glucuronyltransferase catalyses the transfer of glucuronic acid from  a 
donor molecule to an acceptor molecule; the donor molecule is usually 
UDP-glucuronic acid, but translocation of glucuronic acid from  a conjugate can 
occur (Berry and Hallinen, 1974; Wishart and Fry, 1980). The glucuronic acid is 
joined to an O -(after or ester bond), N, S, or C atom of the acceptor molecule 
(D ieterle et al., 1976; Caldwell and Smith, 1977; Isra ili et al., 1977; Kasper and 
Henton, 1980), the joining of the two molecules by a C -C  bond is an unusual form  
o f conjugation (Hirom and M illburn, 1979). The conformation of the metabolised 
product, B-D-glucuronide, suggests an Shl^ type of nucleophilic displacement of 
the UDP moiety (Kasper and Henton, 1980) and kinetic  studies w ith  this enzyme 
have suggested that the mechanism of substrate and co-enzyme addition is o f 
the ordered Theorell-Chance type (Vessey and Zakim, 1972). This enzyme is 
found in a wide number of genera (namely: plants, birds, reptiles, amphibians 
and mammals) and in the m ajority of mammalian tissues, the most im portant 
being the live r, gastrointestinal tra c t, and kidney (Hartia la, 1961; Dutton, 1966; 
A itio , 1974).
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I t  has been proposed that there may be a functional linkage between 
m ixed-function oxidation and glucuronylation (8 tie r, 1976) because both 
cytochrome P-450 and UDP-glucuronyltransferase are located in the 
endoplasmic reticulum , and because both enzymes have a requirement fo r 
phospholipids (Wood et al., 1978; Burchell, 1981), particu larly 
phosphatidylcholine (Tukey and Tephly, 1980; Bosterling et al., 1981). This 
functional linkage could result in the products of phase I metabolism being 
presented to UDP-glucuronyltransferase so that sequential metabolism could 
occur. In addition UDP-N-acetylglucosamine could act in vivo as an endogenous 
messenger to regulate the two enzymes because i t  is known to activate 
UDP-glucuronyltransferase in v itro . This activation could occur by 
UDP-N-glucosamine acting as a permease to enable UDP-glucuronic acid^reach 
the enzyme (Dutton and Burchell, 1975), or it  m ight act by an allosteric 
mechanism to switch the enzyme from a ca ta ly tica lly  incompetent form  to a 
ca ta ly tica lly  active form  (Berry, 1978). The results o f studies using isolated 
hepatocytes indicate tha t there is no tigh t coupling between the form ation of 
phenols by cytochrome P-450 and the subsequent glucuronylation reaction 
(Bridges, 1980; Bridges et al., 1980). A functional linkage between the enzymes 
therefore seems unlikely.
M u ltip lic ity  o f enzymes
The heterogeneity of UDP-glucuronyltransferase has been proposed on the 
evidence that:
a. some substrates (e.g. b ilirubin) fo r UDP-glucuronyltransferase are not 
glucuronylated by the liver from  the Gunn ra t and this has been related to 
a genetic deficiency in this species (Lalani and Burchell, 1979);
b. there are species (Hartiala, 1961) and tissue (Bock et al., 1980) differences 
o f the enzyme a c tiv ity  towards d iffe ren t substrates;
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c. differences are observed in foetal and post-natal development of the
enzyme ac tiv ity  towards d iffe ren t substrates (Dutton, 1975; Wishart, 1978;
Goldstein et al., 1980);
d. d iffe ren tia l induction of enzyme ac tiv ity  towards d iffe ren t substrates is
observed (Bock et al., 1979; Bock et al., 1984).
Although a number of forms of the enzyme have been purified to apparent 
homogeneity (Gorsky and Kasper, 1977; Tukey et al., 1979; Rao and Breuer, 
1980; P fe il and Bock, 1983) subsequent studies have shown tha t enzyme 
activ ities towards some substrates may have been lost during the purifica tion 
procedure. Lack of ac tiv ity  o f a purified form  of UDP-glucuronyltransferase 
towards testosterone (Burchell, 1978) was restored by adding phosphatidylcholine 
to the assay (Weatherill and Burchell, 1980). S im ilarly the inclusion of pentan- 
3-one in live r perfusion preparations and live r microsomal preparations from the 
Gunn ra t restored UDP-glucuronyltransferase ac tiv ity  towards 2-aminophenol, 
an enzyme a c tiv ity  which was previously thought to be lacking in the live r of this 
strain of ra t (Burchell and Bock, 1980). This enzyme has now been purified . 
(Lalani and Burchell, 1979). Isolation and purifica tion of
UDP-glucuronyltransferase has been hindered by the ease w ith  which i t  is 
inactivated (Burchell, 1981), therefore c r itic a l evaluation o f experimental 
procedure is o f great importance. As a working hypothesis, i t  has been proposed 
tha t d iffe ren t forms of UDP-glucuronyltransferase are present in the ra t and 
rabbit live r and that these enzymes have overlapping activ ities  towards certain 
substrates (Table 1.3) (Dutton, 1980; Burchell, 1981).
Latency
The UDP-glucuronyltransferase ac tiv ity  in microsomal preparations can be 
increased 160-830% (Burchell et al., 1976) by treating the preparation w ith  UDP- 
N-acetylglucosamine, neutral or anionic detergents, and phospholipase A, 
amongst other agents or by sonicating or freeze-thawing the preparation (Dutton
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and Burchell, 1975). Therefore only a fraction of the to ta l enzyme a c tiv ity  is
expressed in freshly prepared and untreated (native) microsomal preparations.
This concept is known as latency. The process of treating an enzyme preparation
to increase the enzyme a c tiv ity  is known as activa tion, which is defined as 'an
increase in enzyme a c tiv ity  under conditions precluding enzyme synthesis and
d irectly  re flecting change in a c tiv ity  o f preformed enzyme molecules whose
ca ta ly tic  power is pa rtia lly  or wholly unexpressed1 (Dutton and Burchell, 1975).
Agents which activate the enzyme were not observed to a lter the K and V 3 J m max
of the enzyme and additive activation was not observed when more than one 
activation agent was used on the same enzyme preparation (Vessey and Zakim, 
1971). An explanation fo r the latency of this enzyme has been sought and two 
main hypotheses have been proposed:
1. The in tac t membrane constrains the conformation of the enzyme in a form 
w ith  low a c tiv ity ; mild perturbation of the membrane releases this 
constraint and enables i t  to assume a form  w ith  greater a c tiv ity  (Zakim 
and Vessey, 1976).
2. A lipophylic membrane barrier between the enzyme and the external 
medium restricts the access of substrates to the active site(s) o f the 
enzyme; in microsomal preparations the latency is presumably because the 
active site of the enzyme is located on the internal surface of the 
microsomal vesicle (Wisnes, 1969).
Both these hypotheses have the ir adherents who have sought evidence to promote 
one hypothesis w ith detriment to the other, and this has resulted in a vigorous 
debate (Wood et al., 1978). However, nuclear envelope membrane preparations, 
which remain in the cisternal arrangement, possess non-la tent 
UDP-glucuronyltransferase ac tiv ity  which suggests that latency in microsomal 
preparations may be an a rte fact o f preparation (Wishart and Fry, 1980). But the 
s im ila rity  of the enzyme ac tiv ity  in perfused liver preparations and native 
microsomal preparations suggests that the enzyme is la tent in vivo as w ell as in 
in v itro  preparations (Bock, 1974).
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Induction and inhibition
There are a number of s im ila rities between the induction of the 
UDP-glucuronyltransferases and the mixed-function oxidases. Not only do the 
classical m ixed-function oxidase inducing agents e ffec t increases in 
UDP-glucuronyltransferase a c tiv ity  but they also produce increases in the 
a c tiv ity  o f particu lar forms of the enzyme (Bock et al., 1983). Treatment o f rats 
w ith  3-methylcholanthrene or B-naphthoflavone results in the selective 
stim ulation of activated UDP-glucuronyltransferase ac tiv ity  towards 'group-1' 
substrates (Table 1.3) which are mainly planar phenols (Bock e^ t al., 1979; 
Lilienblum et al., 1982). When rats are pretreated w ith  phenobarbitone there is 
not always a resultant increase in enzyme a c tiv ity  in native live r preparations, 
but there is invariably an increase in activated enzyme a c tiv ity  (Mulder, 1970). 
Phenobarbitone pre ferentia lly  stimulates the j iq c o re la t io n  o f 'group-2' 
substrates (Table 1.3) which are not planar phenols (Bock et al., 1983). Another 
class of inducers includes pregnenolone 16a-carbonitrile  (Watkins and Klaassen,
1982) and c lofibrate (Lilienblum et al., 1982) which selectively increase b ilirub in  
glucuronylation (Table 1.3) w ithout a ffecting the enzyme a c tiv ity  towards 
'group-1' or 'group-2 ' substrates. Also Aroclor 1254 induces
UDP-glucuronyltransferase ac tiv ity  towards both 'group-1 ' and 'group2 ' 
substrates in live r from ra t (Lilienblum et al., 1982). Experiments measuring the 
incorporation of leucine into UDP-glucuronyltransferase a fte r treating animals 
w ith  phenobarbitone or 3-methylcholanthrene have indicated that these agents 
induce de novo synthesis o f the enzyme (Bock et al., 1979). Although treatm ent 
o f animals w ith  some of these inducing agents yields increases in activated 
enzyme a c tiv ity  in v itro , some of these agents have been observed to inh ib it 
glucuronylation in vivo (Dutton and Burchell, 1975). Others agents (such as 
CCI4 ) may increase native hepatic enzyme ac tiv ity  but decrease the activated 
enzyme a c tiv ity  in microsomal preparations (Chojeki and Kern, 1961; Desmond 
et al., 1981).
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UDP-glucuronyltransferase a c tiv ity  is dependent on the ava ilab ility  of 
UDP-glucuronic acid, so fluctuations in co-enzyme ava ilab ility  a fte r animal 
treatm ent w ith  enzyme inducing or inhibiting agents may a ffec t the enzyme 
a c tiv ity  (Moldeus et al., 1979). Thus changes in enzyme a c tiv ity  may be a 
re flection of an alteration in the mechanism of regulation rather than of an 
alteration in the concentration of enzyme per se. For example, treatm ent of 
rats w ith some inducing agents (such as phenobarbitone, 3 -methylcholanthrene, 
etc.) increase the concentration of UDP-glucuronic acid in the live r; others 
(such as pregnenolone 16a-carbonitrile) have l it t le  e ffec t on the concentration 
of this co-enzyme (Watkins and Klaassen, 1983). Also, treatm ent of rats w ith  
some enzyme inhibitors (such as SKF 523A) or inhalation anaesthetics (such as 
halothane) e ffec t decreases in the concentration of UDP-glucuronic acid in the 
live r. Therefore the design of experimental protocols must be carefu lly 
examined before drawing conclusions from the results o f experiments concerning 
the effects on these conjugation reactions produced by treating animals w ith  
various agents.
4. Extrahepatic Metabolism
Although extrahepatic metabolism of drugs may not always be im portant, 
i t  can modify the fate and effects of drugs (Vainio and Hietanen, 1980). A 
variety o f important drug metabolising enzymes (such as m ixed-function oxidase 
(Burke and Orrenius, 1979; Connelly and Bridges, 1980), 
UDP-glucuronyltransferase (Dutton, 1966; A itio , 1974; A itio  and Marniemi,
1980), sulphotransferase (Powell and Roy, 1980), glutathione-5-transferase 
(Chasseaud, 1980), acetyltransferase (Weber e t al., 1980), etc.) are known to 
occur in the m ajority of mammalian tissues. Therefore extrahepatic tissues are 
capable of metabolising drugs. Reviews of biotransformations (Bentley and 
Oesch, 1979) and conjugations (Hirom and M illburn, 1979) in various tissues have
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been published. The metabolism o f drugs by one of these extrahepatic tissues, 
namely the gastrointestinal trac t, is particu larly  important because the m ajority 
o f drugs are given orally (George, 1981).
Drug metabolism by the gastrointestinal tra c t
Drug metabolising enzyme a c tiv ity  in the gastrointestinal tra c t is not 
uniform ly distributed along the whole tra c t; the greatest enzyme activ ities  have 
been observed in the proximal part o f the small intestine and the enzyme 
a c tiv ity  decreases towards the caudal end of the tra c t (Hanninen et al., 1968; 
A itio  et al., 1972). The location of the enzymes and the morphology of the 
gastrointestinal tra c t account fo r these differences in enzyme a c tiv ity . The 
maximum concentration of cytochrome P-450, m ixed-function oxidase a c tiv ity  
and UDP-glucuronyltransferase ac tiv ity , is located in the intestinal mucosal v ill i 
tip  cells (Chhabra, 1979; Hoensch et al., 1979; Schiller, 1979). These intestinal 
v ill i are only located in the small intestine and the epithelium consists of 
columnar and goblet cells; the proportion o f columnar cells being greater in the 
duodenum but decreases along the tra c t towards the caudal end (Burke and 
Orrenius, 1979).
There is much evidence to show that m ixëd-function oxidase a c tiv ity  in the 
intestine is dependent on the constitution of the diet. For example, constitu tive  
enzyme ac tiv ity  in this tissue from rats was low when the animals were fed a 
semi-synthetic diet (Wattenberg, 1971; Pantuck et al. 1976a; Chhabra, 1979; 
McDanell and McClean, 1984). Furthermore, intestinal m ixed-function oxidase 
ac tiv ity  was observed to be related to the amount of iron in the diet; this is not 
so of the enzyme ac tiv ity  in the live r (Hoensch et al., 1975). These reports have 
led to the proposal that m ixed-function oxidation may only be present in the 
intestinal tra c t because of its induction by exogenous factors (Wattenberg, 1971). 
However, intestinal UDP-glucuronyltransferase a c tiv ity  is not so diet-dependent
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as m ixed-function oxidase ac tiv ity ; e.g. when rats were starved, m ixed-function 
oxidation in intestine preparations was reduced to zero, whereas glucuronylation 
by these enzyme preparations was only reduced by 36% (Hietanen and Vainio, 
1973). I t  has been proposed that m ixed-function oxidation in neonatal and 
malignant tissue is prim arily carried out by a p rim itive  form  of cytochrome 
P-450 (cytochrome P-448) (Parke and loannides, 1982). This class of tissue 
includes the gastrointestinal epithelium and indeed there is evidence that the 
predominant form  of cytochrome P-450 in this tissue is cytochrome P-448 
(Burke and Orrenius, 1979; McDanell and McClean, 1984).
The classical substrates fo r m ixed-function oxidase a c tiv ity  (Table 1.4) and 
UDP-glucuronyltransferase ac tiv ity  (Table 1.5) in the live r are also substrates 
fo r these enzymes in the intestine. The specific a c tiv ity  o f m ixed-function 
oxidase in the intestine is much lower (15-50%) than that in the live r, but the 
specific a c tiv ity  of UDP-glucuronyltransferase in the intestine can be sim ilar to 
or greater than that observed in the live r (A itio  et al., 1972; Hietanen and 
Vainio, 1973; Chhabra, 1979). The response of these enzymes in the intestine 
and liver a fte r treating animals w ith  agents which increase the ac tiv ities  of 
these enzymes (Tables 1.6 and 1.7) is sim ilar in that enzyme a c tiv ity  increases 
occur in both tissues. However, the patterns of enzyme induction observed in 
the two tissues d iffe r markedly fo r both m ixed-function oxidation and 
glucuronylation. This has indicated that the mechanisms of regulation of the 
hepatic and intestinal enzymes may d iffe r (Miranda and Chhabra, 1980). The 
observation that benzo(a)pyrene hydroxylation by intestinal preparations was 
increased, and that by hepatic preparations was decreased a fte r the addition of 
prostaglandins (PGE^ and PGE^) to these microsomal preparations (Stohs and Wu,
1981) supports this proposal. D ifferences in enzyme regulation between, the 
intestine and liver may arise because of the fundamental differences between 
the two tissues, namely: (i) differences in h a lf- life  of cells (Schiller, 1979), and 
(ii) differences in protein turnover (Goldspink et al., 1984).
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TABLE 1.6
The e ffe c t of treating animals w ith 3-methylcholanthrene (MC) or 
phénobarbital (PB) on m ixed-functional oxidase enzyme 
activ ities  of the live r and intestine 
(Miranda and Chhabra, 1980)
Species Substrate
Enzyme
inducing
agent
Percentage change from  
control enzyme a c tiv ity 3
L iver Intestine
Rat Ethylmorphine PB 153
Aniline PB 164 -
MC 143 -
Benzo(a)pyrene PB 62 64
MC 156 1615
7-Ethoxycoumarin PB 558 251
MC 1560 1231
Mouse Ethylmorphine PB 305
Aniline PB 152 -
MC 232 -
Benzo(a)pyrene PB 285 478
MC 513 516
7-Ethoxycoumarin PB 387 406
MC 377 25
Guinea pig Ethylmorphine PB 388 113
Aniline PB 593 66
MC 215 240
Benzo(a)pyrene PB 284 85
MC 284 240
7-Ethoxycoumarin PB 504 163
MC 90 58
Rabbit Ethylmorphine PB 218 113
Aniline PB 210 82
MC 90 68
Benzo(a)pyrene PB 205 90
MC 60 83
7-Ethoxycoumarin PB 552 69
MC 63 96
A ll enzyme activ ities  were measured in microsomal fractions
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The evidence collected thus fa r indicates that the main role o f the 
gastrointestinal tra c t in drug metabolism is the catalysis of conjugation 
reactions. Intestinal epithelia l cells isolated from the guinea pig and ra t 
catalysed the O-deethylation of 7-ethoxycoumarin very slowly, but the 
metabolite was rapidly converted to the glucuronic acid or sulphate conjugate 
(Dawson and Bridges, 1979; Shirkey et al., 1979b). The rate of glucuronylation 
and sulphation o f a number of substrates by intestinal cells isolated from  ra t was 
observed to depend on the concentration and structure of the substrate (Dawson 
et al., 1982). Analysis o f blood from the hepatic portal vein of an isolated ra t 
intestine perfused in situ showed that a dose of phenol injected into the 
intestinal lumen was completely metabolised to its sulphate or glucuronide 
during absorption (Powell et al., 1974). S im ilarly, a large proportion (circa 6 6 %) 
of salicylamide absorbed by a perfused isolated ra t intestine was detected as 
glucuronide or sulphate conjugates (Sakai et al., 1980). Other workers have 
shown that 40% of the first-pass metabolism occurring a fte r oral ingestion of 
clonazepam by the ra t can be a ttributed to the intestine (Colburn et al., 1980). 
These experiments w ith animals support c lin ica l evidence, even i f  i t  is somewhat 
circum stantia l, that the gastrointestinal tra c t plays an important role in the 
metabolism o f a number of drugs, namely: isoetharine (sulphation), r im ite ro l
(sulphation), isoniazid (acétylation), hydralazine (acétylation), isoprenoline 
(sulphation), and terbutaline (sulphation) amongst others (George et al., 1974; 
Caldwell and Smith, 1977; George, 1981). However, the rapid and extensive 
induction of intestinal m ixed-function oxidase activ ities  by dietary components 
(Pantuck et al., 1976b) may a ffec t the metabolism of drugs in ways which have 
not yet been observed.
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Section Two:
The Adrenergic System and Labetalol
1. The Adrenergic System
a- and B-Adrenoreceptors
There are two types of adrenoreceptor, namely: a and 6> found in various 
mammalian tissues, including the heart, bronchi and blood vessels (Table 1.8) 
(Frishman, 1980a; Lefkow itz et al., 1983). These adrenoreceptors respond to 
adrenalin or noradrenaline to regulate blood volume, blood pressure, and the 
balance o f sodium and potassium concentrations in the body fluids. This control 
is also effected by a cascade of events which is in itia ted by the production of 
renin (Laragh, 1976). In the peripheral tissues there are two sub-types of 
g-adrenoreceptor (Blakely and Summers, 1977): (i) g^-adrenoreceptors are
usually located post-synaptically on smooth muscle and mediate the response of 
e ffec to r organ to noradrenergic stim ulation, and (ii) g^~adrenoreceptors are 
usually located pre-synaptically on autonomic post-ganglionic nerve term inals, 
where they mediate a negative feedback mechanism which inhibits transm itte r 
release (Langer, 1977). Sim ilarly there are two sub-types of 8 -adrenoreceptor: 
(^-adrenoreceptors are located in the heart, and (^-adrenoreceptors are found 
in the peripheral tissues but are mainly located in the lungs (Frishman, 1980a; 
Lefkow itz et al., 1983). These d iffe ren t types of adrenoreceptor were 
d iffe rentia ted because they d iffe r in the ir sensitiv ity to agonist and antagonist 
chemicals (Drew, 1977 and 1979; Hong and Rion, 1979).
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TABLE 1.8
D istribution and function of a- and ^-adrenoceptors 
(Frishman, 1980a)
Type of E ffec t of
Tissue adrenoreceptor stim ulation
Heart 6i increase in heart rate
s i increase in cardiac co n tra c tility
V acceleration of aurio- ventricular conductic
Bronchi
S2 dilatation
Blood vessels a constriction
B2 dilatation
Eye a dilatation of pupil
Gastrointestinal tra c t a, 8 reduction in m o tility
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8-Adrenoreceptor Agonist and Antagonist Drugs
8 - Adrenoreceptor agonists (such as isoprenaline) are used as therapeutic 
agents fo r bronchodilation (Goldie et al., 1984), whereas 8 -adrenoreceptor 
antagonists have been established as e ffective  therapeutic agents in the 
treatm ent o f hypertension (Meier et ai., 1980). Also, i t  has been suggested that 
selective antagonists fo r a^-adrenoreceptors may be e ffec tive  as 
antihypertensive agents (Hong and Rion, 1979). Studies of the differences 
between 8 -adrenoreceptor agonists and antagonists have shown that there are a 
number of agonist specific phenomena which are not shared by the antagonists 
(Abramson and M olinoff, 1984). These are:
i) an increase in the a ffin ity  o f the receptor fo r agonists mediated by 
divalent cations;
ii) an induction of a configurational change in the receptor by the agonists;
i ll)  a decrease in the a ffin ity  of the receptor on in tact cells fo r other agonist
molecules;
iv) an increase in adenylate cyclase ac tiv ity ;
v) uncoupling of the adenylate cyclase system in in tact cells which u ltim ate ly  
causes a decrease in the density of membrane-bound receptors.
These differences in response of the 8 -adrenoreceptor to agonists and 
antagonists may help to elucidate the mechanism of action of these two types of 
molecule.
The most widely used 8 -adrenoreceptor antagonists are either derivatives 
of oxypropanolamine (e.g. propranolol) or derivatives of phenylethanolamine (e.g. 
labetalol); the la tte r group of chemicals are closely related s tructu ra lly  to 
adrenergic agonists, such as adrenalin, noradrenalin, or isoprenaline (Figure 1.8) 
(Bourne, 1981). The blockade of the 8 -adrenoreceptor effects (Meier et al., 
1980):
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1. Reduction of the sympathetic tone by action on the efferent sympathetic 
nerves;
2 . inhibition of renin release (and hence angiotensin I and II release into the 
blood);
3. reduction of cardiac output and counteraction of vasoconstriction.
Although other properties o f the 8 -adrenoreceptor antagonist (such as organ 
se lectiv ity  or intrinsic sympathomimetic ac tiv ity ) may be im portant in regard to 
patient tolerance of the drug, they play no part in the reduction of blood 
pressure.
2. Labetalol
Pharmacology and Toxicology of Labetalol
Labetalol
Labetalol hydrochloride (trade name Trandate, A llen and Hanbury's L td ., 
laboratory code AH 3158A) is 2 -hyd roxy-5 -(l-hyd roxy-2$ l-m e thy l-
3-phenylpropyl) aminoethyl) benzamide hydrochloride (Figure 1.8) and is 
chemically synthesized as described in British Patent 1266058. There are two 
asymétrie centres in the labetalol molecule (Figure 1.9) (Oxford, 1980) and the 
commercially available drug consists of equal proportions of the four 
stereoisomers (B ritta in  et al., 1981; C lifton  et al., 1982) and the m ixture is 
optica lly  inactive. Labetalol is a specific competitive antagonist at both a- and 
8 -adrenoreceptors (Farmer et al., 1972) and has been established as an e ffec tive  
therapeutic agent in the treatm ent o f hypertension (Bolli et al., 1976; Pugsley et 
al., 1976). Recent studies have indicated that labetalol may be useful in the 
treatm ent of other cardiovascular disorders such as ischemic heart disease and 
cardiac arrhythmias (Frishman, 1980b).
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OH
Ri -OCH2CHCH2NH-R2
OH
I
CH2 CH2 NH
A. Oxypropanolamine deriva tives
= usually a substituted aromatic 
ptng
Rg = alkyl yroup such as isopropyl
0CH2CHCH2NH
OH CH(CH3)2
B. Phenyl ethanol ami ne
h2nco
HO
.OH ÇH3
chch2nhchch2ch2
C. Propranolol D. Labetalol
HO
OH
I
CHCH2NHCH3
HO
HO
OH
I
chch2nh2
HO
E. Adrenaline F. Noradenaline
Figure 1.8; The s truc tu re  o f g-adrenoreceptor antagonists compared 
w ith  the structures of adrenaline and noradrenaline 
(endogenous agon is ts ).
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Pharmacology of labetalol
Labetalol is a non-selective antagonist at 8 -adrenoreceptors (Harichaux 
and Hary, 1976) and is known to block 8^ - and 8^-adrenoreceptors to a sim ilar 
extent (B ritta in  and Levy, 1976). However, this drug is a specific antagonist at 
the a ^ -adrenoreceptor w ith  l it t le  e ffec t at the o^-adrenoreceptor (Blakely and 
Summers, 1977; Levy and Richards, 1980). The adrenoreceptor antagonist 
properties are not equally distributed between the four stereoisomers of the drug 
(B ritta in  et al., 1982). The RR stereoisomer is a strong 8 -adrenoreceptor 
antagonist, the SR stereoisomer is a strong a^-adrenoreceptor antagonist, and 
the SS and RS stereoisomers are weak ct^- and 8 -adrenoreceptor antagonists 
(Table 1.9). The pharmacological e ffects of labetalol stem from a combination 
o f the pharmacological ac tiv ities  of the stereoisomers of the chemical.
The potency of labetalol at the two adrenoreceptors varies w ith  the 
experimental situation. In isolated tissue studies labetalol was found to be
4-8 times more potent as an antagonist at the 8 - than at the a-adrenoreceptor 
(Farmer et al., 1972). In the anaesthetised dog and in man its potency was found 
to be 3-16 times greater at the 8 - than at the a-adrenoreceptor (B ritta in  and 
Levy, 1976; Richards et al., 1976; Frishman, 1980b). Compared w ith  other 
adrenoreceptor antagonists, labetalol was 7 times less potent than phentolamine 
as an antagonist at the a-adrenoreceptor, 4 times less potent than propranolol at 
the 8 j-adrenoreceptor (cardiac), and 11-17 times less potent than propranolol at 
the 8^-adrenoreceptor (vascular bronchial) (B ritta in  and Levy, Î976).
The antihypertensive action of labetalol results from the combined effects 
of a - and 8 -adrenoreceptor blockade (McNeil and Louis, 1984). In contrast to 
conventional 8 -adrenoreceptor antagonist drugs (e.g. propranolol) which usually 
cause an in itia l increase in peripheral vascular resistance, labetalol lowers 
peripheral vascular resistance (Brogden et al., 1978). This action can be
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attributed to the a-adrenoreceptor antagonist properties of labetalol which 
drugs like propranolol lack. Consequently the therapeutic e ffe c t o f labetalol is 
sim ilar to the combined administration of propranolol and hydralazine (Pritchard 
et al., 1975). The lowering of peripheral vascular resistance a fte r labetalol 
adm inistration is like ly  to be the cause of the postural hypotension observed in 
some patients (Joekes and Thompson, 1976). Another c lin ica l e ffe c t of labetalol 
is the prevention of bronchoconstriction (Frishman, 1980b) which could be of 
particu lar importance when asthmatic subjects are being treated for 
hypertension. Labetalol has also been shown to reduce the plasma renin 
concentration (Zech et al., 1980) and to decrease glomerular f iltra tio n  rate and 
renal plasma flow  (Keusch et al., 1980).
The plasma concentration of labetalol which exerts the therapeutic e ffec t 
is 100 ng/m l. The recommended doses to achieve this plasma concentration are 
(British National Formulary, 1984):
1 . oral - 1 0 0 -2 0 0  mg taken tw ice daily w ith  food
increasing at 14 day intervals to a maximum 
of 2.4 g daily;
2. intravenous - 50 mg over a period of 1 min; repeat a fte r 5
min to a maximum of 200  mg;
3. intravenous infusion - 2 mg/m l to a maximum of 200  mg.
4. during pregnancy - 200 mg/hr doubled every 30 min to a
maximum rate of 160 mg/hr.
Adverse side-effects and to x ic ity
Adverse side-effects of labetalol have been reported by some 5% of 
patients (Harris and Richards, 1978); these are: tiredness, lethargy, headaches 
and tingling scalp (Manderson, 1979; Nicholls et al., 1980). These are sim ilar to 
those observed w ith other drugs which blockade the 8 -adrenoreceptors and there 
may be less incidence of these side-effects than w ith the other drugs. However, 
caution has to be taken in prescribing labetalol because postural hypotension
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(Pritchard at ai., 1975; Belli et al., 1976) and mild reduction in kidney function 
(Keusch et al., 1980) have been observed in a number of patients given the drug.
A ll the animals in a ra t carcinogenicity test were subjected to careful 
c lin ica l examinations and post-mortem examinations at both macroscopic and 
microscopic levels (Levy and Richards, 1980). These studies revealed no toxic 
e ffec t thought to be c lin ica lly  significant, but i t  was observed that labetalol, 
though not its metabolites, was reversibly bound to melanin. Further 
investigations focussing on the uveal tra c t carried out in the ra t, rabbit, cat and 
dog showed no changes indicative of ocular tox ic ity . Reproductive studies in ra t 
and rabbit did not show any adverse e ffec t o f labetalol on foeta l development or 
in the offspring. Also no evidence of any mutagenic e ffec t was observed when 
labetalol was subjected to the Ames' test.
Labetalol Metabolism and Kinetics
Metabolism in animals and man
Five metabolites of labetalol were in it ia lly  separated from  the urines of
ra t, rabbit, dog and man by paper chromatography. A ll except one of the
metabolites from ra t and from  dog were hydrolysed by 8 -glucuronidase and none
were hydrolysed by sulphatase (Hopkins et al., 1976; M artin  et al., 1976). The
metabolites of labetalol have been characterised by various methods of chemical 
13analysis (including C-nuclear magnetic resonance spectra studies) and have 
been shown to be: the secondary amine glucuronide; the O-phenylglucuronide; 
the secondary alcohol glucuronide; hydroxylabetalol; and hydroxylabetalol 
monoglucuronide (Figure 1.10) (Oxford, 1980; Martin and Reid, 1981). In the 
common laboratory animals (e.g. rat and rabbit) only one major metabolite of 
labetalol is formed whereas in higher animals and in man three major 
metabolites of the drug are formed (Table 1.10) (Martin and Reid, 1981).
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CHCH z NHCHCH2 CH2-4
Labetalol
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O-phenylglucuronide:
►Rat, Rabbit, Dog © - 0  
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CH,
CHCH 2 NHCHCH 2 CH 2 -<x »
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Dog, Monkey, and 
Man
HLNOC
CHCH2 NHCHCH2 CH 2
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hydroxy labeta lo l: 
(minor pathway) 
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glucuronyl residue:
glucuronide conjugate 
o f hydroxy labe ta lo l: 
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Figure 1.10. Metabolic fa te  of labeta lo l in ra t ,  ra b b it ,  dog, monkey and man.
- 52 -
TABLE 1.10
Metabolites of Labetalol Excreted in the Urines of 
Rat, Rabbit, Dog, Monkey and Man 
(Levy and Richards, 1980; Martin and Reid, 1981)
Species
Percentage o f labeta lo l dose excreted in the urine 
N-glucuronide O-phenylglucuronide glucuronide
Rat
Rabbit
Dog
Monkey
Man
6
40
10
>90
>90
30
20
30
36
30
48
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Subsequent studies in man have shown that labetalol undergoes stereoselective 
glucuronide conjugation at the secondary alcohol and secondary amine positions 
of the molecule, but not at the phenolic position of the molecule (Oxford, 1980).
Pharmacokinetics in animals and man
Labetalol is well absorbed from the gastrointestinal tra c t by the ra t, 
rabbit, dog, monkey and man (Hopkins et al., 1976), and the subsequent plasma 
concentration of the drug is dose related (Martin et al., 1976). The peak plasma 
concentrations of labetalol are attained 1 -2  h a fte r oral adm inistration, and the 
plasma h a lf- life  in man was observed to be 3.5-4.5 h (Martin et al., 1976). 
However, the urine concentration o f unchanged drug, a fte r oral adm inistration, 
was observed to be circa 5% of the dose (Martin et al., 1976). The b ioava ilab ility  
in man was found to range between 11-86% (mean 33%) in middle aged 
hypertensives (average age 50 years) but was found to be much lower (average 
b ioavailab ility = 18%) in a younger group of normal volunteers (McNeil and Louis, 
1984).
Labetalol is rapidly removed from the plasma and taken up by the tissues 
(Martin et al., 1976). The plasma proteins were also found to bind labetalo l over 
a wide range o f concentrations (10-5000 pg/ml); the proportion of labetalol in 
the blood bound to these proteins was found to be 35% in rabbit, 54% in dog, and 
50% in man. Autoradiographic examination and radiochemical analysis of ra t 
tissues, a fte r giving the animal a radioactive dose of labetalol showed that the 
drug was well distributed but that the m ajority of the drug was located in the 
liver, lung and kidney. Extensive tissue metabolism of labetalol was observed; 
e.g. 6 h a fte r an intravenous dose to the dog, the proportion of unchanged 
labetalol was decreased to 40% of the in itia l plasma concentration. Sim ilar 
studies in the ra t showed that the in itia l concentration of unchanged labetalol 
(1 00%) in the plasma was decreased to 26% of the to ta l plasma labetalol a fte r 
6 h.
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Excretion of labetalol by animals and man is rapid and occurs via the urine 
and bile. The proportion of rad ioactiv ity  in the urine o f various species 96 h 
a fte r an oral dose was; mouse 72%, rabbit 61%, dog 6 6%, monkey 50% and man 
60% (Hopkins et al., 1976; M artin et al., 1976). The remainder of the 
radioactive dose was excreted in the bile and appeared in the faeces. Most of 
the labetalol excretion occurs in the f irs t 24 h a fte r the drug is taken.
Section Three:
The Aims of the Project
First-pass metabolism of drugs by the gastrointestinal tra c t reduces the 
b ioavailability of many drugs, and the extent of first-pass metabolism varies 
from  individual to individual. Therefore i t  is d if f ic u lt to establish the most 
e ffective  therapeutic dose o f a drug fo r an individual. During research on new 
drugs considerable e ffo rt is put into finding analogues of an active drug moiety 
which w ill not be subjected to extensive first-pass metabolism in order to 
overcome this problem. However, i f  the mechanisms of first-pass metabolism 
were better understood this knowledge may help in the design of new drugs.
The publication of a new method for preparing subcellular fractions of 
intestinal mucosal epithelia l cells was considered useful fo r investigating drug- 
metabolising enzyme activ ities  in the gastrointestinal tra c t. This new method 
incorporated two innovations; one, the use of d iffe ren tia l vibration to harvest 
the epithelia l cells instead of using the scraping method; and two, the use of 
hypotonic sucrose medium during homogenisation to assist w ith the disruption of 
the cells (Shirkey, 1977; Shirkey et al., 1979a; Schiller, 1979). The microsomal 
fraction prepared in this way was shown to be largely uncontaminated by other 
subcellular components or haemoglobin. The use of this .method of preparing 
subcellular fractions would enable a new look to be taken of phase I and phase II 
metabolism in d iffe rent sections of the gastrointestinal trac t.
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The extensive first-pass metabolism of labetalol, and the difference 
observed between the metabolism of the drug by common laboratory animals and 
its metabolism by dog, monkey and man (Martin et al., 1976), suggest a number 
o f questions. These are:
does the live r or the gastrointestinal tra c t have the greater role 
in labetalol metabolism?
why do common laboratory animals metabolise labetalol in a 
d iffe ren t way to the dog, monkey and man; do they lack certain 
enzymes which the other species possess?
are all the labetalol metabolites formed by enzymes in the liver 
and/or gastrointestinal trac t, or are d iffe ren t metabolites 
formed in d iffe ren t tissues?
Not only would the answers to these questions reveal the site(s) o f labetalol
conjugation, but they would also help to elucidate the role of the gastrointestinal
tra c t in drug metabolism.
The aims o f this investigation were:
1. To use microsomal fractions of live r and various sections o f the
gastrointestinal tra c t to observe the profile  of drug-metabolising enzyme 
activ ities. However, only a small amount of microsomal fraction  can be 
prepared from  the gastrointestinal tra c t, and consequently only a lim ited  
number o f enzymes may be studied. Therefore, the m ixed-function 
oxidases were chosen as the most important phase I reaction and the 
UDP-glucuronyltransferases were chosen as the phase II reaction fo r  study, 
the la tte r because this is the fam ily of enzymes which metabolises 
labetalol. Furthermore these enzyme activ ities were investigated to 
enable a comparison to be made w ith other sim ilar studies reported in the 
lite ra tu re . Two animal species were chosen fo r this study; the ra t because 
i t  is a common laboratory animal and the fe rre t because i t  is a non-rodent, 
non-coprophagic species therefore the gastrointestinal tra c t is not heavily 
contaminated w ith faecal m icroflora.
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2 . To use a variety o f techniques to study the contributions made by the
liver and gastrointestinal tra c t in labetalol metabolism. In itia lly  this would 
involve the isolation of the three metabolites in pure forms so that these 
could be used as standards when analysing samples which contained 
labetalol and its metabolites. Also to investigate the use of various in 
vivo, in situ and in v itro  methods (such as metabolism using whole animals, 
perfused organ preparations, isolated cell preparations, and isolated 
microsomal fraction  preparations) to d iffe rentia te  between the live r and 
intestine in the metabolism of labetalol. The species chosen fo r this study 
were the ra t, as a common laboratory animal; the dog, as an animal model 
fo r the metabolism of labetalol in man; and the fe rre t, because labetalol 
metabolism in this species had not previously been studied.
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Chapter 2
Comparison of the mixed-function oxidase activity in the 
liver and gastrointestinal tract of the rat and ferret
- 58 -
INTRODUCTION
The m ixed-function oxidase system, located in the endoplasmic reticu lum  
of the live r, gastrointestinal tra c t and a number of other tissues (Parke, 1982b), 
is known to be involved in the metabolism of endogenous compounds such as bile 
acids, vitam in D, cholesterol, corticosteroids, sex hormones. I t  is also involved 
in the synthesis of the prostaglandins, and the ^-hydroxylation o f fa tty  acids, 
etc., as well as in the oxidation of xenobiotic chemicals (Connelly and Bridges, 
1980; Parke, 1980). The membrane-bound m ixed-function oxidase system 
consists of a haemoprotein term inal oxidase, cytochrome P-450, linked to two 
electron transport chains by phosphatidylcholine (Nebert et al. 1975; Parke, 
1979b). The major chain is mediated through an NADPH-dependent flavoprotein 
reductase, cytochrome P-450 reductase, whereas the other chain is mediated 
through NADH-dependent cytochrome b5. The cytochrome P-450 enzyme 
system oxidises a substrate by sp litting  molecular oxygen d irec tly , form ing water 
as a by-product (Estabrook 1982). The major routes of xenobiotic chemicals into 
the body are via the main portals o f entry, particu larly the oral route. In the 
diet this may be as food additives or therapeutic agents, or as natually occurring 
toxins, water pollutants or food contaminants (Chhabra, 1979; Parke, 1979b). An 
awareness o f the role tha t the gastrointestinal tra c t plays in m ixed-function 
oxidase biotransformation of xenobiotic chemicals is necessary, w ith  particu lar 
reference to the metabolism of therapeutic agents.
Animal pretreatm ent w ith m ixed-function oxidase inducing agents a ffects 
the gastrointestinal tra c t and liver enzymes in d iffe ren t ways (Miranda and 
Chhabra, 1980). These inducing agents fa ll into three main categories (Parke, 
1979a): (1) drugs, such as phenobarbitone, increase the level o f cytochrome P- 
450, its related enzyme a c tiv ity  (Scharf and U llrich , 1974; Koivusaari et al. 1980) 
and its reductases (Kohli et al. 1980); (2) polycyclic aromatic hydrocarbons, such
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as 3-methylcholanthrene, raise the level of cytochrome P-448, its related 
enzyme a c tiv ity  (A itio  et al. 1972; Burke et al. 1977; Hietanen et al. 1980) but 
not its reductases; and (3) catatoxic steroids, such as pregnenolone 16a- 
carbonitrile , increase the cytochrome P-450 reductase level in the endoplasmic 
reticulum  (Fang and Strobel, 1981). Other compounds, such as safrole (loannides 
et al. 1981) and Arochlor 1254 (Alvares et al. 1973; L itte rs t et al. 1974; Kennedy 
et al. 1981 Parkinson et al. 1980; Parkinson et al. 1981; ), stim ulate both 
cytochrome P-450 and P-448 levels and the ir related enzymes.
Several forms of cytochrome P-450 have been isolated from  the ra t live r 
and purified su ffic ien tly  fo r characterisation (Botelho et al. 1979; Thomas et al. 
1981; Reik et al. 1982; Guengerich, 1984). The various investigations have 
resulted in a tenta tive  classification of five d iffe ren t cytochromes in the ra t 
live r: a a minor haemoprotein present a fte r treating rats w ith  phenobarbitone 
(PB) or 3-methylcholanthrene (MC); b the predominant haemoprotein a fte r PB- 
treatm ent; c the major haemoprotein a fte r M C-treatm ent; d a major 
haemoprotein a fte r isosafrole-treatment; and e a minor haemoprotein present 
a fte r PB-treatment. The purified forms of cytochromes P-450a, P450b, and P- 
450c have been shown to be d iffe ren t proteins by a variety o f c rite ria  (Botelho et 
al. 1979; Thomas et al. 1981; Reik et al. 1982). Cytochrome P-450 purifica tion  
from  the livers o f rats treated w ith  Aroclor 1254 (Ar) has shown that equal 
amounts of cytochromes P-450b and P-450c were present in association w ith  
small amounts of cytochromes P-450a and P-450e. The form(s) o f the 
cytochromes(s) in the livers o f untreated rats was observed to be dissim ilar to 
any of those of the above classification. Other workers have separated two 
forms of cytochrome P-450 from  microsomal preparations of intestinal mucosal 
cells from rabbit (Ichihara et al. 1980). Although the concentration of 
cytochrome P-450 in intestinal mucosal cells is less than that in live r cells, i t  is 
like ly that there are s im ilarities between the forms o f cytochrome P-450 in the 
two tissues.
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Drug metabolising enzyme a c tiv ity  is not distributed uniform ly along the 
gastrointestinal tra c t. Most of the m ixed-function oxidase a c tiv ity  has been 
observed in the duodenum and jejunum, w ith  lower activ ities  in the ileum, 
caecum, colon, and stomach (Hietanen and Vainio, 1973; Hietanen, 1974; 
Chhabra, 1979). Also the intestinal villous tip  cells have been shown to contain 
most o f the cytochrome P-450 arid m ixed-function oxidase a c tiv ity  (Hoensch et 
al. 1975). Gastrointestinal m ixed-function oxidase is more sensitive to 
components in the diet than the live r m ixed-function oxidase. For example, lack 
o f iron in the diet decreases the intestinal cytochrome P-450 concentration in 
the mucosal epithelia l cells (Hoensch et al. 1975) and components in the diet, 
such as indoles, a ffe c t the m ixed-function oxidase a c tiv ity  in the intestine 
(Wattenberg, 1971).
Various methods for the preparation of mucosal cell microsomes have been 
reported, but only three have resulted in the recovery of measureable amounts of 
cytochrome P-450 in this tissue preparation from  the ra t (Hoensch et al. 1975; 
Shirkey et al. 1979a; Strobel et a l. '1980). Some methods require the addition of 
glycerol, heparin and trypsin inh ib itor (Stohs et al. 1976), or 
phenylmethylsulphonylfluoride, a protease inh ib itor (Strobel et al. 1980), to the 
normal tissue homogenising medium so that the cytochrome P-450 may be 
stabilized during microsome preparation. The mucosal cells are usually 
harvested by scraping the gastrointestinal tra c t lumen surface w ith  a microscope 
slide (Hoensch et al. 1975; Stohs et al. 1976; Strobel et al. 1980); however an 
alternative method, by vibrating the everted intestine, has been developed 
(Schiller, 1979; Shirkey et al. 1979a). In this investigation three c rite ria  were 
used to identify a suitable method of preparing gastrointestinal tra c t 
microsomes:
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a The composition of the cell homogenising medium should be w ithout
chemical additions which m ight in terfere  w ith  the enzyme activ ities  to be 
measured in this study ;
b recovery of cytochrome P-450;
c comparison of the enzyme activ ities  measured w ith  those reported in the
lite ra tu re .
Two animal species were chosen fo r this investigation, the ra t, because it  
is a common laboratory animal, and the fe rre t, because i t  is a non-rodent (non- 
copraphagic) animal species. Although the ab ility  of the fe rre t to metabolise 
xenobiotics has not been extensively studied, i t  has been established that 
oxidative reactions do occur in this species (Smith & Tim brell, 1974). The 
m ixed-function oxidase activ ities of live r and intestine from the fe rre t measured 
in v itro  have sim ilarities w ith those in the ra t (loannides et al. 1977; Lake et al. 
1979).
The object of this study was to a) investigate the comparative roles of the 
gastrointestinal tra c t and liver m ixed-function oxidases, and b) to test the 
hypothesis that gastrointestinal tra c t enzymes are mainly related to induced 
cytochrome P-448 rather than to constitu tive cytochrome P-450 (Burke and 
Orrenious, 1979) using the ra t and fe rre t.
MATERIALS AND METHODS
Materials
Glucose 6 -phosphate (monosodium salt), glucose 6 -phosphate dehydrogenase 
(bakers yeast type VII, E.G. No. 1.1.1.49), cytochrome c (horse heart type III), 
and 3-methylcholanthrene (practical grade) were obtained from  Sigma Chemical 
Co., Poole, Dorset, U.K.; bovine serum albumin (fraction V), Folin-C iocalteau
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phenol reagent and sodium phenobarbitone from BDH Chemicals Ltd.," Poole, 
Dorset, U .K.; NADP and NADPH from  Cambrian Chemicals, Croydon, U.K.; 
biphenyl, 2- and 4-hydroxybiphenyl from Hopkin and Williams, Chadwell Heath, 
Essex, U.K.; 7-ethoxyresorufin and resorufin from  Piece and Warinner (U.K.) 
L td ., Chester, U .K.; ethylmorphine HC1 from May and Baker L td ., Dagenham, 
U.K.; and Aroclor 1254 from  Monsanto Chemical Col., St. Louis, Michigan, 
U.S.A.
A ll other chemicals and solvents used were of Analar grade.
Animals and Experimental Procedures
Anim al pre-treatm ent
Male Wistar albino rats (200-340g) bred at the University o f Surrey and 
male ferrets, mustela putorius fu ro , (1.0 - 1.7 kg) obtained from  Froxfie ld  Rabbit 
Farm, Petersfield, Hants were used in this study. Food and water were available 
to the animals ad lib itum .
Aroclor 1254 (500 mg/kg) was given in corn o il (500 mg/m l) in tra - 
peritoneally on day 1, the animals being killed on day 6 . 3-Methylcholanthrene 
(25 mg/kg) in corn oil (5 or 10 mg/m l) or phenobarbitone (80 mg/kg) in distilled 
water (55 mg/m l) was injected intra-peritoneally daily fo r three successive days, 
the animals being killed on the fourth day.
Experimental Procedures
Preparation of ra t and fe rre t hepatic and gastrointestinal tra c t mucosal cell 
microsomes (Shirkey, 1977; Shirkey et al. 1979a - modified)
The rats and ferrets were routinely killed by cervical dislocation or 
term inal exsanguination by cardiac puncture under ether anaesthesia, 
respectively, between 8.30 and 9.45 a.m. A ll buffered solutions used in preparing
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the microsomes were ice-cold and all the procedures were carried out in a 4°C
cold-room, except fo r the excision of tissue from the animals which was carried 
out at room temperature. In each experiment six rats or two ferrets were used 
to provide: two livers, the stomachs and the intestines which were used to 
prepare the various tissue microsomes.
The liver was carefu lly excised and plunged into 0.3 M sucrose, 20 mM 
Tris-HC l buffer pH 7.4 at 4°C (sucrose buffer A). The stomach was removed, 
cutting away the mesentery, and immersed in 0.9% NaCl, 20 mM Tris-HC l buffer 
pH 7.4 at 4°C (saline buffer A). The intestinal lumen was perfused w ith  saline 
buffer A via the open pylorus using a cannula attached to a syringe; clamping 
the pylorus, the intestine was stripped of mesentery as fa r as the rectum. The 
saline buffer in the intestine lumen was flushed out and the intestine was plunged 
into fresh saline buffer A.
Preparation of gastrointestinal tra c t microsomes
Each stomach was cut open along the greater curvature and rinsed w ith  
d istilled water to remove the gastric contents. Using a microscope slide, the 
mucosal epithelia l surfaces were carefu lly scraped to remove the cells, which 
were washed into a tared centrifuge tube w ith  0.14 M NaCl, 3 mM EOT A, 20 mM 
Tris-HCl pH 7.4 at 4°C (saline buffer B). The gastric cells from  the six rats or 
two ferre ts were pooled.
The intestines from each animal were cut into four sections as follows:
Rat Ferret
Duodenum 0 - 1 0  cm 0 - 18 cm
Jejunum 10 - 30 cm 18 - 33 cm
Ileum 30 - 90 cm 53 - 160 cm
Caecum/Colon 90 - 100 cm 160 - 178 cm
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A ll measurements were from  the pylorus; in the ra t the appendix and upper 
caecum were not used.
Similar sections of the intestine from each of the six rats or two ferrets 
were pooled and everted on to metal rods, tying at both ends w ith  cotton, 
attached to a Vibroxmix (EM., Clandon Scientific, Ash Vale, Aldershot) and were 
vibrated ve rtica lly  at high frequency (50 Hz) and low amplitude (1.5 mm) in 
saline buffer A  fo r an in itia l period of 1 min. The sloughed o ff cells w ith  
acellular m ateria l in strands of mucus were discarded. The everted intestines, 
bathed in fresh saline buffer B, were vibrated fo r a fu rther 30 min. The 
epithelia l cells harvested from the d iffe ren t sections of the intestine were used 
for the preparation of microsomes.
The intestinal mucosal cell suspensions were poured into tared centrifruge 
tubes and centrifuged, along w ith  the gastric mucosal cell suspension, at 
approximately 1000g in a bench centrifuge fo r 4 min. The tared tubes were re- 
weighed, a fte r carefu lly discarding the supernatants, and the fresh wet cell 
weight of mucosal cells was determined.
The mucosal cells from the d iffe ren t parts of the gastrointestinal tra c t 
were homogenised, separately, in three cell volumes of 75 mM sucrose, 20 mM 
Tris-HC l buffer pH 7.4 at 4°C (sucrose buffer B) using a Potter-Elvehejm  
teflon/glass homogeniser (10 strokes). An equal volume, to the sucrose buffer B, 
of 0.52 M sucrose, 20 mM Tris-HCl buffer pH 7.4 at 4°C (sucrose buffer C) was 
added to adjust the homogenate to isotonicity before d iluting the suspension to 
25 ml w ith sucrose buffer A. A fte r centrifuging the homogenates at 1000g fo r 4 
min in a bench centrifuge, the supernatants were poured into clean centrifuge 
tubes, the remaining pellets being washed three times w ith 8 ml sucrose buffer A. 
These supernatants were centrifuged at 14,000g in a M5E Highspeed 18
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Qcentrifuge fo r 10 min at 4 C; the pellets being resuspended, tw ice, w ith  12.5ml 
sucrose bu ffe r A and recentrifuged using the same conditions. The microsomal 
supernatants were centrifuged at 167,900g in a Beckman L5-65B Ultracentrirjftjge 
fo r 40 min at 4°G. A fte r discarding the supernatant, 1ml o f 50 mM Tris-HC l 
buffer pH 7,4 was gently added to cover the pellet which was stored at -40°C 
overnight.
The microsomal pellets were resuspended in 50 mM Tris-HC l buffer pH 7.4 
at 37°C, to make e ither a 40% (Ig  wet cell weight = 2.5ml) preparation or a 
minimum volume of 5.5ml, necessary fo r carrying out all the assays.
Preparation of live r microsomes
The livers were washed in sucrose buffer A (the gall bladders being 
removed from the fe rre t livers), blotted on f i l te r  paper, and weighed. 
Approximately 6.25g, from  d iffe ren t lobes, taken from  each of the two livers 
were homogenised, separately, in fresh sucrose buffer A  using a Potter-E lvehejm  
teflon/glass homogeniser (3 strokes) and made up to 25ml w ith  the same buffer. 
The two homogenates were centrifuged at 14,000g in a MSE Highspeed 18 fo r 20 
min at 4°C, and the microsomal supernatants were centrifuged a t 167,900g in a 
Beckman L5-65B U ltracentrifuge fo r 40 min at 4°C. A fte r discarding the 
supernatant, 5 ml of 50 mM Tris-H C l buffer pH 7.4 was carefu lly poured on to 
each pellet which was then stored at ~40°C overnight.
The stored pellets were resuspended in 50 mM Tris-H C l buffer pH 7.4 at 
37°C to give a 25% ra t liver (1 g wet live r = 4 ml) or 50% fe rre t live r (1 g wet 
live r = 2 ml) microsomal suspensions.
- 66 -
Assays
Biphenyl 2- and 4-hydroxylase determination (Creaven et al., 1965
Delaforge, 1980)
The incubation m ixture consisted of:
An NADPH generating system:
1.95 Mmol NADP"1*, 15 Mmol glucose 6-phosphate, and 
1 unit glucose 6-phosphate dehydrogenase in buffer
100 mM MgSO^
100 mM Tris-HC l buffer pH 7.6 at 37°C 
microsomal suspension 
1.25 M Biphenyl in dimethylformamide
Each determ ination was carried out in duplicate. The NADPr , glucose 
6 -phosphate, and glucose 6 -phosphate dehydrogenase were om itted from the 
blanks and standards. The amount o f buffer added to these tubes was adjusted to 
maintain a constant to ta l volume of 2.0 ml. Separate blank and standard 
determinations were carried out fo r the hepatic and gastrointestinal tra c t 
microsomal preparations.
A pre-incubation period of 5 min was carried out at 37°C in a M ickle 
shaking water bath prior to the addition of substrate. A fu rthe r incubation, w ith  
substrate, o f 10 min was terminated by the addition of 0.5 ml of ice-cold 2 M 
HG1 and the tubes were plunged into ice. The substrate was added to the blanks 
and standards, along w ith  the standards (0.5 ml of 30 ug/ml 2-hydroxybiphenyl or 
60 Mg/ml 4-hydroxybiphenyl) to the ir respective tubes, a fte r the incubation. 
Addition of 7 ml n-heptane, containing 1% isoamylalcohol, to each tube was 
carried out before storing the tubes overnight at -15°C. The incubation 
mixtures were extracted w ith  n-heptane fo r 15 min on a rotary extractor at 
room temperature. A fte r centrifugation at 1000-2000 g fo r 15 min at 4°C in a
- modified by
0.25 ml
0 .10  ml 
1.15 ml 
0.50 ml 
4 pi
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Beckman J6 centrifuge, 2 ml o f the n-heptane phase was extracted w ith  5 ml o f 
100 mM NaOH followed by centrifugation, as previously. The n-heptane was 
removed by aspiration and a 2 ml aliquot of the aqueous phase was brought to 
pH 5.5 by the addition of 0.5 ml o f 0.25 M succinic acid.
The fluorescence o f 2- and 4-hydroxybiphenyl in each tube was measured 
at 420 and 338 nm, excitation wavelengths being 295 and 275 nm respectively, 
using a Perkin-Elmer MFP3 spectrofluorim eter. Although 2-hydroxybiphenyl 
fluorescence at 338 nm was negligible, the fluorescence of 4-hydroxybiphenyl at 
420 nm was considerable. A correction factor, therefore, had to be subtracted 
from  the fluorescence measured at 420 nm:
Fluorescence of . , , , , , . , , .
-  4-hydroxybiphenyl x amount of 4-hydroxybiphenyl in assay
standard at 420 nm amount of 4-hydroxybiphenyl in standard
The specific activ ities  of the enzymes were calculated from the amount o f
fluorescence observed at 338 and 420 nm in each assay compared to that o f the
standards and the amount of protein in the assay.
Ethylmorphine N-demethylase determination (Holtzman et al., 1968)
The incubation m ixture consisted of:
hepatic g.i. tra c t
enzyme assay enzyme assay
1 .00  ml 1 .0 0  ml
An NADPH generating system:
1.5 pmol NADP+, 30 gmol glucose 
6 -phosphate, 2 units glucose 
6 -phosphate dehydrogenase in 15 mM MgCl^
50 mM Tris-HC l buffer pH 7.4 at 37°C 0.50 ml 0.25 ml
Semicarbazide hydrochloride 2% at pH 7.0 0.25 ml 0.25 ml
microsomal suspension 0.25 ml 0.50 ml
3 mM ethylmorphine HC1 in buffer 1.00 ml 1.00 ml
Each determination was carried out in duplicate. The NADP+, glucose
6 -phosphate, and glucose 6 -phosphate dehydrogenase were om itted from  the 
blanks and standards, as w ith the substrate from the blanks, and an amount o f
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buffer was added to these tubes to maintain a constant volume of 3.0 m l. Blank 
and standard determinations were carried out fo r both hepatic and 
gastrointestinal tra c t microsomal preparations.
A pre-incubation period o f 5 min was carried out at 37°C in a Mickle
shaking water bath prior to the addition of substrate. A fu rther incubation, w ith
substrate, fo r a period of 10 min was terminated by the addition of 1 .0  ml o f ice-
cold 5% w/v ZnSQ^ and plunging the tubes into ice. The substrate and standards
(100 and 200 nmol formaldehyde) were added to the standard tubes. The addition
of 2.0 ml of a 3:1 (v/v) m ixture o f saturated barium hydroxide and sodium
tetraborate solutions were followed by centrifugation at 1500 g fo r 10 min at
4°C in a Beckman J6 centrifuge. A 3.0 ml aliquot o f clear supernatant was
removed from each tube to measure the amount of formaldehyde produced by
the addition o f 3.0 ml of freshly prepared Nash reagent (Nash, 1953):
acetylacetone 0 .2  ml ) made up to
glacial acetic acid 0.3 ml ) 100 ml w ith
ammonium acetate 15.0 g ) d istilled water
The m ixture was incubated at 37°C in a Mickle shaking water bath fo r 40 min.
The tubes were allowed to cool to room temperature and the absorbance was
measured at 412 nm in a SP 500 Pye Unicam spectrophotometer.
7-Ethoxyresorufin Q-deethylase determination (Burke and Mayer, 1974; Burke et 
a l., 1977)
The incubation m ixture consisted of:
hepatic g.i. tra c t
enzyme assay enzyme assay
100 mM Tris-HC l buffer pH 7.8 at 30°C 1.90 ml 1.85 ml
microsomal suspension 100 gl 150 pi
50 pM 7-ethoxyresorufin in methanol 10 pi 10 pi
50 mM NADPH in buffer 10 pi 10 pi
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The live r microsomal suspensions from animals pretreated w ith  3-methylcholantrene 
and Aroclor 1254 were diluted 1 in 10 for the enzyme a c tiv ity  determinations. Each 
determination was carried out in duplicate. A pre-incubation, in the temperature 
controlled cuvette compartment o f fluorim eter, Perkin-Elmer MFP3, fo r 3 min at 
30°C, was carried out a fte r addition of the incubation m ixture, but before the addition 
of NADPH into the cuvette, and the solutions were mixed by inversion. A chart 
recorder, chart speed 25 mm/min, continuously monitored the fluorescence at 586 nm, 
using an excitation wavelength o f 530 nm. Following the addition o f NADPH, a 
fu rther incubation was carried out fo r a period of 4 min. The change in fluorescence 
a fte r addition o f 100  pmol resorufin standard, in 10 pi methanol, the slope of the 
fluorescence trace and the protein content o f the assay, were used to calculate the 
specific a c tiv ity  o f the enzyme.
NADPH-dependent cytochrome c reductase determ ination (Williams and Kamin, 1962)
cl
The incubation m ixture, place^in the sample cuvette, consisted of:
hepatic g.i. tra c t
enzyme assay enzyme assay
100 mM cytochrome c in buffer 1.00 ml 0.50 ml
100 mM Tris-HC l buffer pH 7.6 at 37°C
containing 1 mM KCN 1.95 ml 0.85 ml
microsomal suspension 0.05 ml 0.10 ml
30 mM NADPH in buffer 0.10 ml 0.05 ml
A reference cuvette, containing buffer instead of the NADPH solution was used.
The sample and reference cuvettes, w ithout the NADPH solution, were pre­
incubated at 37°C in the temperature controlled cuvette compartment o f a sp lit 
beam spectrophotometer, Carey 219, Varian, fo r a period of 2 min and a 
difference spectra base-line was established at 550 nm. A fte r the addition of 
the NADPH to the sample cuvette, the in itia l ve locity of the reduction of 
cytochrome c was recorded. A molar extinction co -e ffic ien t o f 18.5 m M ~^cm ^ 
was used to calculate the specific a c tiv ity  o f the enzyme from  the in itia l
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velocity of the cytochrome c reduction and the protëin content of the assay. 
Only one determ ination for each sample was carried out.
Protein determ ination (Lowry et al., 1951)
The hepatic microsomal suspensions were diluted 1 in 15 to 1 in 20; the 
gastrointestinal tra c t microsomal suspensions were diluted between 1 in 12 and 1 
in 50 using 0.5 M NaOH. An aliquot, 0.5 ml, of the diluted microsomal 
suspensions added to 0.5 ml o f 0.5 M NaOH followed by the addition of 5 ml 
of freshly prepared copper solution:
1% w/v Cu5O^.5H^0 0.5 ml
2% w /v Na+/K + Tartra te 0.5 ml
2% w /v Na2C 0 3 50.0 ml
A suitable blank and a series of bovine serum albumin standards (50-300 pg) were 
prepared in the same manner. The assay m ixture was allowed to stand at room 
temperature fo r a period o f 10 min. The Folin-C iocalteau phenol reagent was 
diluted 1 in 3 w ith  distilled water, 0.5 ml being added to each tube followed by 
immediate m ixing. The tubes were le f t fo r a fu rther period o f 30 min at room 
temperature to allow the colour to develop and the absorbance of each solution 
was determined at 720 nm using an SP 500 Pye Unicam spectrophotometer. Each 
determination was carried out in duplicate.
Verification o f assays
Enzyme tim e courses and the effects of protein concentrations on the 
various enzyme activ ities  were studied to ensure that each determ ination was 
performed in the linear phase of product formation and that the standards used 
were at a relevant concentration. More than 90% of the a c tiv ity  of fresh 
microsomal enzyme preparation was retained a fte r storing the microsomal 
pellets overnight at -40°C.
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RESULTS
The microsomal preparations of the gastrointestinal tracts from ra t and 
fe rre t contained less protein, per g fresh tissue, than the preparations of the 
livers (Table 2.1). The upper small intestine and liver microsomal preparations 
of the fe rre t contained less protein than the sim ilar preparations from the ra t; 
however, pretreatm ent o f the animals w ith MC effected a greater increase in 
protein concentration o f the live r microsomal preparation from the fe rre t than 
in tha t from the ra t. Increases in protein concentration of the live r microsomal 
preparations from the ra t were observed a fte r pretreatm ent of the animals w ith 
PB or A r, but not w ith  MC. The differences observed in the protein 
concentrations o f the gastrointestinal tra c t a fte r the various animal 
pretreatments could be w ith in  the range o f normal animal variation. However, 
increases of protein concentration of between 30-50% were observed in the 
microsomal preparations of stomach from  rats pretreated w ith  PB, MC or A r; in 
those of duodenum from  rats pretreated w ith MC or Ar, and those of 
caecum/colon from rats pretreated w ith  MC.
The activ ities o f biphenyl 2 - and 4-hydroxylase in the live r microsomal 
preparations from the untreated fe rre t were sim ilar to those in the untreated ra t 
(Table 2.2 and 2.3). However, the 2-hydroxylase activ ities in the gastrointestinal 
tra c t microsomal preparations from the untreated ra t were greater than those in 
sim ilar preparations from  the untreated fe rre t; the reverse being true fo r the 
4-hydroxylase activ ities  in the gastrointestinal trac t microsomal preparations 
from  the untreated ra t and fe rre t. Also, in the untreated ra t biphenyl 
2 -hydroxylase ac tiv ity  was greater in the jejunum than in the live r microsomal 
preparations. Treatment of the fe rre t w ith  MC only produced increases of 
biphenyl 2- and 4-hydroxylase activ ities in the jejunum and ileum microsomal 
preparations. Rat pretreatment w ith  PB effected increases in the 2-hydroxylase 
a c tiv ity  in preparations of liver and duodenum; w ith MC the e ffe c t was to
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TABLE 2.1
E ffec t of adm inistration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal protein concentration in the
ra t and fe rre t
Rat Ferret
Treatment: Control PB MC Ar Control MC
(mg per g tissue) (mg per g tissue)
Tissue
Liver 27.2 31.7 28.5 31.9 21 .8 31.9
+ 0.9 (117) (105) (117) (146)
Stomach 4.3 6.3 5.6 5.8 4.6 4.1
Mucosa + 0.3 (147) (130) (135) (89)
Duodenum 6 .8 5.7 9.3 8.7 5.4 5.0
Mucosa + 0.5 (84) (137) (128) (93)
Jejunum 10 .1 1 1 .1 8.9 10.7 6.7 6 .2
Mucosa
i—1 + 1 (1 1 0 ) (89) (106) (93)
Ileum 6.5 7.6 5.2 6.7 6.5 5.2
Mucosa + 0.9 (117) (80) (103) (80)
Caecum/Colon 1 .8 0.9 2 .6 1.7 2.3 3.5
Mucosa + 0.4 (50) (144) (94) (152)
The ra t control results are the means + SEM of determinations of microsomal 
preparations of the livers from  six animals or three microsomal preparations of 
the various sections of the gastrointestinal tra c t each of which were made from  
the pooled mucosal cells harvested from  the tissues of six animals. A ll the other 
results are determinations of two live r microsomal preparations or one set o f 
grastointestinal microsomal preparations, the la tte r being made from  the pooled 
tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as mg protein per g liver or fresh wet cell 
weight harvested from the stomachs or intestines. Percentage changes from 
control values are shown in parentheses. The animals were treated w ith  sodium 
phenobarbitone (PB) (80 mg/kg i.p.), 3-methylcholanthrene (MC) (23 mg/kg i.p.), 
or Aroclor 1254 (Ar) (500 mg/kg i.p.). For details of the animal treatm ents, 
microsomal preparations or protein assay, see ’Materials and Methods'.
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TABLE 2.2
E ffe c t of administration of inducing agents on the hepatic and 
gastrointestinal trac t microsomal m ixed-function oxidases in the
ra t and fe rre t
1. Biphenyl 2-hydroxylase
Rat Ferret
Treatment: Control PB MC Ar Control MC
Tissue
nmol product per min per 
mg protein
nmol product per 
min per mg 
protein
L iver 0.05 
+ 0 .01
0 .21
(420)
0.83
(1660)
1 .10
(2 2 0 0 )
0.05 0.03
(60)
Stomach
Mucosa
0 .02  
+ 0 .02
ND 0 .02
(1 0 0 )
0.06
(300)
ND ND
Duodenum
Mucosa
0 .01  
+ 0 .01
0.03
(360)
0 .22
(2 2 0 0 )
0 .10
(1 0 0 0 )
0 .02 ND
Jejunum
Mucosa
0.07 
+ 0.03
0.05
(71)
0.29
(414)
0.09
(129)
0 .02 0 .02
(1 00 )
Ileum
Mucosa
0.05 
+ 0 .02
0 .02
(32)
0.15
(296)
0.03
(60)
0 .0 1 0 .01
(1 0 0 )
Caecum/Colon
Mucosa
0.06 
+ 0.06
ND 0 .02
(33)
ND ND ND
The ra t control results are the means + SEM of determinations o f microsomal
preparations o f the livers from  six animals or three microsomal preparations of 
the various sections o f the gastrointestinal tra c t each of which were made from 
the pooled mucosal cells harvested from  the tissues of six animals. A ll the other 
results are determinations of two live r microsomal preparations or one set of 
gastrointestinal microsomal preparations, the la tte r being made from  the pooled 
tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as nmol 2-hydroxybiphenyl produced per 
min per mg protein. Percentage changes from control values are shown in 
parentheses. ND means that there was no detectable amount of 2- 
hydroxybiphenyl produced. The animals were treated w ith  sodium 
phenobarbitone (PB) (80 mg/kg i.p.), 3-methylcholanthrene (MC) (25 mg/kg i.p.), 
or Aroclor 1254 (Ar) (500 mg/kg i.p.). For details of the animal treatm ents, 
microsomal preparations or enzyme assay, see 'Materials and Methods'.
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TABLE 2.3
E ffe c t of adm inistration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal m ixed-function oxidases in the
ra t and fe rre t
2. Biphenyl 4-hydroxylase
Rat Ferret
Treatment: Control PB MC Ar Control MC
Tissue
nmol product per min per 
mg protein
nmol product per 
min per mg 
protein
Liver 0.67 
+ 0.09
2.43
(363)
1.41
(2 1 0 )
2.72
(406)
0.61 0.45
(74)
Stomach 0.13 0.07 0.08 0.17 0.27 0.26
Mucosa + 0.13 (54) (62) (131) (96)
Duodenum 0.08 0.42 0.54 0.30 0.78 0.28
Mucosa + 0.08 (525) (675) (375) (36)
Jejunum 0.09 0.54 0.59 0.18 0.41 0.76
Mucosa + 0.06 (600) (656) (2 0 0 ) (185)
Ileum 0.23 0 .21 0.55 0.18 0.52 0.74
Mucosa + 0.18 (91) (239) (78) (132)
Caecum/Colon
Mucosa
0 .10  
+ 0 .10
0.45
(450)
0.83
(830)
ND 0.36 ND
The ra t control results are the means + SEM o f determinations of microsomal
preparations of the livers from  six animals or three microsomal preparations of 
the various sections of the gastrointestinal trac t each of which were made from  
the pooled mucosal cells harvested from the tissues of six animals. A ll the other 
results are determinations of two liver microsomal preparations or one set o f 
gastrointestinal microsomal preparations, the la tte r being made from  the pooled 
tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as nmol 4-hydroxybiphenyl produced per 
min per mg protein. Percentage changes from control values are shown in 
parentheses. ND means that there was no detectable amount o f 4- 
hydroxybiphenyl produced. The animals were treated w ith  sodium 
phenobarbitone (PB) (80 mg/kg i.p.), 3-methylcholanthrene (MC) (23 mg/kg i.p.), 
or Aroclor 1254 (Ar) (500 mg/kg i.p.). For details o f the animal treatm ents, 
microsomal preparations or enzyme assay, see ’Materials and Methods'.
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increase the enzyme ac tiv ity  in preparations of live r and the small intestine, and 
w ith Ar the increase of enzyme ac tiv ity  was in preparations of live r, stomach 
and upper small intestine. Biphenyl 4-hydroxylase a c tiv ity  increases were 
observed in the same preparations as were the increases in 2 -hydroxylase 
ac tiv ity , but treatm ent o f the ra t w ith PB and MC also increased the 
4-hydroxylase a c tiv ity  in preparations o f caecum/colon.
Ethylmorphine N-demethylase was only detectable in the ra t and fe rre t 
live r microsomal preparations, the enzyme specific a c tiv ity  in the la tte r 
preparation being lower (16%) than tha t in the former (Table 2.4). The various 
animal treatments did not a lte r the specific a c tiv ity  of the ra t hepatic enzyme, 
all the values determined being sim ilar. The lack of increase of the microsomal 
enzyme a c tiv ity  a fte r treating the ra t w ith  PB does not agree w ith  reports in the 
lite ra tu re ; this anomalous result w ill be examined in the discussion.
The 7-ethoxyresorufin Q-deethylase a c tiv ity  was only observed in the 
microsomal preparations of liver and upper small intestine from  untreated rats 
or those pretreated w ith  PB, the small intestine activ ities being approximately 
ha lf o f those in the liver (Table 2.5). A greater increase in enzyme a c tiv ity  
(33-fold) was observed in preparations of liver from rats pretreated w ith  A r than 
in those pretreated w ith  MC (23-fold). The reverse was observed in small 
intestine preparations from the same animals although the enzyme a c tiv ity  
increases were lower than those of the live r. The 7-ethoxyresorufin 
Q-deethylase ac tiv ity  in liver microsomal preparations from the untreated fe rre t 
was less (43%) than that observed in the untreated ra t live r preparation. Also 
pretreatm ent of these animals w ith  MC resulted in a smaller increase of the 
enzyme a c tiv ity  of the fe rre t live r preparation (5-fo ld) than that of the ra t live r 
preparation (23-fold). No 7-ethoxyresorufin O-deethylase a c tiv ity  was detected
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TABLE 2.4
E ffect of administration of inducing agents on the hepatic and 
gastrointestinal tract microsomal mixed-function oxidases in the
rat and ferre t
3. Ethylmorphine N-demethylase
Rat Ferret
Treatment: Control PB MC Ar Control MC
Tissue
nmol product per min per 
mg protein
nmol product per 
min per mg 
protein
Liver 2.89 
+ 0.26
0.84
(29)
2.34
(81)
2.63
(91)
0.46
Stomach
Mucosa NP \MD MO Ni> XiV
Duodenum
Mucosa M> NO No Ho
Jejunum
Mucosa nr Uj> No No rip
Ileum
Mucosa MO No No Hd
Caecum/Colon
Mucosa tty MO Mb liD NO -
The rat control results are the means + SEM of determinations of microsomal 
preparations of the livers from six animals or three microsomal preparations of 
the various sections of the gastrointestinal trac t each of which were made from 
the pooled mucosal cells harvested from the tissues of six animals. A ll the other 
results are determinations of two liver microsomal preparations or one set of 
gastrointestinal microsomal preparations, the la tte r being made from the pooled 
tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as nmol formaldehyde produced per 
min per mg protein. Percentage changes from control values are shown in 
parentheses. ND means that there was no detectable amount of formaldehyde 
was produced, and (-) means that this determination was not carried out. The 
animals were treated with sodium phenobarbitone (PB) (80 mg/kg i.p.), 3- 
methylcholanthrene (MC) (23 mg/kg i.p.), or Aroclor 1254 (Ar) (500 mg/kg i.p.). 
For details of the animal treatments, microsomal preparations or enzyme assay, 
see 'Materials and Methods'.
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TABLE 2.5
E ffec t of administration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal m ixed-function oxidases in the
ra t and fe rre t
4. Ethoxyresorufin O-deethylase
Rat Ferret
Treatment: Control PB MC Ar Control MC
Tissue
pmol product per min per 
mg protein
pmol product per 
min per mg 
protein
Liver 38 
±  ^
37
(97)
864
(2274)
1270
(3342)
16 79
(494)
Stomach
Mucosa
ND ND 5 18 ND ND
Duodenum
Mucosa
17 
+ 1
18
(106)
104
(612)
32
(188)
ND 7
Jejunum
Mucosa
18 
+ 2
20
(1 1 1 )
122
(678)
27
(150)
ND 21
Ileum
Mucosa
4
+ 2
4
(1 0 0 )
99
(2475)
42
(1050)
ND 15
Caecum/Colon
Mucosa ND ND ND ND ND ND
The ra t control results are the means + SEM o f determinations of microsomal
preparations of the livers from six animals or three microsomal preparations of 
the various sections of the gastrointestinal tra c t each o f which were made from  
the pooled mucosal cells harvested from the tissues of six animals. A ll the 
other results are determinations of two live r microsomal preparations or one set 
o f gastrointestinal microsomal preparations, the la tte r being made from  the 
pooled tissue of six rats or two ferre ts. A ll determinations were carried out in 
duplicate. The results are expressed as pmol resorufin produced per min per 
mg protein. Percentage changes from control values are shown in 
parentheses. ND means that there was no detectable amount o f resorufin 
was produced. The animals were treated w ith sodium phenobarbitone (PB) (80 
mg/kg i.p.), 3-methylcholanthrene (MC) (25 mg/kg i.p.), or Aroclor 1254 (Ar) 
(500 mg/kg i.p.). For details of the animal treatments, microsomal preparations 
or enzyme assay, see 'Materials and Methods'.
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in any of the microsomal preparations o f the gastrointestinal trac t from the 
untreated fe rre t or in the preparations of stomach and caecum/colon from the 
untreated ra t. However, treatm ent o f the fe rre t w ith  MC resulted in this 
enzyme ac tiv ity  being detected in the small intestine, and treatm ent of ra t w ith 
MC or A r resulted in this enzyme a c tiv ity  being detected in the stomach 
preparations.
The cytochrome c reductase activ ities  in the preparations of live r, 
duodenum, jejunum, and ileum from  ra t were sim ilar, even a fte r pretreatm ent o f 
animals w ith  the various enzyme inducing agents, and those in the stomach and 
caecum/colon preparations were lower than in the other tissues (Table 2.6). The 
fe rre t liver and stomach reductase activ ities  were lower than in the 
corresponding ra t tissues, whereas the fe rre t and ra t intestine enzyme activ ities  
were sim ilar. Decreases of reductase ac tiv ity  were observed in microsomal 
preparations of the liver and intestine from rats pretreated w ith  PB or MC. 
However, reductase activ ities were observed to increase in live r and decrease in 
ileum and caecum/colon preparations from rats pretreated w ith  A r.
The distribution of protein concentration (Figure 2.1), and the activ ities  of 
7-ethoxyresorufin O-deethylase (Figure 2.4) and cytochrome c reductase 
(Figure 2.5) in microsomal preparations of the gastrointestinal tra c t from  the ra t 
was not uniform . The greater protein concentration and enzyme activ ities  were 
observed in the duodenum and jejunum, followed by that of the ileum and then 
those of the caecum/colon and stomach preparations. The distribution of protein 
concentration (Figure 2.1) and cytochrome c reductase a c tiv ity  (Figure 2.5) in 
the microsomal preparations from the various parts of the gastrointestinal tra c t 
of the untreated fe rre t was sim ilar to that o f the ra t. However, no 
7-ethoxyresorufin O-deethylase a c tiv ity  (Figure 2.4) was observed in the
TABLE 2.6
E ffec t of administration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal m ixed-function oxidases in the
5. Cytochrome c reductase
ra t and fe rre t
Rat Ferret
Treatment: Control PB MC Ar Control MC
Tissue
nmol cytochrome c reduced per min 
per mg protein
Liver 76 
±  9
57 52 
(75) (6 8 )
87
(114)
18 -
Stomach
Mucosa
24 
+ 6
17 17 
(71) (71)
20
(83)
9 -
Duodenum
Mucosa
113 
±  20
99 66 
(87) (58)
109
(76).
84 -
Jejunum
Mucosa
88 
+ 16
53 46 
(60) (52)
67
(76)
75 -
Ileum
Mucosa
61 
+ 3
44 38 
(72) (63)
18
(29)
57 -
Caecum/Colon
Mucosa
20 
+ 6
13 18 
(65) (90)
21
(105)
28
The ra t control results are the means + SEM of determinations of microsomal
preparations of the livers from  six animals or three microsomal preparations of 
the various sections of the gastrointestinal tra c t each of which were made from 
the pooled mucosal cells harvested from  the tissues of six animals. A ll the 
other results are determinations of two live r microsomal preparations or one set 
o f gastrointestinal microsomal preparations, the la tte r being made from  the 
pooled tissue of six rats or two ferre ts. Only one determ ination was carried out 
fo r each sample. The results are expressed as nmol cytochrome c reduced per 
min per mg protein. Percentage changes from control values are shown in 
parentheses. (-) means that this determination was not carried out. The 
animals were treated w ith sodium phenobarbitone (PB) (80 mg/kg i.p.), 3- 
methylcholanthrene (MC) (25 mg/kg i.p.), or Aroclor 1254 (Ar) (500 mg/kg i.p.). 
For details of the animal treatments, microsomal preparations or enzyme assay, 
see 'Materials and Methods'.
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Figure 2.1
Control ra t  and fe r r e t  hepatic and ga s tro in te s t in a l microsomal 
prote in concentrations
The ra t  resu lts  are means o f determinations made on s ix  l i v e r  and three 
sets of g a s tro in te s t in a l microsomal preparations, the bars representing 
S.E.M., w h i ls t  the fe r re t  resu lts  are from two l i v e r  and one set of 
ga s tro in tes t in a l microsomal preparations. L = l i v e r ,  S = stomach,
D = duodenum, J = jejunum, I = ileum, and C = caecum/col on microsomal 
preparations, fo r  d e ta i ls  see 'M ateria ls  and Methods' section.
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Figure 2.2
Hepatic and ga s tro in te s t in a l t ra c t  microsomal biphenyl 2-hydroxylase 
a c t iv i t ie s  in the control ra t  and fe r re t
The ra t resu lts  are means of determinations made on s ix  l i v e r  and three 
sets o f ga s tro in tes t in a l t ra c t  microsomal preparations, the bars 
representing the S.E.M., w h i ls t  the fe r re t  resu lts  are from two l i v e r  
and one set of gas tro in tes t in a l t ra c t  microsomal preparations. L = l i v e r ,  
S = stomach, D = duodenum, J = jejunum, I = ileum, and G = caecum/col on 
microsomal preparations, fo r  d e ta i ls  see 'M ateria ls  and Methods' section.
ND means no detectable amount o f 2-hydroxybiphenyl was produced.
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S D J I 
Fe r re t
Hepatic and g a s tro in te s t in a l t r a c t  microsomal biphenyl 4-hydroxylase 
a c t iv i t ie s  in  the control ra t  and fe r r e t
The ra t  resu lts  are means o f determinations made on s ix  l i v e r  and three 
sets o f ga s tro in tes t in a l t r a c t  microsomal preparations, the bars 
representing the S.E.M., w h i ls t  the fe r re t  resu lts  are from two l i v e r  
and one set of ga s tro in te s t in a l t r a c t  microsomal preparations. L = l i v e r ,  
S = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  d e ta i ls  see 'M ateria ls  and Methods' section.
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Ferret
Hepatic and g a s tro in tes t in a l t ra c t  microsomal ethoxyresorufin O-deethylase 
a c t iv i t ie s  in  the control ra t  and fe r re t
The ra t  resu lts  are means of determinations made on s ix  l i v e r  and three 
sets of ga s tro in te s t in a l t ra c t  microsomal preparations, the bars 
representing the S.E.M., w h i ls t  the fe r re t  resu lts  are from two l i v e r  
and one set o f gas tro in tes t in a l t ra c t  microsomal preparations. L = l i v e r ,  
S = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/col on 
microsomal preparations, fo r  d e ta i ls  see 'M ateria ls  and Methods' section.
ND means tha t no detectable amount o f resoru fin  was produced.
-  8 2  -
120-1
c
E
* o
<u
u
zs
-O
d)
S-
o
CD
E c
O
s - CD
■J= -P
u O
o s_
+J CL
> )
u Ü )
E
o S-
E cu
c CL
60 -
L S S J I G L 
Rat
Figure 2.5
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Hepatic and g a s tro in tes t in a l t ra c t  microsomal cytochrome c reductase 
a c t iv i t ie s  in the control ra t  and fe r re t
The ra t  resu lts  are means o f determinations made on s ix  l i v e r  and 
three sets of ga s tro in te s t in a l t ra c t  microsomal preparations, the 
bars representing w h i ls t  the fe r re t  resu lts  are from two
l i v e r  and one set o f g a s tro in te s t in a l t ra c t  microsomal preparations. 
L = l i v e r ,  S = stomach, D = duodenum, J = jejunum, I = ileum, and 
C = caecum/col on microsomal preparations, fo r  d e ta i ls  see 'M ateria ls  
and Methods' section.
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gastrointestinal tra c t of the untreated fe rre t, and the biphenyl 2 - and 
4-hydroxylase activ ities  (Figures 2.2 and 2.3) in the gastrointestinal tra c t from 
untreated rats and ferrets were not observed to f i t  any defin ite d istribution 
pattern. The general d istribution o f m ixed-function oxidase a c tiv ity  along the 
gastrointestinal tra c t from  ra t and fe rre t was not altered when the animals were 
pretreated w ith  PB, MC or Ar.
DISCUSSION
The results o f prelim inary investigations showed that the method o f
harvesting epithelia l mucosal cells by vibrating everted intestines was superior
^ (
to the method of scraping the mucosal surface of intestines fo r microsomal
preparations. The vibrated everted intestine yielded more epithelia l cells fo r 
microsomal preparation; a measureable amount o f cytochrome P-450 was 
recovered in the microsomal preparations thus produced (this was not so in the 
preparations from  cells harvested by the scrape method), and the activ ities  of 
biphenyl 2- and 4-hydroxylases were greater in preparations from  cells harvested 
by vibrating everted intestines than those from  cells harvested by the scrape 
method. The optimum vibration period fo r harvesting intestinal mucosal 
epithelia l cells was found to be 30 min, although cell counts were d if f ic u lt to 
achieve because of the aggregation caused by the mucus present, which is sim ilar 
to that previously reported (Shirkey, 1977). A validation of this method o f 
intestinal microsomal preparation has been described in the lite ra tu re  (Shirkey, 
1977; Shirkey et al., 1979a). The mucosal epithelia l cells of the stomach were 
collected by the scraping method because the vibration method is not suitable 
fo r this tissue.
The s im ila rities and differences between ra t and fe rre t
The m ixed-function oxidase a c tiv ity  in the liver and gastrointestinal tra c t 
preparation from ra t was observed to be greater than that in the s im ilar tissue
preparation from  fe rre t, except fo r biphenyl hydroxylation (Tables 2.2 and 2.3). 
Contradictory results have been reported in the lite ra tu re ; some workers have 
shown m ixed-function oxidation to be greater in the liver from  the fe rre t than in 
the liver from the ra t (loannides et a l., 1977), and other workers have shown the 
reverse (Lake et al., 1979). The results reported here can be a ttributed to the 
lower body weight o f the ra t, since oxidative metabolism has been shown to vary 
inversely w ith  log body weight (Walker, 1978). The lower concentration of 
protein in the microsomal preparations of the gastrointestinal tra c t compared to 
those of the live r, from  both species, indicates that the gastrointestinal tra c t 
ep ithe lia l cells have a lower microsomal enzyme capacity than those of the live r. 
S im ilarly, the enzyme specific activ ities  were observed to be greater in the 
livers than in the gastrointestinal tracts, from both species, and this agrees w ith  
published reports (Chhabra et al., 1974; Lake et al., 1979). Ethylmorphine 
N-demethylase a c tiv ity  was not detected in the intestine of the ra t, as has been 
previously reported (Chhabra e t al., 1974; Miranda and Chhabra, 1980), or in 
that o f the fe rre t. One major difference between the two species was that no 
ethoxyresorufin O-deethylase ac tiv ity  was detected in the small intestine o f the 
untreated fe rre t; this could be caused by the diet o f the ra t containing more 
natural inducing agents, such as flavanoids (Wattenburg, 1972), than tha t of the 
fe rre t.
D istribution studies of m ixed-function oxidase enzymes along the length of 
the small intestine of a number of species using various substrates, such as 
benzpyrene or aniline, or measuring cytochrome P-450 concentration have shown 
that the highest enzyme a c tiv ity  and cytochrome P-450 concentration occurs in 
the proximal part of the small intestine w ith  a decline towards the caudal end 
(Hietanen and Vainio, 1973; Chhabra, 1979). Although d iffe ren t substrates were 
employed in this investigation, the same distribution of m ixed-function oxidase 
ac tiv ity  was observed along the gastrointestinal tracts from ra t and fe rre t
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(Figures 2.1, 2.3, 2.4 and 2.3). Treatment o f animals w ith PB, MC or A r, did not 
a lte r the distribution of enzyme ac tiv ity  along the gastrointestinal trac t.
S im ilarities and differences between the three d iffe ren t inducing agents
Treatment o f ra t w ith  PB usually results in increased ethylmorphine 
N-demethylase ac tiv ity  in the liver, although MC and Ar may have only minor 
inductive effects (Alvares et al., 1973; L itte rs t and Van Loon, 1974; Miranda 
and Chhabra, 1980). S im ilarly hepatic cytochrome c reductase ac tiv ity  is 
increased a fte r treating rats w ith  PB or polychlorinated biphenyls, sim ilar to Ar, 
but l it t le  increase in a c tiv ity  is observed a fte r treating rats w ith  MC (Kohli et 
al., 1980; Parkinson et al., 1981). Therefore the decreases in ethylmorphine 
N-demethylase (Table 2.4) and cytochrome c reductase (Table 2.6) activ ities 
observed a fte r treatm ent of rats w ith  PB or Ar are anomalous results. However, 
the e ffe c t of PB treatm ent of rats on the other enzyme activ ities  (Tables 2.2, 
2.3 and 2.5) and on UDP-glucuronyltransferase activ ities  (Chapter 3) in the live r 
agreed w ith  the published reports (Lake et al., 1973; Bock et al., 1979; Kohli et 
al., 1980). The anomalous results observed in this investigation could be 
a ttributed to lower s tab ility  of ethylmorphine N-demethylase and cytochrome c 
reductase activ ities during storage at ~40°C overnight, to natural variation 
because only two ra t livers were assayed for enzyme ac tiv ity , or to some error 
in experimental procedure. The exact cause of these anomalous results was not 
determined.
Although no simple pattern of. enzyme induction was observed in the live r 
and gastrointestinal tra c t from ra t a fte r pretreatment w ith PB, MC or A r, the 
inducing agents produced d iffe ren t effects in the preparations of the two tissues. 
The order of inducing agent a ffec t on cytochrome P-448-related m ixed-function 
oxidation (Tables 2.2 and 2.5) in the ra t liver was A r > MC > PB, whereas in the 
ra t small intestine MC > Ar > PB. However, the order of inducing agent a ffec t
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on biphenyl 4-hydroxylase ac tiv ity , related to both cytochrome P-450 and P-448 
m ixed-function oxidations in the ra t live r was Ar > PB > MC, whereas that in the 
ra t small intestine was MC > PB > Ar. This is fu rther evidence that the 
pretreatment o f rats w ith  inducing agents affects the m ixed-function oxidase 
enzymes of the live r and intestine in a d iffe ren t manner, as previously reported 
(Miranda and Chhabra, 1980).
In conclusion, i t  appears that both cytochrome P-450-related and 
cytochrome P-448-related m ixed-function oxidase a c tiv ity  occurs in livers from  
both ra t and fe rre t and cytochrome P-448-related m ixed-function oxidase 
ac tiv ity  occurs in the small intestine of the ra t. Less m ixed-function oxidation 
occurs in the gastrointestinal tra c t from  the fe rre t than in that from the ra t. 
The biochemical characteristics of m ixed-function oxidation in the 
gastrointestinal tra c t are sim ilar to those in the live r fo r both ra t and fe rre t. 
However, the results indicate that the mechanism of regulation of mixed- 
function oxidation in the gastrointestinal tra c t d iffers from that in the live r.
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Chapter 3
Comparison of the UDP-glucuronyltransferase activity 
in the liver and gastrointestinal tract 
of the rat and ferret
INTRODUCTION
Uridine diphosphate (UDP)-glucuronyltransferase catalyses the transfer o f 
glucuronic acid from  a donor molecule, usually uridine diphosphate but can be a 
conjugate, to an acceptor molecule (Dutton, 1966; Berry and Hallinen, 1974). 
This enzyme is located in the endoplasmic reticulum  of the liver, gastrointestinal 
tra c t and a number of other mammalian tissues (Dutton and Burchell, 1975). The 
livers from  ra t and rabbit have been shown to possess a closely related fam ily  of 
d iffe ren t forms of UDP-glucuronyltransferase (Burchell, 1981) whose activ ities  
towards various substrates d iffers. In ra t the live r microsomal UDP- 
glucuronyltransferase activ ities  towards various substrates have been classified 
into groups on the basis of the ir inducib ility  by xenobiotic inducing agents (Bock 
et al., 1983). 'Group-1' activ ities  are mainly inducible by 3-methylcholanthrene 
(3- to 6 -fo ld ) and 'group-2' activ ities are mainly inducible by phenobarbitone (2- 
to 5-fo ld) (Bock et al., 1979). The group-1 substrates are mostly planar phenols 
and include l-naphthol, 4-nitrophenol, 4-methylumbelliferone, and 2 -aminophenol 
amongst others whereas group-2  substrates are non-planar phenols and include 
morphine and 4-hydroxybiphenyl amongst others. Another group of substrates 
can be distinguished because their glucuronylation is only moderately a ffected by
3-methylcholanthrene and phenobarbitone (less than 2-fo ld induction occurs) and 
it  includes oestrone, phenolphthalein, and paracetamol (Lilienblum et al., 1982).
UDP-glucuronyltransferase ac tiv ity  in various subcellular enzyme 
preparations, such as homogenate, microsomal supernatant or microsomal 
preparations, can be increased 160-830% (Burchell et al; 1976) by treating  the 
preparation w ith  neutral or anionic detergents, sonication, or freeze-thawing 
amongst other agents (Dutton and Burchell, 1975). Only a fraction of the to ta l 
enzyme a c tiv ity  is expressed in fresh, untreated, or native enzyme preparations. 
Therefore there is some unexpressed or latent enzyme a c tiv ity  in native enzyme 
preparations. In order to estimate the to ta l UDP-glucuronyltransferase a c tiv ity ,
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the enzyme preparation is usually treated w ith  an agent, such as a neutral or 
anionic detergent, under conditions which produce the maximum ac tiv ity  o f the 
enzyme. This treatm ent of an enzyme preparation is called activation which is 
defined as 'an increase in enzyme a c tiv ity  under conditions precluding enzyme 
synthesis and d irectly  re flecting  change in ac tiv ity  of pre-formed molecules 
whose ca ta ly tic  power is partia lly  or wholly unexpressed' (Dutton and Burchell, 
1975).
There have been numerous reports that the UDP-glucuronyltransferase 
ac tiv ity  of the small intestine of ra t, rabbit and mouse, using 4-nitrophenol as 
substrate w ith  homogenate or microsomal supernatant enzyme preparations, was 
greater than that of the live r fo r both native and activated enzyme (A itio  et al., 
1972; Hietanen and Vainio, 1973; Del V illa r et al., 1974; Hietanen, 1977; 
Koivusaari et al., 1980). However, live r UDP-glucuronyltransferase a c tiv ity  has 
been shown to be greater than that in the small intestine of the guinea pig and 
mouse, using 4-nitrophenol as substrate, and in that o f the ra t and fe rre t using 1- 
naphthol as substrate, and in that o f the ra t using 4-methylumbelliferone as 
substrate (A itio , 1974; Hietanen and Vainio, 1976; Lake et al., 1979; Bock et al., 
1980). Pretreatm ent o f the ra t w ith  phenobarbitone (PB) or l, l, l- tr ic h lo ro -2 ,2 ~  
bis(p-chlorophenyl)ethane (DDT) produced no observable increase in native 
hepatic 4-nitrophenol glucuronyltransferase a c tiv ity , but increases in activated 
enzyme levels have been reported (Vainio, 1974; Dutton, 1975; Hietanen, 1980). 
Pretreatment of rats w ith 3-methylcholanthrene (MC), 3,4-benzpyrene, 2,3,7,8- 
tetrachlorodibenzo-p-dioxin (TCCD), or Aroclor 1254 (Ar) has been observed to 
increase live r and gastrointestinal tra c t UDP-glucuronyltransferase activ ities  in 
native and activated preparations using 4-nitrophenol or l-naphthol as substrates 
(A itio  et al., 1972; Lake et al., 1979; Schiller, 1979; Hietanen, 1980). However, 
pretreatm ent o f rats w ith  CCl^, or CCl^ and PB, increased the a c tiv ity  o f 4- 
nitrophenol glucuronyltransferase in the live r whilst the enzyme level in the 
duodenum decreased (Koivusaari et al., 1980).
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The distribution of UDP-glucuronyltransferase along the gastrointestinal 
tra c t has been investigated in the rabbit, ra t, mouse, guinea pig and cat, using 4- 
nitrophenol as substrate, and in the ra t using 2 -aminophenol as substrate 
(Hanninen et al., 1968; Hietanen and Vainio, 1973; Hietanen, 1974). The 
activated enzyme level was highest in the duodenum and then progressively 
declined along the intestine towards the aboral end un til the caecum, the 
stomach and colon enzyme levels being sim ilar to those in the ileum and jejunum, 
respectively.
The object o f this investigation, therefore, was to study the comparative 
roles of the liver and various sections of the gastrointestinal tra c t in drug 
metabolism, using microsomal UDP-glucuronyltransferase(s) and the mixed- 
function oxidases (see Chapters 2 and 7) as parameters of metabolism in the ra t 
and fe rre t. A ll previous studies of UDP-glucuronyltransferase a c tiv ity  along the 
gastrointestinal tra c t have used 4-nitrophenol or 2-aminophenol as the substrate 
w ith  homogenate or microsomal supernatant enzyme preparations. This study 
set out to measure the a c tiv ity  o f this enzyme in microsomal preparations using 
three 'group-1' substrates, namely: 4-nitrophenol, l-naphthol, and 4-
methylumbelliferone.
MATERIALS AND METHODS
Materials
Brij 33, 8-glucuronidase (E.Coli, bacterial type II, E.C. No. 3.2.1.31), a- 
naphthol (grade III), 3-methylcholanthrene (practical grade), and uridine 5'- 
diphosphoglucuronic acid (ammonium salt) were obtained from Sigma Chemical 
Co., Poole, Dorset, U.K.; sodium phenobarbitone and 4-nitrophenol from BDH 
Chemicals L td., Poole, Dorset, U .K.; 4-methylumbelliferone and 1-naphthyl-B-D- 
glucuronide (sodium salt, pure AR) from Koch Light Laboratories L td ., 
Colnbrook, Bucks., U.K.; and Aroclor 1234 from Monsanto Chemical Co., St. 
Louis, Michigan, U.S.A.
A ll other chemicals and solvents used were of Analar grade.
Animals and Experimental Procedures
Animal pre-treatm ent
Male Wistar albino rats (200-340 g) bred at the University o f Surrey, and 
male albino ferre ts, mustela putorius furo (1 .0 - 1 .7 kg), obtained from Froxfie ld  
Rabbit Farm, Petersfield, Hants., were used in this study. Food and water were 
available to the animals ad lib itum .
Phenobarbitone (80 mg/kg) in d istilled water (55 mg/m l), or 3- 
methylcholanthrene (25 mg/kg) in corn o il (5 or 10 mg/ml) was injected in tra - 
peritoneally every 24 h for three successive days, the animals being killed on the 
fourth day. Aroclor 1254 (500 mg/kg) was given in corn o il (500 mg/m l) in tra - 
peritoneally on day 1 , the animals being killed on day 6 .
Experimental procedures
Preparation o f ra t and fe rre t hepatic and gastrointestinal tra c t mucosal cell 
microsomes (Shirkey, 1977; Shirkey et al., 1979a - modified).
See Chapter 2, Materials and Methods, Experimental procedures section.
Assays
1-Naphthol glucuronyltransferase determination (Bock, 1974)
The incubation m ixture consisted of:
25 mM UDPGA in 0.25 M Tris-HCl buffer
pH 7.6 at 37°C 0.2 ml
25 mM MgCl^ in 0.5% (v/v) aqueous B rij 35 0.1 ml
microsomal suspension 0 .1  ml
2 mM l-naphthol in 0.1 M Tris-HC l buffer
pH 7.6 at 37UC 0.1 ml
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The uridine diphosphoglucuronic acid (UDPGA) was om itted from the blanks and 
standards, the amount of buffer added being adjusted to maintain a constant 
to ta l volume o f 0.5 ml. Blank and standard assays were carried out fo r both 
hepatic and gastrointestinal tra c t microsomal preparations. The live r 
microsomal suspensions were diluted 1 in 10 for a ll the determinations. Each 
determination was carried out in duplicate.
A pre-incubation period of 5 min. was carried out at 37°C in a M ickle 
shaking water bath prior to the addition of substrate. A fte r a fu rthe r incubation, 
w ith  substrate, o f 4 min., the reaction was term inated by addition o f 1.0 m l ice- 
cold 0.5 M g lycine-trich loroacetic acid bu ffe r pH 2.2 followed by plunging the 
tubes into ice. The substrate was added to the blank and standard tubes, which 
also had the addition of standard solution (10 ul o f 1 mM 1-naphthol glucuronide) 
a fte r the incubation. The addition of 6 ml chloroform to each tube was carried 
out before storing them at -15°C. The incubation m ixture was extracted w ith  
chloroform for 15 min. on a ro tary extractor at room temperature, followed by 
centrifugation at 1500 g fo r 15 min. at 40C in a Beckman J6 centrifuge. A 
1.0 ml aliquot o f the aqueous layer was added to 1.0 ml of 1 M glycine-NaOH 
buffer pH 10.6.
The amount of 1-naphthol glucuronide fluorescence in each tube was 
measured at 334 nm w ith  an excitation wavelength o f 303 nm in a Perkin-E lm er 
MFP3 spectrofluorieter, the fluorescence of 1-naphthol did not in terfere  at these 
wavelengths. The specific a c tiv ity  o f the enzyme in the various tissue 
preparations was then calculated.
4-Nitrophenol glucuronyltransferase determ ination (Hollman and Touster, 1962)
The incubation m ixture consisted of:
30 mM UDPGA in 0.5 M Tris-HCl buffer
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pH 7.4 at 37°C 0.10 ml
0.5 M Tris-HC l bu ffe r pH 7.4 at 37°C
in 0.43% (v/v) 9 r ij 35 0.14 ml
microsomal suspension 0.30 ml
1.7 mM 4-nitrophenol in 0.1 M Tris-HCl
buffer pH 7.4 at 37°C 0.06 ml
The 4-nitrophenol was om itted from the blanks, as was the UDPGA from the 
blanks and standards; the amount of buffer was therefore adjusted in these tubes 
to maintain a constant to ta l volume of 0.6 ml. The live r microsomal suspensions 
were diluted 1 in 10 fo r a ll determinations. Each determination was carried out 
in duplicate.
A pre-incubation period of 5 min was carried out, w ithout the UDPGA 
solution, at 37°C in a Mickle shaking water bath . A fu rthe r incubation, w ith  
UDPGA solution, of 4 min in the control experiments, or 3 min in the 
experiments using tissue preparations from  pre-treated animals, was term inated 
by the addition of 2.4 ml ice-cold 0.1 M trich loroacetic acid followed by plunging 
the tubes into ice. The tubes were then stored at -15°C overnight. A fte r the 
addition of 0.06 ml 10 M KOH, the tubes were centrifuged at 1300 g fo r 20 min 
at 4°C in a Beckman J6 centrifuge.
The absorbance of the supernatant in each tube was measured at 400 nm in 
a Pye-Unicam SP 500 spectrophotometer, the reduction o f absorbance from  tha t 
o f the standard was taken to be the amount of 4-nitrophenol conjugated w ith  
glucuronic acid, the specific activ ities  of the enzyme were consequently 
calculated for each tissue preparation.
4-Methylumbelliferone glucuronyltransferase determination (A itio , 1974 
modified)
The incubation m ixture consisted of:
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25 mM UDPGA in 0.1 M Tris-HC l buffer pH 7.0 
at 37°C 0.1 ml
0.TM  Tris-HC l bu ffe r pH 7.0 at 37°C in 0.5% 
(v/v) B rij 35 0 .1  ml
microsomal suspension 0 .2  ml
0.1 mM 4-methylumbelliferone in aqueous 
solution 0 .1  ml
The UDPGA solution was om itted from the blank and standard determ inations, 
the amount of buffer being adjusted to maintain a constant to ta l volume of
0.5 ml. The liver microsomal suspensions were diluted 1 in 10 fo r a ll 
determinations. Blank and standard assays were carried out fo r both live r and 
gastrointestinal tra c t microsomal preparations. Each determ ination was carried 
out in duplicate.
oA pre-incubation period of 5 min was carried out at 37 C in a M ickle 
shaking water bath prior to the addition of substrate, which was stored at 37°C 
in the dark. A further incubation, w ith  substrate, o f 4 min in contro l 
experiments, or 2 min in experiments using tissue preparations from  pre treated 
animals, was term inated by the addition of 5.0 ml chloroform  followed by 
plunging the tubes into ice. The substrate was then added to the blanks and 
standards, a fte r which 5.0 ml o f 0.1 M Tris-HC l buffer pH 7.0 at 37°C was added 
to each tube before storing them at -15°C overnight. The incubation m ixture 
was then extracted w ith  chloroform on a rotary extractor fo r 15 min at room 
temperature and centrifuged at 1500 g fo r 15 min at 4°C. A fte r removing the 
chloroform, the extraction was repeated, tw ice, using fresh solvent under the 
same conditions. The addition of 0.1 ml of the 4-m ethylum belliferone solution
- 95 -
to the standard tubes and 1.5 ml o f 0.1 M buffer containing 100 units
0-glucuronidase to each tube was followed by an overnight incubation at 37°C in 
the shaking water bath.
A fte r cooling the tubes to room temperature, 1.0 ml o f 1.6 M glycine- 
NaOH buffer pH 10.35 was added to each solution. The fluorescence of 
4-m ethylum belliferone was measured at 450 nm using an excitation wavelength 
o f 370 nm in a Perkin-Elmer MFP3 spectrofluorim eter.
The amount o f 4-m ethylum belliferone measured was taken to be the 
amount of glucuronide formed during the incubation and hence the enzyme 
specific ac tiv ity  fo r each tissue preparation was determined.
Microsomal protein determination (Lowry et al., 1951)
See Chapter 2, Materials and Methods, Experimental procedures section.
Enzyme tim e course studies and investigations of the enzyme a c tiv ity  w ith  
respect to the protein content of the assays were carried out to ensure tha t each 
determination was in the linear phase of product formation and tha t relevant 
standard concentrations were used. The activated enzyme a c tiv ity  w ith  respect 
to detergent concentration of the assay was also investigated to ensure tha t 
optimum enzyme activation conditions were used. More than 95% of the fresh 
activated microsomal UDP-glucuronyltransferase a c tiv ity  was retained a fte r 
storing the microsomal pellets overnight at -40°C.
The UDP-glucuronyltransferase assays were carried out on the same 
microsomal preparations and on the same day as the m ixed-function oxidase 
determinations (see Chapter 2). The assays were always carried out in the same
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order to enable comparison of the results from d iffe ren t experiments. The 
concentration of B rij 35 in the three assays was the same, and the concentration 
of UDPGA was the same fo r the assays w ith  4-nitrophenol and 
4-m ethylum belliferone as substrates; the UDPGA concentration fo r the 
1 -naphthol glucuronyltransferase assay was tw ice that of the other two assays 
but this was found not to a ffe c t the enzyme ac tiv ity  w ith  1 -naphthol as 
substrate.
RESULTS
Glucuronylation o f 1-naphthol, 4-nitrophenol, and 4-m ethylum belliferone 
occurs in the hepatic and gastrointestinal tra c t microsomal preparations from 
ra t and fe rre t (Tables 3.1, 3.2 and 3.3). However, fo r a given substrate the 
specific a c tiv ity  o f the UDP-glucuronyltransferase varies between d iffe ren t 
tissue preparations of the same species or between sim ilar tissues of the two 
species. Also d iffe ren t rates of glucuronylation were observed fo r  each 
substrate by the same tissue preparation.
S im ilarities and differences between ra t and fe rre t
With 1-naphthol (Table 3.1), 4-nitrophenol (Table 3.2), and 
4-methylum belliferone (Table 3.3) as substrates, UDP-glucuronyltransferase 
a c tiv ity  was observed to be greater in live r and gastrointestinal tra c t 
preparations from  ra t than in those from  fe rre t. Although there were increases 
in glucuronylation o f 1-naphthol and 4-nitrophenol by the livers and 
gastrointestinal tracts from both species a fte r they had been pretreated w ith  
MC, the enzyme of the fe rre t was less sensitive to induction than that of the ra t. 
With the three substrates the specific ac tiv ity  of UDP-glucuronyltransferase was 
generally greater in the livers than in the gastrointestinal tracts from  both 
species, whether treated or untreated animals. However, the glucuronylation of
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TABLE 3.1
E ffec t o f administration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal UDP-glucuronyltransferase in the
ra t and fe rre t
1. 1-Naphthol glucuronyltransferase
Rat Ferret
Treatment: Control PB MC Ar Control MC
nmol glucuronide produced per min per mg protein
Tissue
Liver 60 + 6 100 161 571 24 37
(167) (268) (952) (154)
Stomach 3.4 + 1.6 4.4 25 35 0.4 0.4
Mucosa (129) (735) (1029) (1 0 0 )
Duodenum 79 + 9 86 133 292 2.6 3.9
Mucosa (109) (168) (370) (150)
Jejunum 60 + 6 45 108 143 3.4 5.0
Mucosa (75) (180) (238) (147)
Ileum 45 + 11 33 102 98 6 .2 5.0
Mucosa (75) (232) (223) (81)
Caecum/Colon 13 + 7 6 23 25 2.3 4.0
Mucosa (46) (177) (192) (174)
The ra t control results are the means + SEM of determinations of microsomal 
preparations of the livers from  six animals or three microsomal preparations of 
the various sections of the gastrointestinal tra c t each of which were made from  
the pooled mucosal cells harvested from the tissues of six animals. A ll the 
other results are determinations of two live r microsomal preparations or one set 
o f gastrointestinal microsomal preparations, the la tte r being made from  the 
pooled tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as nmol 1-naphthol glucuronide produced 
per min per mg protein. Percentage changes from control values are shown in 
parentheses. The animals were treated w ith  sodium phenobarbitone (PB) (80 
mg/kg i.p.), 3-methylchoianthrene (MC) (23 mg/kg i.p.), or Aroclor 1254 (Ar) 
(500 mg/kg i.p.). For details of the animal treatments, microsomal preparations 
or enzyme assay, see 'Materials and Methods'.
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TABLE 3.2
E ffec t of adm inistration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal UDP-glucuronyltransferase in the
ra t and fe rre t
2. 4-Nitrophenol glucuronyltransferase
Rat Ferret
Treatment: Control PB MC Ar Control MC
nmol glucuronide produced per min per mg protein
Tissue
Liver 23 + 1.0 36
(157)
47
(2 0 1 )
69
(299)
4 6
(150)
Stomach
Mucosa
9 + 3.0 14
(156)
14
(156)
10
(119)
2 7
(350)
Duodenum
Mucosa
15 + 1.0 28
(187)
23
(153)
19
(127)
7 8
(114)
Jejunum
Mucosa
9 + 1.0 11
(1 2 2 )
16
(179)
10
(118)
3 4
(133)
Ileum
Mucosa
7 + 0.1 7
(1 0 0 )
16
(229)
9
(129)
- 5
Caecum/Colon
Mucosa
31 + 17.0 103
(332)
11
(35)
49
(158)
7 8
(114)
The ra t control results are the means + SEM o f determinations of microsomal 
preparations of the livers from  six animals or three microsomal preparations of 
the various sections o f the gastrointestinal tra c t each o f which were made from 
the pooled mucosal cells harvested from  the tissues of six animals. A ll the 
other results are determinations of two live r microsomal preparations or one set 
o f gastrointestinal microsomal preparations, the la tte r being made from  the 
pooled tissue of six rats or two ferrets. A ll determinations were carried out in 
duplicate. The results are expressed as nmol 4-nitrophenol glucuronide 
produced per min per mg protein. Percentage changes from control values are 
shown in parentheses. (-) means that this determination was not carried out. The 
animals were treated w ith  sodium phenobarbitone (PB) (80 mg/kg i.p.), 3- 
methylcholanthrene (MC) (23 mg/kg i.p.), or Aroclor 1254 (Ar) (500 mg/kg i.p.). 
For details o f the animal treatments, microsomal preparations or enzyme assay, 
see 'M a te r ia ls  and M ethods '.
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TABLE 3.3
E ffe c t of administration of inducing agents on the hepatic and 
gastrointestinal tra c t microsomal UDP-glucuronyltransferase in the
ra t and fe rre t
3. 4-Methylumbelliferone glucuronyltransferase
Rat Ferre t
Treatment: Control PB MC Ar Control MC
nmol glucuronide produced per min per mg protein
Tissue
Liver 126 + 18 87 176 239 32
(69) (140) (190)
Stomach 10 + 2 9 36 32 2
Mucosa (90) (360) (324)
Duodenum 37 + 2 44 55 60 11
Mucosa (119) (149) (163)
Jejunum 24 + 3 20 49 37 10
Mucosa (87) (204) (154)
Ileum 37 + 10 27 65 38 14
Mucosa (73) (176) (103)
Caecum/Colon 43 + 6 51 46 71 11
Mucosa (119) (107) (165)
The ra t control results are the means + SEM of determinations o f microsomal 
preparations of the livers from  six animals or three microsomal preparations of 
the various sections of the gastrointestinal tra c t each of which were made from  
the pooled mucosal cells harvested from  the tissues of six animals. A ll the 
other results are determinations of two liver microsomal preparations or one set 
o f gastrointestinal microsomal preparations, the la tte r being made from  the 
pooled tissue of six rats or two ferre ts. A ll determinations were carried out in 
duplicate. The results are expressed as nmol 4-m ethylum belliferone 
glucuronide produced per min per mg protein. Percentage changes from  contro l 
values are shown in parentheses. (-) means tha t this determ ination was not 
carried out. The animals were treated w ith sodium phenobarbitone (PB) (80 
mg/kg i.p.), 3-methylcholanthrene (MC) (23 mg/kg i.p.), or A roclor 1254 (Ar) 
(300 mg/kg i.p.). For details of the animal treatments, microsomal preparations
n r  p n 7 v m a  a r r a v .  r p a  ' M a ^ p t i a I r  a h H  M p t ' h n H R 1.
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1 -naphthol in the duodenum from  the untreated ra t was greater than that o f the 
live r; a fte r treating the ra t w ith  PB, MC or A r, this was reversed (Table 3.1).
The d istribution of UDP-glucuronyltransferase a c tiv ity  along the 
gastrointestinal tracts from the ra t and fe rre t d iffered. The highest enzyme 
a c tiv ity  occurred in the proximal part o f the small, intestine from the ra t, and 
the a c tiv ity  progressively declined along the gastrointestinal tra c t towards the 
aboral end (Figures 3.1, 3.2 and 3.3). Glucuronylation a c tiv ity  in the stomach 
was sim ilar to that in the caecum/colon. However, the highest enzyme a c tiv ity  
occurred in the ileum from  the fe rre t w ith  a progressive decline along the 
gastrointestinal tra c t towards the oral and towards the aboral ends (Figures 3.1, 
3.2 and 3.3). I f  the enzyme activ ités are expressed per mg microsomal protein 
(Figures 3.4, 3.5 and 3.6) instead of per g tissue, only the distribution of UDP- 
glucuronyltransferase a c tiv ity  towards 1 -naphthol along the gastrointestinal 
tracts o f the ra t and fe rre t follows these patterns.
The glucuronylation of 4-methylum belliferone by the live r microsomal 
preparations from  the untreated ra t and untreated fe rre t was greater than tha t 
o f 1-naphthol, which was greater than that o f 4-nitrophenol. However, the 
UDP-glucuronyltransferase a c tiv ity  in the intestine from  the untreated ra t was 
greatest towards 1-naphthol, and that towards 4-m ethylum belliferone was 
greater than that towards 4-nitrophenol. This was also d iffe ren t from  the fe rre t 
intestine which had UDP-glucuronyltransferase activ ities  towards
4-m ethylum belliferone greater than towards 4-nitrophenol, which were greater 
than the activ ities towards 1 -naphthol.
S im ilarities and differences between the three inducing agents
Treatment of the ra t w ith PB had l it t le  e ffec t on the glucuronylation of 
the three substrates of this study, except the UDP-glucuronyltransferase a c tiv ity
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Figure 3. 1
Hepatic and g a s tro in te s t in a l t ra c t  microsomal 1-naphthol g lucuronyl­
transferase levels in the control ra t  and fe r re t
The ra t  resu lts  are means o f determinations made on s ix  l i v e r  and 
three sets of g a s tro in te s t in a l microsomal preoarations, the bars 
representing S.E.M., w h i ls t  the fe r re t  re su lts  are from two l i v e r  
and one set of g a s tro in te s t in a l microsomal preparations. L = l i v e r ,
5 = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  d e ta i ls  see 'M ateria ls  and Methods' 
section.
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Figure 3.2
Hepatic and gas tro in tes t ina l t ra c t  microsomal 4-nitrophenol g lucuronyl­
transferase levels in the control ra t and fe r re t
The ra t resu lts  are means of determinations made on s ix  l iv e r  and 
three sets of ga s tro in tes t ina l microsomal preparations, the bars 
representing S.E.M., w h ils t  the fe r re t  resu lts  are from two l iv e r  
and one set of ga s tro in tes t ina l microsomal preparations. L = l iv e r ,
S = stomach, D = duodenum, J = Jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  d é ta i ls  see 'Materia ls and Methods' 
section.
a = This determination was not carried out.
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Figure 3.3
Hepatic and gas tro in tes t ina l t ra c t  microsomal 4-methylumbelliferone 
glucuronyltransferase levels in the control ra t and fe rre t"
The ra t  resu lts  are means of determinations made on s ix  l i v e r  and 
three sets of ga s tro in tes tina l microsomal preoarations, the bars 
representing S.E.M., w h ils t  the fe r re t  resu lts  are from two l iv e r  
and one set of ga s tro in tes t ina l microsomal preparations. L = l i v e r ,
S = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  d e ta i ls  see 'Materia ls and Methods' 
section.
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Hepatic and gastro in testina l t ra c t  microsomal 1-naphthol g lucuronyl­
transferase levels in the control ra t and fe r re t  '
The ra t results  are means of determinations made on s ix  l iv e r  and 
three sets of gastro in tes tina l microsomal preparations, the bars 
representing S.E.M., w h ils t the fe r re t  resu lts  are from two l iv e r  
and one set of gastro in testina l microsomal oreparations. L = l iv e r ,
S = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  de ta ils  see 'Materials and Methods' 
section.
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Hepatic and gastro in testina l t ra c t  microsomal 4-nitrophenol glucuronyl 
transferase levels in the control ra t and fe r re t
The ra t  results are means of determinations made on s ix  l iv e r  and 
three sets of gastro in testina l microsomal preoarations, the bars 
representing S.E.M., whils t the fe r re t  results  are from two l iv e r  
and one set of gas tro in testina l microsomal preparations. L = l iv e r ,
S = stomach, D = duodenum, J = jejunum, I .= ileum, and C = caecum/colon 
section.
a = This determination was not carried out.
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Figure 3 .6
Hepatic and ga s tro in tes t ina l t ra c t  microsomal 4-methylumbel11 ferone 
glucuronyltransferase levels in  the control ra t and fe r re t
The ra t  resu lts  are means of determinations made on s ix  l i v e r  and 
three sets of ga s tro in tes t in a l microsomal preparations, the bars 
representing S.E.M., w h ils t  the fe r re t  resu lts  are from two l i v e r  
and one set of gas tro in tes t in a l microsomal preparations. L = l iv e r ,
5 = stomach, D = duodenum, J = jejunum, I = ileum, and C = caecum/colon 
microsomal preparations, fo r  d e ta i ls  see 'Materials and Methods' 
section.
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towards 1 -naphthol of the liver microsomal preparation was increased and that 
o f the caecum/colon preparation was decreased (Table 3.1). Small increases of 
enzyme a c tiv ity  w ith  4-nitrophenol as substrate were observed in live r, stomach, 
duodenum and caecum/colon preparations from  ra t pretreated w ith  PB. 
However, adm inistration of MC or A r to the ra t produced increases in enzyme 
ac tiv ity  o f all the preparations w ith  the three substrates. Although MC and A r 
produced sim ilar e ffects on the enzyme activ ities of the various tissue 
preparations w ith  4-nitrophenol and 4-m ethylum belliferone as substrates, w ith
1-naphthol as substrate pretreatm ent of the ra t w ith  A r produced much greater 
increases in enzyme a c tiv ity  than that w ith  MC.
DISCUSSION
The major c ritic ism  of the methods of assay used in this investigation was 
tha t 6 -glucuronidase a c tiv ity  in the gastrointestinal tra c t microsomes could 
have reduced the specific activ ities of the UDP-glucuronyltransferase (Dutton, 
1966; Dutton and Burchell, 1975). Other workers have shown tha t 
6 -glucuronidase a c tiv ity  did not a ffe c t the measurement o f UDP- 
glucuronyltransferase a c tiv ity  towards 4-nitrophenol, 4-m ethylum belliferone, or
2 -aminophenol in sim ilar tissue preparations from  the same strain o f ra t 
(Hanninen et al., 1968; A itio , 1974). Therefore, although this c ritic ism  is valid 
i t  was not thought to invalidate the results.
UDP-glucuronyltransferase a c tiv ity  in the liver and intestine from ra t
A wide variety o f substrates, including 1-naphthol and 
4-m ethylum belliferone, have been used to measure UDP-glucuronyltransferase 
ac tiv ity  in the live r and intestine from ra t, and the specific a c tiv ity  o f the live r 
enzyme has been observed to be greater than that of the intestine (A itio , 1974; 
Bock et al., 1980). With 4-nitrophenol as substrate the reverse has been 
observed (Hanninen et al., 1968; A itio  et al., 1972; Koivusaari et al., 1980). In
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this study glucuronylation of 1 -naphthol was greater in the duodenum than in the 
liver (Table 3.1), and glucuronylation of 4-nitrophenol was greater in the live r 
than in the small intestine (Table 3.2); these results contrast w ith those reported 
by other workers. The a c tiv ity  of the liver enzyme towards 1-naphthol observed 
in this study was sim ilar to that in published reports (Bock et al., 1979). Also the 
only difference between the methods used in this study and those used by other 
workers was the procedure used to prepare the microsomal fraction  from  
intestinal mucosal ep ithe lia l cells. The reason fo r the higher enzyme a c tiv ity  
towards 1 -naphthol in the small intestine observed in this study could therefore 
be a ttributed to the method of microsomal fraction preparation. The UDP- 
glucuronyltransferase ac tiv ity  towards 4-nitrophenol in live r microsomal 
preparations from  untreated rats observed in this study (Table 3.2) agreed w ith  
that reported by certain workers (Burchell, 1977; Bock et al., 1979; Bock et al., 
1983). Furthermore the enzyme activ ities of the intestinal preparations from  ra t 
observed in this study agreed w ith enzyme activ ities  previously reported 
(Hietanen and Vainio, 1973). However, some workers (Hanninen et al., 1968) 
report that 4-nitrophenol glucuronyltransferase a c tiv ity  in intestine preparations 
from ra t is greater than that in liver preparations. I t  would seem from the 
present study, confirmed by other workers (Bock et al, 1979), tha t these workers 
(Hanninen et al, 1968; A itio  et al, 1972; Koivusaari et al, 1980) have 
underestimated the ac tiv ity  of the hepatic enzyme.
D istribution of UDP-glucuronyltransferase a c tiv ity  along the gastrointestinal 
trac t from ra t
The ac tiv ity  of UDP-glucuronyltransferase towards 2-aminophenol and 
4-nitrophenol has been shown to decrease along the small intestine. The 
enzyme ac tiv ity  in the stomach was observed to be sim ilar to that in the lower 
small intestine, but that in the colon, especially w ith  4-nitrophenol as substrate, 
was sim ilar to that in the upper small intestine (Hanninen et al., 1968; Hietanen
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et al., 1972; Hietanen and Vainio, 1973). The pattern of d istribution o f the 
enzyme a c tiv ity  towards 1-naphthol (Figure 3.1) and 4-nitrophenol (Figure 3.2) 
agrees w ith  the published reports. With 4-m ethylum belliferone (Figure 3.3) as 
substrate the pattern of enzyme a c tiv ity  was disturbed by an enzyme a c tiv ity  in 
the ileum which was higher than those observed w ith the other substrates. 
However, the protein concentrations of the various gastrointestinal tra c t 
microsomal preparations varied widely (Chapter 2). Expression o f the enzyme 
activ ities as nmol product/m in/mg protein (Figures 3.4, 3.3 and 3.6) gave a 
better indication of enzyme a c tiv ity  d istribution along the gastrointestinal trac t. 
The significance o f this pattern of enzyme a c tiv ity  d istribution is not clear. 
Because these enzymes are sensitive to inducing agents, and because the 
m ajority o f nutrients and anutrients are absorbed in the upper small intestine 
(Wagner, 1961), i t  may be that the a c tiv ity  o f this enzyme in the gastrointestinal 
tra c t is related to the amount o f inducing agents in the diet.
D iffe ren tia l inducib ility  of UDP-glucuronyltransferase by MC, PB and A r
The three substrates used in this study have been previously classified in 
the late foeta l group of substrates (Wishart, 1978) and in the group-1 substrates 
(Bock et al., 1979) for the ra t live r enzyme. In the present study not only was 
the characteristic pattern of d iffe ren tia l inducib ility  of the enzyme a c tiv ity  by 
MC and PB (Bock et al., 1983) observed in the live r preparations from  the ra t 
(Tables 3.1, 3.2 and 3.3), but i t  was also observed in the various gastrointestinal 
tra c t preparations. The form of UDP-glucuronyltransferase in the ra t 
gastrointestinal tra c t whose enzyme a c tiv ity  was measured in this study may be 
sim ilar to that of the enzyme in the ra t liver which conjugates the group- 1  
substrates. The e ffec t of pretreating the ra t w ith  Ar resulted in increases in 
enzyme ac tiv ity  in the various tissue preparations which differed from  those 
which were observed a fte r pretreating the ra t w ith  MC or PB. For example, 
a fte r pretreating the ra t w ith MC the increases in enzyme a c tiv ity  were 3 -fo ld
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in the live r, 7 -fo ld  in the stomach and 2-fo ld  in the duodenum preparations. 
A fte r pretreating the rats w ith  Ar the enzyme a c tiv ity  increases in sim ilar tissue 
preparations were 9-fo ld , 10-fold and 4 -fo ld , respectively. Therefore, although 
there were s im ila rities between the enzymes from the live r and from  the 
gastrointestinal tra c t which conjugate these substrates, these results indicate 
that the mechanisms of enzyme regulation in the two tissues may not be sim ilar.
Comparison of UDP-glucuronyltransferase a c tiv ity  in the ra t and fe rre t
Glucuronylation o f 1-naphthol by the live r and intestinal enzymes from  the 
fe rre t has been shown to occur at a lower rate than that in sim ilar tissues from  
the ra t (Lake et al., 1979). The present study has shown that 4-nitrophenol and 
4-m ethylum belliferone glucuronylation also occurs in the fe rre t live r and 
intestine at a lower rate than that observed in the ra t (Tables 3.2 and 3.3). 
These results also indicate that at least one of the UDP-glucuronyltransferases 
of the liver and gastrointestinal tra c t from  the fe rre t may have sim ila r 
characteristics to the enzyme in ra t live r which catalyses the conjugation of the 
group-1 substrates (Bock et ai., 1979). However, the UDP- 
glucuronyltransferases in the liver and gastrointestinal tra c t from  the fe rre t was 
less sensitive to the induction e ffe c t o f MC (Tables 3.1 and 3.2). This species 
difference of enzyme inducib ility  has previously been observed w ith  1 -naphthol 
as substrate in homogenates of liver and gastrointestinal tra c t from ra t and 
fe rre t a fte r A r pretreatm ent (Lake et al., 1979). The d istribution o f UDP- 
glucuronyltransferase a c tiv ity  along the gastrointestinal tra c t from ra t and 
fe rre t was also observed to d iffe r (Figures 3.1-3.6 ). Although the highest 
enzyme ac tiv ity  was observed in the duodenum o f the ra t, the highest enzyme 
ac tiv ity  occurred in the ileum of the fe rre t.
The results of the present study indicate that drugs which are group-1 
substrates for UDP-glucuronyltransferase would undergo more extensive f irs t-
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pass metabolism in the ra t than in the fe rre t. Also, any entero-hepatic 
recircu la tion of the drug a fte r hydrolysis o f glucuronide conjugates in the 
gastrointestinal tra c t could occur at a faster rate in the ra t than in the fe rre t. 
I f  the glucuronides undergo hydrolysis in the gastrointestinal tra c t a fte r 
excretion in the bile, the aglycone may exert a toxic e ffec t, such as 
gastrointestinal ulcers induced by indomethacin (Brodie et al., 1970; Duggan et 
al., 1973). This type o f event would be expected to occur w ith  more frequency in 
the ra t than in the fe rre t as a result o f the d iffe ren t rates of glucuronylation in 
the intestines of these two species.
In conclusion, the results o f this investigation showed tha t the 
glucuronylation o f group- 1  substrates occurred in the livers and gastrointestinal 
tracts of the ra t and fe rre t. The d istribution of enzyme a c tiv ity  towards
1 -naphthol and 4 -m ethylum belliferone along the gastrointestinal tra c t from  ra t 
was observed to be sim ilar to that previously observed w ith  4-nitrophenol and
2-aminophenol as substrates (Hietanen et al., 1972). The distribution o f enzyme 
a c tiv ity  along the gastrointestinal tra c t from  fe rre t was observed to d iffe r from  
that along the gastrointestinal tra c t o f ra t and other species previously 
investigated (Hietanen and Vainio, 1973). Increases in enzyme a c tiv ity  occurred 
in a ll the tissue preparations from the ra t and fe rre t which had been pre treated 
w ith  MC, and from  ra t pretreated w ith  A r, but not from ra t pretreated w ith  PB. 
Variations in the increases in enzyme ac tiv ity  were observed between the live r 
and gastrointestinal preparations from  the same species and between sim ilar 
tissue preparations from both species. This indicated that the mechanisms of 
enzyme regulation may d iffe r between tissues and between species. 
Glucuronylation of group-1 substrates occurred at a greater rate in the livers 
than in the gastrointestinal tracts of both species and was greater in the tissues 
of the rat than in the tissues of the fe rre t.
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Chapter 4
Isolation of Radioactive Metabolites from the Urine 
of Female Beagles, Collected after an Oral Dose of 
^C-Labetalol
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INTRODUCTION
Labetalol glucuronide standards were not commercially available so it  was
necessary to isolate each of the major metabolites in a pure form  fo r use in the
labetalol studies. The dog, monkey and man produce three major labetalol
metabolites (Figure 4.1) whereas rodents only produce one (metabolite II) (M artin
and Reid, 1981). The most convenient source of a large quantity o f the three
labetalol glucuronides was the urine of dogs given oral doses of labetalol; 42% of
14the rad ioactiv ity  o f a C -labeta lo l dose is elim inated in dog urine during 0-24 h 
period (Martin et al., 1976).
A procedure fo r the metabolite isolation, from  urine, had been previously 
developed (Hopkins et al., 1978; Oxford, 1980), which consists of three stages. 
The firs t, to concentrate the urine and remove the labetalol from  the urinary 
m ixture by a series o f extractions; the second, to separate the metabolites by 
elution through a QAE Sephadex A23 column; the th ird , to purify the metabolites 
by a fu rthe r Sephadex column elution.
Biological samples containing a m ixture of labetalol and its metabolites 
can be analysed using a variety of techniques. These are: th in layer
chromatography (TLC) and paper chromatography (Martin et al., 1976), gas 
chromatography (GC) or gas chromatographic mass spectroscopy (GCMS) 
(Oxford, 1980); but the best separation of labetalol and its individual 
glucuronides is achieved by ion-pair high pressure liquid chromatography (HPLC) 
(Martin et al., 1978). Labetalol and its glucuronides all absorb UV, but this was 
not a suitable method of detecting these compounds during the purifica tion  
procedure because many components in the urine also absorb UV. Those 
metabolites w ith a free phenyl group have the same fluorescence spectrum as 
labetalol, but when glucuronide conjugation is at the phenolic hydroxyl group of 
labetalol this metabolite does not fluoresce. Therefore, measurement o f
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position o f the C-label.
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fluorescence in the HPLC eluate detects labetalol and metabolites I and III, but 
not metabolite II. As ^ C - la b e ta lo l (Figure 4.1) was available i t  was possible to 
detect labetalol and each of its metabolites in the HPLC eluate by radiochemical 
analysis.
The purpose o f this work was to isolate the three major glucuronides of 
labetalol from  dog urine, in pure forms fo r use as standards in the analysis of 
samples in the labetalol metabolism studies (Chapters 5 and 6 ).
MATERIALS AND METHODS
Materials
Labetalo l-HC l and ^ C -la b e ta lo l-H C l, specific a c tiv ity  25 m C i/g  
(Amersham), were g ifts  from Dr. L.E. M artin, Glaxo, Ware; ^C -hexadecane, 
specific ac tiv ity  0.39 pCi/g, was obtained from Amersham, England; ce ty l- 
trimethylammonium bromide (cetrim ide) and Am berlite XAD -2 from  BDH 
Chemicals L td ., Poole, U .K.; tetraheptylammonium chloride from  Eastman 
Kodak Co., Rochester, New York, U.S.A.; m yristic acid from  Sigma Chemicals 
Co., Poole, U.K.
Internally polished stainless steel 5 mm i.d. x 100 mm high pressure liquid 
chromatography column shells were purchased from Shandon Southern Products 
Ltd., Runcorn, U .K.; Spherisorb-ODS from  Phase Separations L td ., Clwyd, U .K.; 
QAE Sephadex A25 from Pharmacia Fine Chemicals AB, Uppsala, Sweden; Silica 
thin layer chromatography plates 60 F-254 from Merk, Germany; and 
G1500 LS 254 from  Schleichler and Schull, Germany.
P icofluor-30 was obtained from  Packard, Instrument Co., Reading, U .K., 
and Dynagel from J.T. Baker Co., Phillipsburg, New Jersey, U.S.A.
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The solvents used fo r HPLC were o f HPLC grade, a ll the rest of the 
solvents and chemicals used were of Analar grade.
Animals and Experimental Procedures
Animal treatm ent
A fte r oral adm inistration of labetalol two female beagles (7 and 6.7 kg), 
bred and housed at Glaxo, Ware, were placed in individual metabolic cages, for 
72 h, to fa c ilita te  the collection of urine. Food and water were provided ad 
lib itum .
Three oral doses of labetalol (20 mg/kg) were given; the firs t, in week one, 
to ensure that no adverse e ffec t occurred; the other two were in weeks two and 
four, respectively. Each dose was given in a gelatin capsule, as labeta lo l-H C l, 
and the second two doses each included 6 mg of ^ C - la b e ta lo l-H C l.
The urine was collected in separate containers, surrounded w ith  solid 
carbon dioxide, fo r the periods 0-24 h and 24-48 h. A fte r collection the urine 
was filte red , each volume measured and a few drops o f chloroform added, to 
prevent bacteria l ac tiv ity , before storing at -15°C.
Labetalol flurorescence
An aqueous solution of labeta lo l-H C l (a 0.1 or b 0 .0 1 m g /m l) at 
approximately pH 7 was used to determine the optimum fluorescence excita tion 
and emission wavelength fo r the two fluorim eters used:
(a) a Locarte Mark 4; a zinc lamp filte red  between 254-400 nm provided the 
excitation wavelength and the emission wavelength was variable;
(b) a Perkin-Elmer 3000 had variable excitation and emission wavelengths.
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Column chromatography (Oxford, 1980)
Three QAE Sephadex A25 columns were used:
(1) a 30 x 1 cm column to study the labetalol metabolite profile  in dog urine;
(2) a 40 x 2,5 cm column, to separate the three labetalol glucuronides;
(3) a 90 x 1.5 cm column to purify each labetalol metabolite.
In each case the QAE Sephadex A25 was equilibrated overnight, w ith  
eluent, before use; fo r columns 1 and 2 the eluent was 0.025 M sodium phosphate 
buffer pH 8.2, and fo r column 3 deionised water. Fresh sephadex was always 
used fo r columns 2 and 3.
A ll the columns were routinely packed employing an LKB peris ta ltic  pump 
to provide an eluent flow  rate o f 1 m l/m in. Subsequent equilibration fo r at least 
6h and chromatography of samples were both carried out at the same flow  rate. 
A fte r each column had been equilibrated a sample of labeta lo l-H C l standard 
solution was eluted to determine the retention tim e of the parent compound.The 
fluorscence of labetalol and its two fluorescent metabolites in the various 
column eluates was monitored using either the Locarte or Perkin-Elmer 
spectrofluorim eter using the optimum excitation and emission wavelengths fo r 
labetalol (see 'Results’). Successive fractions of eluate from the fluo rim ete r 
outlet were routinely collected (5, 15 and 10 ml using columns 1, 2 and 3^, 
respectively) using an LKB Redirac. Aliquots of each fraction (0.2-0.5 ml) were 
added to either Dynagel or P icofluor-30 (5-10 ml) liquid sc in tillan t to determinq 
the levels o f rad ioactiv ity .
Reverse-phase ion-pair HPLC method of analysis (Martin et al., 1978)
The high pressure liquid chromatography (HPLC) stainless steel column 
shells (5 mm i.d. x 100 mm) were packed at Glaxo, Ware, w ith  Spherisorb-ODS, 
5 pm partic le size, w ith  a Magnus column packer at a pressure o f 5000 psi. The
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Sperisorb-ODS was mixed w ith  methanol, sonicated for 10 min, and packed using 
80% aqueous methanol.
The eluate from  the HPLC (Waters Associates) was successively passed 
through a UV monitor (Water Associates), A ^ ^ ,  and a fluorim eter (Perkin- 
Elmer). The fluorim eter flow  cell was 60 ml and the optimum excita tion and 
omission wavelengths fo r detecting labetalol fluorescence were employed (see 
’Results').
The mobile phase consisted of 60% v/v 50 mM sodium phosphate buffer
-3pH 7, 40% v/v methanol, and 10“ M w ith  respect to cetrim ide. The pressure 
drop of the column at a flow  rate o f 1 m l/m in was approximately 1000  psi. 
Chromatography was carried out at pH 7 to prevent hydrolysis o f any of the 
labeta lo l-H C l metabolites.
For analysis of radioactive labetalol or its metabolites the eluate was 
collected from the fluorim eter outle t at 0.5 min intervals, using an LKB 
U ltrorack 7000 fraction co llector, loaded w ith  counting vials containing 5 ml of 
Dynagel or P icofluor-30 liquid sc in tillan t. The levels of rad ioactiv ity  in each 
fraction  were determined.
TLC method of analysis
Various samples were analysed by thin layer chromatography (TLC) using 
silica plates and the follow ing solvent system:
Ethylacetate 50%
Propan-2-ol 30%
D istilled water 16%
Ammonia solution (sp.g. 0.88) 4%
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A fte r allowing the solvents to evaporate from  the plates they were examined fo r 
fluorescence using a M ineralight UVSL 58 to provide UV ligh t, 254 nm. The 
d istribution of rad ioactiv ity  on the plates was determined d irectly  by a Berthold 
scanner.
The average values fo r the radioactive peaks of -labe ta lo l-H C l and 
the m ixture o f ^ G -la b e ta lo l-H C l metabolites, o f the dog urines, observed 
follow ing 9 determinations were 0.58 + 0.07 and 0.19 + 0.04 respectively.
Liquid sc in tilla tion  determ ination o f rad ioactiv ity
The levels o f rad ioactiv ity  were determined in an LKB Wallac U ltrabeta 
liquid sc in tilla tion  counter which had a quench curve coe ffic ien t fa c ility  to 
convert counts per minute (c.p.m.) into disintegrations per minute (d.p.m.) by the 
external standard ratio  method.
The quench curve coefficients were obtained by adding various amounts of 
chloroform (0.1-1.4 ml) to a via l containing sc in tillan t (Dynagel or P icofluor-30, 
8 ml) w ith  a known amount o f ^C-hexadecane (10 pi = 8630 d.p.m.). The 
relevant control experiments were carried out; the levels o f rad ioactiv ity  in the 
sc in tillan t, before and a fte r the addition of "^C-hexadecane, were determined 
prior to the addition o f chloroform . Each assay was carried out in duplicate.
The b es t-fitting  th ird  degree polynomial expression, by the least squares 
method (a computer programme supplied w ith  the liquid sc in tilla tion  counter), 
was used to calculate the quench curve coefficients from  the c.p.m. and 
external standard ra tio  values thus obtained. These coeffic ients were then used 
routinely to determine the d.p.m. values for the various samples containing 
rad ioactiv ity .
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Labetalol extraction from dog urine
Two samples of 0-24 h dog urine, collected a fte r the adm inistration of an 
oral dose of "^C -labe ta lo l HC1, were desalted, (see later), using XAD resin. The 
metabolites were extracted from  the urine, one sample w ith an equal volume of 
ethylacetate and the other w ith  chloroform, for 30 min on a rotary extractor at 
room temperature. A fte r centrifugation at 1000 g for 15 min at 5°C, samples 
from each phase were analysed by TLC.
Labetalol metabolite pro file  in dog urine and the e ffec t o f urinary pH on the 
e ffic iency of labetalol extraction (Oxford, 1980)
A fte r oral adm inistration o f 14C -labe ta lo l-H C l, two portions o f 0-24 h 
collection of dog urine, one portion (5 ml) at the original pH (6 .6 ) and the other 
(10 ml) brought to pH 8.5 w ith  0.2 M NaOH, were extracted w ith  equal volumes 
of chloroform fo r 30 min at room temperature. The two phases were separated 
by centrifugation at 1000 g fo r 15 min at 5°C.
Various samples were eluted on column JL (see 'Column chromatography'): 
(a) a series of labetalol HC1 standards (0.26-1.07 mg in aqueous solution); (b) 0.8 
and 0.65 ml dog urine; (c) 0.8 ml dog urine at pH 6 .6 ; and (d) 0.8 ml dog urine at 
pH 8.5 a fte r chloroform extraction. The fractions containing each of the 
radioactive peaks, a fte r elution of 0.65 ml dog urine, were combined and freeze 
dried. The three residues were separately taken up in 0.5 ml d istilled water and 
analysed by HPLC.
Isolation of radioactive metabolites from the urine of female beagles a fte r oral 
administration of ^ - la b e ta lo l-H C l (Martin et al., 1976; Hopkins et al., 1978; 
Oxford, 1980)
The urine was divided into six portions (Table 4.1) and the isolation 
procedure (Figure 4.2) carried out in batches which were combined at various
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TABLE 4.1
The batches of dog urine used to isolate the labetalol metabolites
Batch Urine Volume
(ml)
Total 
rad ioactiv ity  
in the urine 
(dpm x 107)
% Dose
I Dog A
1st oral dose 
0-24h collection 114 1.34 4
II Dog A
1st oral dose 
0-24h collection 120 1.41 4
III Dog A
1st oral dose 
0-24h collection 124 1.46 4
IV Dog B
1st oral dose 
0-24h collection 
24-48h collection
170
120
290
3.43
0.13
3.38 9
V Dog B
2nd oral dose 
0-24h collection 226 13.47 46
IV Dog A
2nd oral dose 
0-24h collection 360 16.86 51
Total rad ioactiv ity  in all the urine batches 40 x 10? d.p.m. 
Equivalents of ^C -la b e ta lo l-H C l 192 mg
The dogs were administered oral doses of labetalol (20 mg/kg), including 
6 mg l^C -labe ta lo l-H C l except in the case of dog B fo r the 1st oral dose 
when 7mg l^C -labe ta lo l was included. The urine was collected in vessels 
surrounded w ith solid carbon dioxide, and contained a few drops of 
chloroform to prevent bacterial ac tiv ity .
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Figure 4 .2 . Procedure fo r  the is o la t io n  o f rad ioactive  metabolites 
from the urine o f dogs a f te r  oral adm in is tra tion o f 
^ O la b e t a l o l ,
Urine
Desalt using Amber!ite XAD-2
I
Extract w ith  chloroform (pH 8.5)
Aqueous phase Organic phase
I I
Extract w ith Butan-l-o l Discard
(three times)
Aqueous phase Organic 'phase
I i
Discard Evaporate B u ta n - l-o l,  d issolve residue
in  d i s t i l l e d  water and add equal volume
2M (NH^gSO^ ^
Extract 0.1 M Tetraheptyl-ammonium ch lo ride  
in  ethylacetate (tw ice)
Aqueous phase Organic phase
Discard Add 0.5 volume 0.3M M yr is t ic
acid in carbon te t ra c h lo r id e
i
Extract w ith  d i s t i l l e d  water
Aqueous phase Organic phase
i i
Desalt w ith  Amber!ite XAD-2 Discard
Elute through QAE Sephadex A25 
column 2 (40 x 2.5 cm)
I
Three rad ioactive  metabolites separated
/ I NDesalt
Elute through^ QAE Sephadex A25---------------------► Samples analysed by HPLC
column 3.1 (90 x 1.5 cm)
Desalt
Elute through QAE Sephadex A25---------------------► Samples analysed by HPLC
column 3.2 (90 x 1.5 cm)
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stages (Table 4.2). This was both a safety precaution and a method fo r ease of 
handling the volume of urine. Samples were taken at each stage to determine 
the levels o f rad ioactiv ity  by liquid sc in tilla tion  counting and TLC analyses to 
detect the presence of labetalol and its metabolites.
A ll glassware used fo r this work was washed w ith concentrated n itr ic  acid, 
followed by distilled water, prior to use.
Desalting procedure
A fte r equilibration overnight w ith  distilled water, an equal volume of 
A m erlite  XAD -2 resin to  the volume of urine was poured into a Buchner funnel, 
attached to a flask, and dried over a slight vacuum. The urine was passed 
through the resin four times to ensure retention of the metabolites. The XAD-2 
was then washed w ith five volumes of d istilled water followed, a fte r bringing the 
resin to dryness, by four volumes of methanol.
The methanol fraction was d istilled at 30-40°C under reduced pressure 
using a Buchi ro tary evaporator, and the residue dissolved in d istilled  water 
(1 0 -2 0  ml).
Extractions
The dissolved residue from the desalting step was firs t extracted w ith  an 
equal volume of chloroform for 30 min using a rotary extractor. The two phases 
were separated by centrifugation at 1000-2000g (Beckman J6 centrifuge) for 15 
min at 5°C and the upper aqueous phase containing the labetalol metabolites was 
removed using a Pasteur pipette. This phase was further extracted three times 
w ith equal volumes of bu tan-l-o l which were subsequently combined and d istilled  
at 30-40°C, under reduced pressure, using a Buchi ro tary evaporator. The
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residue was dissolved in distilled water (1 0 -2 0  ml) and was then added to an equal 
volume of 2M ammonium sulphate. The chloroform and bu tan -l-o l used fo r these 
extractions were saturated w ith  distilled water prior to use.
The ammonium sulphate solution was extracted, tw ice, w ith  0.1 M 
tetraheptylammonium chloride in ethylacetate (THAC). The ion pair formed 
between the THAC and metabolites was broken by the addition of 0.5 volume of 
0.3 M m yristic acid in carbon tetrachloride. Two successive aqueous extractions 
o f the two organic solvent m ixtures followed.
The fina l aqueous extract was desalted as before and the evaporated 
methanol fraction residue dissolved in 3-5 ml d istilled water.
Separation and purification o f metabolites
The aqueous solution, a fte r the second desalting procedure, was applied to 
the top o f column 2 (see 'Column chromatography') and eluted. The fractions 
containing each o f the three radioactive peaks were combined, and freeze dried. 
Each residue was desalted as before and the evaporated methanol fraction  
residue dissolved in 3-5 ml d istilled water.
The solution containing metabolite I was then applied to the top of 
column 3.1 I (see 'Column Chromatography' and Figure 4.2) and eluted. The 
eluate fractions containing metabolite I were then combined and freeze-dried. 
The residue was dissolved in a small volume of d istilled water (10 ml) and a 
sample was taken for HPLC analysis. This solution was desalted as stated and 
the evaporated methanol fraction residue dissolved in 3-5 ml d istilled water 
which was then applied to the top of column 3.2 I (see 'Column Chromatography' 
and Figure 4.2). A sample (250 pi) of each fraction was then injected on to the
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HPLC column to check the purity o f the metabolite. The same procedure was 
used to purify metabolites II and III, except metabolite II had an additional 
chloroform extraction step using the same procedure described earlier. This step 
was used to remove labetalol which was found to contaminate this metabolite.
RESULTS
The optimum wavelengths fo r detecting labetalol flurorescence were: 
(i) an excitation wavelength provided by a zinc lamp w ith  an LF1 f i l te r  
(254-400 nm) and an emission wavelength of 415 nm using the Locarte Mark 4 
fluorim eter; (ii) excitation and emission wavelengths of 334 and 420 nm, 
respectively, using the Perkin-EImer 3000 (Figure 4.3). Labetalol and 
metabolites I and III were routinely detected by either of the two flo rim eters 
using these wavelengths; in each case the phenolic group was responsible fo r the 
fluorescence.
Unlabelled and "^C -labe ta lo l-H C l were found to be of su ffic ien t purity , 
> 95% by TLC, prior to beginning these studies (Figure 4.4, Table 4.3).
Labetalol metabolite profile  in dog urine
A 30 x 1 cm QAE Sephadex A25 column was used to investigate the 
labetalol metabolite p ro file  in urine (Oxford, 1980). There was a linear 
correlation, r = 0.98, between the amount of labetalol loaded on to the column 
and the eluted fluorescent peak height (Figure 4.5). Three fluorescent and 
radioactive peaks (I, II and III) and one radioactive peak w ith no associated 
flurorescence (X) were eluted from the column a fte r loading a sample of dog 
urine containing labetalol and its metabolites (Figure 4.6). The three fluorescent 
radioactive peaks have been previously identified as the secondary amine 
glucuronide (I), the O-phenylglucuronide (II) and labetalol , and the secondary 
alcohol glucuronide (III). The non-fluroescent radioactive peak (X) is a 
metabolite o f labetalol which has not been previously identified.
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Figure 4.3
The fluorescent e xc ita t io n  and emission spectra of labe ta lo l
An aqueous so lu tion  of labetalol-HCl (0.1 mg/ml) was used to  determine the 
optimum fluorescent exc ita t ion  and emission spectra at approximately pH 7. 
Perkin-EImer 3000:
  fixed emission wavelength = 415 nm, variab le  e xc ita t io n  wavelength
  f ixed e xc ita t io n  wavelength = 333nm, variab le  emission wavelength
Locarte Marke 4:
; exc ita t ion  spectra provided by a z inc lamp, an LF1 f i l t e r  (254-400 nm)
o — o emission spectra
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Figure 4.4 f ro n t
14,Thin layer chromatogram o f  C-labetalol-HCl 
14.11 ug C-labetalol-HCl was eluted on a TLC pla te and the 
d is t r ib u t io n  o f ra d io a c t iv i ty  along the p la te  was determined 
using a Berthold scanner.
Table 4.3
Comparison of Rf  a f te r  e lu t ing  unlabelled and 14C- labeta lo l-HC l on 
a TLC p la te
Sample Fluorescence Radioactive 
Peak Rf
Unlabelled
1abetalol-HCl 0.59 -
(14 yg)
1'tC-l abetal ol-HCl 0.58 0.58
(11 ug)
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Figure 4.5
Elution of labe ta lo l from a QAE Sephadex A25 column (30 x 1 an)
Various samples of an aqueous labetalo l-HCl standard so lu tion  (1.07 mg/ml) 
were eluted through the column using 0.025 M phosphate b u ffe r  pH 8.2 
and a flow  rate o f 1 ml/min. Fluorescence in  the eluate was measured 
using a Locarte Mark 4 f lu o r im e te r :
e xc ita t io n  wavelength = z inc lamp f i l t e r e d  (LF1 )
between 254-400 nm
emission wavelength = 415 nm
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Figure 4.6
Chromatogram of dog urine eluted through a QAE Sephadex A25 column (30 x 1 cm)
0.65 ml dog u rine , from dog A, collected a fte r  the 2nd oral dose of 
14C-1abetalol (20 mg/kg), eluted through the column with 0.025 M sodium 
phosphate b u ffe r pH 8.2 and a flew rate  of 1 ml/min. The fractions containing 
peaks I ,  I I ,  and I I I  were freeze dried . The amount of ra d io a c tiv ity  added 
to  the column was 3.04 x 105 d.p.m.
  = Radioactivity
  * Fluorescence (Perkin-EImer, exc ita tion  wavelength = 334 nm,
■ emission wavelength = 420 nm)
Y = Elution of labeta lo l standard
Figure 4.7
HPLC analysis o f peak I I  a fte r  elu tion  of dog urine through a QAE Sephadex 
A25 column (30 x 1 cm)
The residue of the freeze dried fractions containing peak I I ,  see 
figure  4 .6 , was redissolved in 0.5  ml d is t i l le d  water and a sample (6 y l )
was injected on to an HPLC column and chromatographed in the io n -p a ir mode.
  » R adioactivity
  *  Fluorescence (Perkin-EImer 3000, exc ita tion  wavelength = 334 nm,
• emission wavelength = 420 nm)
1  = Elution of labetalo l standard
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The three fluorescent radioactive peaks collected from  the 30 x 1 cm 
Sephadex column were analysed by HPLC to confirm  the identity  of the 
metabolites. The HPLC chromatogram of peak II, from the Sephadex column, 
(Figure 4.7) shows a fluorescent radioactive component w ith  a retention time 
identical to labetalol and another non-fluorescent radioactive component w ith  
characteristics of the O-phenylglucuronide (metabolite II). The HPLC 
chromatogram of peak III, from  the Sephadex column, (Figure 4.8) shows a 
fluorescent radioactive peak w ith  a retention tim e sim ilar to that o f the 
secondary alcohol glucuronide (metabolite III). The HPLC chromatogram of 
peak I, from  the Sephadex column, (Figure 4.9) shows a non-fluorescent 
radioactive peak (i) w ith  a retention tim e of 17 min which has not been 
previously identified, and two fluorescent peaks (ii and iii) which have small 
amounts of rad ioactiv ity  associated w ith  them. Peak ( iii)  had sim ilar 
characteristics to the 'H PLC  chromatogram o f the partia lly  purified secondary 
amine glucuronide of this study.
Extraction of labetalol from dog urine
A comparison of labetalol extraction from  dog urine w ith  chloroform  and 
ethylacetate, using TLC, showed l it t le  difference in e ffic iency (Figure 4.10). 
Ethylacetate or chloroform, or a combination of both solvents, have been used in 
other metabolite isolations (Hopkins et al., 1978; Oxford, 1980) to extract 
labetalol from a urinary m ixture. I t  was decided to use chloroform fo r routine 
extraction of labetalol from  urine in this protocol.
The metabolite profiles of untreated dog urine (Figure 4.11), o f dog urine 
extracted w ith chloroform at normal pH (6 .6 ) (Figure 4.12), and o f dog urine 
extracted w ith chloroform at pH 8.3 (Figure 4.13) were compared. The volume 
o f urine in each case was identical and from the same source. It appeared that 
the fluorescent peak (II) a ttributed to labetalol was reduced to a greater extent
To
ta
l 
ra
di
oa
ct
iv
ity
 
(d
.p
.m
.) 
in 
fr
ac
tio
ns
- 129 -
Labetalol
standard
-0 .0 4 r  0.04Labetalol
standard
150 -
-  0.03-0 .0 3
100  -100  -
V)
-M
-  0.02
+->
50 -5 0 -
- 0.01-0.01 =3 4->
L u  >
"O
i n i ^ s n r y  L r :
Time (min 
Figure 4.9
Peak I
Figure 4. 
Peak I I I
HPLC analysis o f fra c tio n s  containing peak I I I  or peak I a fte r  
dog urine through a QAE Sephadex A25 column ( 30 x 1 cm)
e lu t io n  o f
The residues o f the freeze dried  fra c tio n s  conta in ing peak I I I  or peak I ,  
see fig u re  4 .6 , were each dissolved in  0.5 ml d is t i l le d  water and a sample 
(6 or 10 y l , respective ly ) was in jec ted  on to  an HPLC column and chromatographed 
in  the io n -p a ir  mode.
  = R ad io ac tiv ity
  = Fluorescence (Perkin-EImer 3000 e x c ita tio n  wavelength = 334 nm,
emission wavelength = 420 nm)
= E lu tion  o f la b e ta lo l standard
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Figure 4.10 f ro n t
Radioactive th in  layer chromatogram trac ings o f dog urine a f te r  ex trac t ion  
w ith e i th e r  chloroform or e thy lacetate.
The urine o f dogs, given oral doses o f 14C-labeta lo l (20 mg/kg), were 
desalted, the methanol f ra c t io n  evaporated and the residue dissolved in
d is t i l l e d  water. Two samples o f urine were then extracted with
chloroform or e thy laceta te , respec tive ly , and various samples (40 y l  except 
(E) 80 'yl ) were subjected to TLC analys is:
(A) aqueous phase before e x tra c t io n ; (B) aqueous phase a f te r  ethylacetate  
e x tra c t io n ; (C) aqueous phase a f te r  chloroform e x tra c t io n ; (D) e thy lacetate  
a f te r  ex tra c t io n ; (E) chloroform a f te r  ex trac t ion .
The arrow ind icates the pos it ion  o f 14C-labeta lo l standard (Rf  = 0.58).
The rad ioactive peak R, values are included.
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Figure 4.11
Chromatogram of dog urine eluted through a QAE Sephadex A25 column (30 x 1 cm)
0.8 ml dog urine, from dog A, co llected a f te r  the 1st oral dose of 
l l tC-labetalol (20 mg/kg), was eluted through the column with 0.025 M 
sodium phosphate buffer pH 8.2 and with a flow rate o f 1 ml/min. The
amount o f ra d io a c t iv ity  added to the column was 9.4 x 104 d.p.m.
  = Radioactiv ity
  = Fluorescence (Locarte Mk 4, exc ita t ion  wavelength provided
by a zinc lamp f i l t e r e d  (LF1) between 254-400 nm,
i emission wavelength = 415 nm)= Elution o f labetalo l standard
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Figure 4.12
Chromatogram of chloroform extracted dog urine (pH 6.6) eluted through 
a QAE Sephadex A25 column (30 x 1 cm). ~"
0.8 ml chloroform extracted dog urine (pH 6 .6 ) ,  from dog A, co llected 
a f te r  the 1st oral dose o f labeta lo l (20 mg/kg), was eluted through the 
column with 0.025 M sodium phosphate bu ffer pH 8.2 and with a flow rate 
of 1 ml/min. The amount of ra d io a c t iv ity  added to the column was 6.5 x 
104 d.p.m.
  = Radioactiv ity
= Fluorescence (Locarte Mk 4, exc ita t ion  wavelength was provided 
by a zinc lamp f i l t e r e d  (LF1) between 254-400 nm, 
emission wavelength = 415 nm)
= Elution of labetalo l standard
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Figure 4.13
Chromatogram o f chloroform extracted dog urine (pH 8.5) eluted through 
a QAE Sephadex A25 column (3Û x 1 cm)
0.8 ml chloroform extracted dog urine (pH 8 .5 ) ,  from dog A, co llec ted
a f te r  the 1st oral dose 14C-labeta lo l (20 mg/kg), was eluted through
the column with 0.025 M sodium phosphate b u ffe r  pH 8.2 and w ith a flow  
rate o f 1 ml/min. The amount o f ra d io a c t iv i ty  added to the column was 
4.4 x 104 d.p.m.
  = R ad ioactiv ity
— —  = Fluorescence (Locarte Mk 4, e xc ita t io n  wavelength was provided
by a zinc lamp f i l t e r e d  (LF1) between 254-400 nm, 
emission wavelength = 415 nm)
w = E lution o f labe ta lo l standard
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when the urine was brought to pH 8.5. Previous studies have observed that 
pH 8.5 is the optimum pH fo r labetalol extraction from biological samples 
(M artin et al., 1976; Oxford, 1980). In the procedure fo r isolating the labetalol 
glucuronides the labetalol was routinely extracted from urine which had been 
brough to pH 8.5.
The differences observed between Figures 4.5 and 4.11 were due to the 
urine samples being from d iffe ren t sources and also to the d iffe ren t equipment 
used to elute the samples from  the column.
Isolation of labetalol glucuronides
The labetalol metabolite isolation from  dog urine was in it ia lly  carried out 
in a number o f batches (Table 4.1), which were combined at various stages 
(Table 4.2) to prevent loss of yield. A ll yields quoted, fo r each stage of isolation, 
are averages o f the batches expressed as percentages of to ta l rad ioactiv ity  in 
the original urine.
The desalting procedure using XAD resin had two functions: one, to
remove some of the urinary pigments from  the urine w ithout loss o f labetalol 
glucuronides; and two, to concentrate the urine. An average of 80% (range 
60-90%) of the rad ioactiv ity  in the dog urine was conserved in the methanol 
fraction  a fte r XAD resin elution. TLC analysis of the various XAD resin eluents 
(Figure 4.14) showed the presence of radioactive labetalol (R^ = 0.68) and its 
metabolites (R^ = 0.24) in the untreated urine and the firs t methanol wash, but 
not in the distilled water or la tte r methanol washes. The radioactive labetalol 
and metabolite concentration in the la tte r methanol eluates were too dilute for 
this method of detection.
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TABLE 4.2
Flow chart to show the procedure fo r the Isolation of 
radioactive metabolites from the six batches of urine 
collected from  dogs given oral doses of C -iabetalol (ZOmq/kq)
Urine Batch 
Number
I II III IV V VI Average 
% Y ie ld*
Metabolite 
Isolation Stage
1st XAD procedure
Chloroform extraction
Butanol extractions
THAC/M A extractions*
2nd XAD procedure
40 x 2.5 cm column 
elution
t  t
80 (60-94)
Aq. 53 (32-86)
Or. 12 (9-14)
Aq. 16 (10-24)
Or.
V
33 (19-50)
1 Aq. 15 (7-25)
Or. 4 (2-7)
11 (6-19)
see Table 4.4
Batch
3rd XAD procedure
1st 90 x 1.5 cm 
column elution
4th XAD procedure
2nd 90 x 1.5 cm 
column elution
M etabolite I 
I-VI
Metabolite II 
I-VI
Metabolite III 
I-IV V&VI
I  1 see
table
4.5
see
table
4.6
Average % yield - % yields quoted are averages of the rad ioactiv ity  in 
each batch of urine, fo r each stage of isolation, 
expressed as percentages of the to ta l rad ioactiv ity  in 
the in itia l urine. Ranges of results are given in 
parentheses.
Aq. - aqueous phase a fte r extraction.
Or. - organic phase a fte r extraction.
*TH AC /M A - Tetraheptylammonium chloride in ethylacetate a fte r the 
addition of m yristic acid in carbon tetrachloride see figure 4.2.
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Figure 4.14. Radioactive th in  layer chromatogram trac ings of samples 
at various stages of labetalo l metabolite is o la t io n  from 
urine of dogs. 1. Desalting procedure?
The urine of dogs, given oral doses of 14C-labeta lo l (20 mg/kg), were 
desalted using XAD-2 res in . Samples o f the various aqueous and methanol 
washes were analysed by th in  layer chromatography. The amount o f rad io ­
a c t i v i t y  in each lane was measured using a Berthold scanner. For d e ta i ls  
o f procedure see 'M ateria ls  and Methods'. The trac ings are chromatographs 
o f :  (A) untreated ur ine, (B) 1st. d i s t i l l e d  water wash, (C) 2nd d is t i l l e d  
water wash, (D) 1st methanol wash, (E) 2nd and 3rd methanol washes combined, 
(F) 4th methanol wash. The arrow indicates the pos it ion  o f an unlabelled 
labetalo l-HCl standard detected by fluorescence (Rf  = 0.68). The f igu res  
included are the rad ioactive peak R^  values.
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The chloroform and butan-l-o l extractions were performed to remove the 
m ajority of the labetalol which was present w ith the labetalol glucuronides in the 
urine concentrate. The chloroform  extraction removed an average of 15% of the 
rad ioactiv ity  in the desalted urine (Table 4.2). This was mostly labetalol (Figure 
4.15), R | = 0.58, but there was a labetalol metabolite, = 0.4, present which 
was not one of the major glucuronide conjugates and this may be 
hydroxylabetalol (Martin et a l.,1976). The butan-l-ol extractions removed 62% 
of the rad ioactiv ity  in the chloroform extracted urine (Table 4.2) and TLC 
analysis showed that this was mainly glucuronide conjugates of labetalol, 
R^ = 0.15 (Figure 4.15).
The tetraheptylammonium cation forms an ion-pair w ith labetalol 
glucuronides, this non-polar ion-pair then partitions into the organic phase of the 
extraction. The subsequent addition of m yristic acid breaks this ion-pair and the 
polar labetalol glucuronides then partition  into the aqueous phase o f the 
extraction. This procedure was performed to concentrate the labetalol 
glucuronides whilst removing urinary pigment contamination. The 
tetraheptylammonium chloride (THAC) extraction of the aqueous butan-l-o l 
extract, and the aqueous extraction of the TH AC /m yristic acid (THACMA) 
solution, were not very e ffic ie n t. Only 15% of the original urine rad ioactiv ity  
remained in the fina l aqueous extract (Table 4.2) and this was mainly labetalol 
glucuronides (Figure 4.16). I t  was therefore decided to carry out each of these 
extractions tw ice:
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Figure 4.15. Radioactive th in  layer chromatogram tracings o f samples at 
various stages of labeta lo l metabolite iso la t io n  from t[ie 
urine of dogs. 2. Chloroform and bu tan-l-o l extractions".
The urine o f dogs, given oral doses of ^C - la b e ta lo l  (20 mg/kg), were 
desalted and extracted with chloroform and b u ta n - l-o l.  Samples o f the 
various aqueous and organic phases a f te r  extraction  were analysed by th in  layer 
chromatography. The amount o f ra d io a c t iv i ty  in each lane was measured by a 
Berthold scanner. For de ta i ls  o f procedure see 'Materia ls and Methods'. The 
tracings are chromatographs o f:  (A) aqeous phase a f te r  chloroform ex tra c t io n ,
(B) chloroform layer a f te r  ex trac t ion , (C) bu tan-l-o l layer a f te r  1st ex tra c t io n , 
(D) bu tan-l-o l layer a f te r  2nd ex trac t ion , (E) bu tan-l-o l layer a f te r  3rd
extraction . The arrow indicates the posit ion  of l 4C-labetalol-HCl standard 
( R f  = 0.58). The figures included arq the rad ioactive peak Rf values.
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Figure 4.16. Radioactive thin layer chromatogram tracings of samples at various 
stages of labetalol metabolite isolation from the urine of dogs.
3. Tetraheptylammonium chloride (THÀC) ion-pair extraction.
The urine of dogs, given oral doses of C-labetalol (20 mg/kg), were desalted and 
extracted with various solvents. Samples of the various aqueous and organic phases 
a fte r  extraction were analysed by thin layer chromatography. The amount of radio­
a c t iv i ty  in each lane was measured by a Berthold scanner. For detai ls  of procedure 
see 'Materials and Methods’ . The tracings are chromatographs of: (A) aqueous phase 
a fte r  2nd THAC solution extraction, ( 8 ) aqueous phase a fte r  1st THAC myristic acid 
(MA) solution ( 1 ) /  aqueous extraction, (C) aqueous phase a fte r  2nd THACMA solution
( 1 ) /  aqueous extraction, (0) THACMA solution (1) a f te r  2nd aqueous extraction, (E; 
aqueous phase a f te r  1st THACMA solution (2 ) /  aqueous extraction, (F) aqueous phase 
aft^ç 2nd THACMA solution (2)/aqueous extraction. The arrow indicates the position  
of C-labetalol-HCl standard (R, = 0 .52) .  The figures included are the radioactive  
peak Rf  values.
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Ag. Butan-1 
extract
TLC analysis o f these extractions showed that the la tte r extractions did not 
remove much of the labetalol glucuronide concentration in the THACMA solution 
(Figure 4.16).
The 40 x 2.5 cm QAE Sephadex A25 column was an e ffic ie n t method of 
separating the three major labetalol glucuronides in the aqueous solution 
remaining a fte r performing the various extractions (Figure 4.17). Also the 
percentage recoveries of rad ioactiv ity  (Table 4.4) indicated that there was l i t t le  
loss in yield o f the metabolites during this stage of the isolation procedure.
Purifica tion  o f labetalol glucuronides.
The purification of metabolite I by elution through a 90 x 1.5 cm QAE
Sephadex A25 column (3.1 I) (Figure 4.18) reduced the yield of this metabolite
(Table 4.5). The HPLC chromatogram of the combined fractions from  column 
3.1 containing metabolite I showed that there were s t il l many fluorescent 
components contaminating this solution (Figure 4.19). Another purifica tion  stage 
using column 3.2 I was carried out but no rad ioactiv ity  was detected in the 
eluate from  this column. Metabolite I was lost. It is like ly that this was due to 
hydrolysis o f this glucuronide conjugate which is known to be labile (Oxford,
1980). The HPLC chromatogram (Figure 4.19) of the pa rtia lly  purified
metabolite I showed a fluorescent radioactive component w ith  a retention tim e 
of 35 min and another fluorescent radioactive component w ith a retention tim e 
o f 9 min which is identical to that of metabolite III.
THAC soln. 
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Figure 4.17. Separation of three labe ta lo l metabolites in the urine of 
dogs using a QAE Sephadex A25 column (40 x 2.5 cm).
The urine o f dogs given oral doses of C-labeta lo l (20 mg/kg), were 
desalted and extracted w ith various organic solvents before being 
loaded on to the top o f the QAE Sephadex A25 column and eluted using 
0.025 M_ sodium phosphate b u ffe r ,  pH 8.2, w ith a flow ra te  of 1 m l/m in. 
Fractions (15 ml) were collected and the d is t r ib u t io n  o f ra d io a c t iv i ty  
determined.
The arrow indicates the e lu t ion  of a labe ta lo l standard which was 
detected by fluorescence. The amount of ra d io a c t iv i ty  added to the 
column was 5 x 107d.p.m.
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TABLE 4.4
Percentage recovery of the three major labetalol metabolites
isolated from the urines of dogs a fte r eluting through a QAE
" Sephadex A25 column (40 x 2.5 cm)
The urines of dogs, given oral doses of ^C -la b e ta lo l (20 mg/kg), were desalted and 
subjected to extraction w ith various organic solvents. The three major labetalol 
metabolites were then separated by eluting the urine extracts through a QAE 
Sephadex A25 column (40 x 2.5 cm). The recovery of rad ioactiv ity  from  this 
column was calculated and expressed as a percentage of the rad ioactiv ity  added to 
the column.
Batches of urine 
combined
I-IH IV V & VI
Amount of 
rad ioactiv ity  
added to column 
(dpm x 1 0 )
0.50 0.44 5.00
M etabolite
Fractions
combined
%
recov­
ery
Fractions
combined
% = 
recov­
ery
Fractions % 
combined recov­
ery
I 112-132 8 50-65 12 56-80 14
II 27-34 38 17-27 34 14-29 14
III 53-69 53 30-44 53 32-51 74
Total % 
recovery of 
rad ioactiv ity
99 99 102
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Figure 4.18. P u r i f ic a t io n  o f metabolite I iso lated from the urine of 
dogs using a QAE Sephadex A25 column (90 x 1.5 cm).
The solu tion o f Metabolite I ,  iso la ted from the urine of dogs given oral 
doses of C-labeta lo l (20 mg/kg), was desalted and eluted through the 
column with de-ionised water and with a flow rate of 1 ml/min. Fractions 
(10 ml) were collected and the d is t r ib u t io n  o f ra d io a c t iv i ty  determined. 
The amount o f ra d io a c t iv i ty  added to the column was 5*43 x 106 d.p.m.
  = R ad ioactiv ity
 ------  = Fluorescence (Perkin-Elmer 3000, exc ita t ion  wavelength = 334 nm,
emission wavelength = 420 nm).
E lution of labeta lo l standard.
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Figure 4.19. HPLC analysis o f the combined fra c t ions  containing
labe ta lo l metabolite 1 co llected from the f i r s t  QAE 
Sephadex A25 column (90 x 1.5) used to  p u r i fy  th is  
metabolite.
The fra c t ions  (60-85) containing Metabolite 1, co llec ted from the 
f i r s t  QAE Sephadex A25 column (90 x 1.5 cm), were combined and 
freeze dried. The residue was dissolved in  10 ml d i s t i l l e d  water 
and a sample (20 yl containing 2770 d.p.m.) was chromatographed on 
an HPLC column (see 'Materia ls and Methods'). R ad ioac tiv ity  in each
fra c t io n ,  co llected every 30 sec. is  given as (------) and the fluorescence
(monitored by a Perkin-Elmer 3000 spectrog luorim eter, e xc ita t io n  wave­
length = 334 nm and emission wavelength = 420 nm) detected in  the eluate 
is given as (---------). ( t )  E lu tion o f labe ta lo l standard.
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P urifica tion  of metabolite II by elution through column 3.1 II (Figure 4.20) 
resulted in the separation of labetalol from its O-phenylglucuronide. This was 
not achieved by the other Sephadex columns used in this study (Figures 4.5 and 
4.17). HPLC analysis o f the fractions from column 3.1 II which contained 
metabolite II also contained a s ignificant amount of labetalol. In order to reduce 
this contamination the combined fractions o f eluate from column 3.1 II were 
extracted w ith  chloroform before desalting and loading of a concentrate o f these 
fractions on to column 3.2 II (Figure 4.21). The recoveries of rad ioactiv ity  from 
columns 3.1 II and 3.2 II were not good (Tables 4.5 and 4.6) and the fina l yield of 
metabolite II was equivalent to 0.79 mg ^^C-labetalol, as calculated from  the 
amount o f rad ioactiv ity  in the original doses of ^C -la b e ta lo l given to the dogs. 
The HPLC chromatograms (Figure 4.22) o f various fractions o f eluate collected 
from  column 3.2 II showed that fraction  19 contained the least concentrations of 
contaminants of the O-phenylglucuronide of labetalol, which is observed as a 
non-fluorescent radioactive component w ith  a retention of 7 min. There is a 
labetalol metabolite contaminant (A) in these fractions which is observed as a 
fluorescent radioactive component w ith  an HPLC retention tim e of 4 min. Also 
there is a small amount o f labetalol present in these fractions which is observed 
as a fluorescent component w ith a retention tim e of 12 min.
Purification of metabolite III by elution through 3.1 III (Figure 4.23) 
resulted in a good recovery of rad ioactiv ity  (Table 4.5), but this was not so when 
this metabolite was eluted through column 3.2 III (Figure 4.24, Table 4.6). The 
fina l yield o f metabolite III was equivalent to 2.73 mg ^ C -la b e ta lo l, as 
calculated from the amount o f rad ioactiv ity  in the original oral doses o f "^C - 
labetalol given to the dogs. The HPLC chromatograms (Figure 4.25) o f various 
fractions of eluate collected from column 3.2 III showed that although fraction  
25 contained the most rad ioactiv ity , the fraction which contained the least 
contamination was fraction 27. These HPLC chromatograms also showed that
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Figure 4.20. P u r i f ic a t io n  o f Metabolite I I ,  iso la ted from the urine 
o f  dogs, using a QAE Sephadex A25 column (90 x 1.5 cm)
The so lu tion of^Metabolite I I ,  iso la ted  from the urine o f dogs given 
oral doses o f C-labeta lo l (20 mg/kg), was desalted and eluted through 
the column w ith de-ionised water and w ith a flow ra te  o f 1 ml/min. 
Fractions (10 ml) o f eluate were co llected and the d is t r ib u t io n  o f 
ra d io a c t iv i ty  determined. The amount o f ra d io a c t iv i ty  added to the 
column was 5.74 x 106 d.p.m.
- - —  = R ad ioactiv ity
  = Fluorescence (Perkin-Elmer 3000, e xc ita t io n  wavelength
= 334 nm, emission wavelength = 420 nm)
4 = E lution of labe ta lo l standard
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Figure 4.21. Further p u r i f ic a t io n  o f Metabolite I I ,  iso la ted  from the
urine of dogs, using a second QAE Sephadex A25 column (90 x 1.5cm
The so lu tion  of p u r i f ie d  Metabolite I I ,  iso la ted  from the urine of dogs 
given oral doses o f C-labeta lo l (20 mg/kg), was desalted and eluted 
through a second 90 x 1.5 cm QAE Sephadex A25 column w ith de-ionised water 
and with a flow rate o f 1 ml/min. Fractions (10 ml) o f eluate were 
co llected and the d is t r ib u t io n  o f ra d io a c t iv i ty  determined. The amount of 
ra d io a c t iv i ty  added to the column was 2.8 x 10é' d.p.m.
  = R ad ioactiv ity
  = Fluorescence (Perkin-Elmer 3000, e xc ita t io n  wavelength
= 334 nm, emission wavelength = 420 nm)
= E lution o f labe ta lo l standard.
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TABLE 4.5
Percentage recovery of the three major labetalol metabolites
isolated from the urines of dogs a fte r the ir purifica tion
by eluting through a QAE Sephadex A25 column (90 x 1.5 cm)
The urines of dogs, given oral doses of ^ C -la b e ta lo l (20 mg/kg), were 
desalted and subjected to extraction w ith  various organic solvents. The 
three major labetalol metabolites were then separated by eluting the urine 
extracts through a QAE Sephadex A25 column (40 x 2.5 cm). Each 
metabolite was then subjected to the desalting procedure before being 
further purified by eluting through another QAE Sephadex A25 column (90 
x 1.5 cm). The recovery of rad ioactiv ity  from  this column was calculated 
and expressed as a percentage of the rad ioactiv ity  added to the column.
Metabolite I II III
Batches of urine 
combined
I-VI I-IV V-VI I-VI
Amount of 
rad ioactiv ity  
added to column 
(dpm x 10 )
0.54 0 .21 0.57 3.56
Fractions
combined 60-85 13-26 12-27 21-55
% radioactive 
recovery 26 46 59 73
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TABLE 4.6
Percentage recovery of the major labetalol metabolites
isolated from the urines of dogs a fte r fina l purifica tion
by eluting through the second QAE Sephadex A25 column (90 x 1.5 cm)
The urines of dogs, given oral doses of "^C -labeta lo l (20 mg/kg), were 
desalted and subjected to extraction w ith  various organic solvents. The 
three major labetalol metabolites were then separated by eluting the urine 
extracts through a QAE Sephadex A25 column (40 x 2.5 cm). Each 
metabolite was then subjected to the desalting procedure before being 
fu rther purified by eluting through another QAE Sephadex A25 column (90 
x 1.5 cm).
This last procedure was repeated fo r a second tim e as a fina l purifica tion  
step (Metabolite I failed to elute from  the fina l purifica tion  column). The 
recovery of rad ioactiv ity  from  this column was calculated and expressed 
as a percentage of the rad ioactiv ity  added to the column.
Metabolite II HI
Batches of urine 
combined
Amount of 
rad ioactiv ity  
added to column 
(dpm x 10 )
Fractions
combined
% radioactive 
recovery
I-VI I-VI
0.28 1.75
15-21 21-30
59 32
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Figure 4 .22 . HPLC analysis of various fractions of eluate collected from 
the second QAE Sephadex A25 column (90 x 1.5 cm) used to 
purify Metabolite I I .
The,solution of Metabolite I I ,  isolated from the urine of dogs given oral doses 
of C-labetalol (20 mg/kg), was purif ied by elution through two QAE Sephadex 
A25 columns (90 x 1.5 cm) with de-ionised water. Samples of the fractions of 
eluate from the second Sephadex column, containing Metabolite I I ,  were analysed 
by HPLC. This metabolite was detected by radiochemical analysis of the HPLC 
eluate. The samples injected on to the HPLC column were:
(A) 100 ng 1 4 C-labetalol-HCl standard (5.55 x 10J d .p .m .);  (p) 250 ul Fraction 17 
(9.44 x 103 d .p .m.);  (C) 250 yl Fraction 18 (1.21 x 104 d .p .m .);  (0) 250 ul
Fraction 19 (9.11 x 103 d.p.m.). ------  = Radioactivity in eluate; -------  =
Fluorescence \n eluate (Perkin-Elmer, 3000, excitation wavelength = 334 nm, 
emission wavelength = 420 nm).  ^ = Elutipn of labetalol standard.
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Figure 4.23. P u r i f ic a t io n  o f  Metabolite I I I ,  iso la ted from the urine o f 
dogs, using a QAE Sephadex A25 column (90 x 1.5 cm).
The so lu tion o f^Metaboli te  I I I ,  iso la ted  from the urine o f dogs given 
oral doses o f C-labeta lo l (20 mg/kg),, was desalted and eluted through 
the column with de-ionised water and w ith a flow rate o f 1 ml/min. Fractions 
(10 ml) o f eluate were co llected and the d is t r ib u t io n  o f  ra d io a c t iv i t y  7 
determined. The amount of ra d io a c t iv i ty  added to the column was 3.55 x 10 d.p.m.
  = R ad ioac tiv ity
  = Fluorescence (Perkin-Elmer 3000, exc ita t ion  wavelength = 334 nm,
emission wavelength = 420 nm)
f  = E lution o f labe ta lo l standard
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Figure 4.24. Further p u r i f ic a t io n  of Metabolite I I I ,  iso lated from the 
urine of dogs, using a second QAE Sephadex A25 column 
(90 x 1.5 cm).
The solution of p u r i f ie d  Metabolite I I I ,  isolated from the urine of dogs 
given oral doses of C-labetalol (20 mg/kg), was desalted and eluted 
through a second QAE Sephadex A25 column with de-ionised water and with 
a flow rate of 1 ml/min. Fractions (10 ml) of eluate were collected and 
the d is t r ib u t io n  o f ra d io a c t iv i ty^determined. The amount o f ra d io a c t iv i ty  
added to the column was 1.75 x 10 d.p.m.
  = R ad ioactiv ity
  = Fluorescence (Perkin-Elmer 3000, exc ita t ion  wavelength = 334 nm,
emission wavelength = 420 nm)
*  = E lutjon of labeta lo l standard.
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Figure 4.25. HPLC analysis of various frac tions  of eluate collected from 
the second QAE Sephadex A25 column (90 x 1.5 cm) used to p u r i fy  
Metabolite I I I .
I l l
The solution of Metabolite I I I ,  iso lated from the urine of dogs given oral 
doses o f C-labetalo l (20 mg/kg), was p u r i f ie d  by e lu tion  through two QAE 
Sephadex A25 columns (90 x 1.25 cm) with de-ionised water. Samples o f the 
frac tions of e luate, from the second Sephadex column, containing Metabolite 
were analysed by HPLC. This metabolite was detected by ra d io a c t iv i ty  and 
fluorescenceJn the HPLC eluate. The samples in jected on to the HPLC column were 
(A) 100 ng -  —  —
25 (1.82 x 10
Fraction 27 (1.35 x 10^ d.p.m.).
  = Rad ioactiv ity  in eluate; ^
3000, exc ita t ion  wavelength = 334 nm, emission wavelength = 420 nm).
I  = E lution of labeta lo l standard,
r labe ta lo l-H C l standard (5.55 x 10v d.p .m .); (b) 250 y l Fraction 
d .p .m .); (C) 250 y l Fraction 26 (1.49 x 10 d .p .m .) ;  (D) 250 yl 
^ ■' ■|n . . 
= Fluorescence in eluate (Perkin-Elmer
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fractions 25-27 contained small amounts of two labetalol metabolites (A* and B) 
which are fluorescent radioactive components w ith retention times of 4 min (AO 
and 6 min (B). A ’ is sim ilar to that labetalol metabolite (A) which contaminates 
metabolite II (Figure 4.22). Metabolite III is an highly fluorescent radioactive 
HPLC peak (Figure 4.25) w ith  a retention tim e of 10 min.
There was a linear correlation (r = > 0.9) between the amount o f labetalol- 
HC1 standard injected on to the HPLC column and the eluted fluorescent peak 
height. However, the recovery of rad ioactiv ity  in the HPLC eluate, a fte r 
injection of a known amount (for example lOOng ^C -la b e ta lo i-H C l which is 
equivalent to 5.55 x 10^ d.p.m.) on to the column, was less than 50%. An 
investigation to measure the quenching e ffec t o f the HPLC eluate was carried 
out. This was found to be negligible as compared to this loss of rad ioactiv ity .
This work resulted in the isolation of re la tive ly pure forms of metabolite II 
(O-phenylglucuronide) and metabolite III (secondary alcohol glucuronide) of 
labetalol from  dog urine. These were pure enough to be used as standards fo r 
HPLC identifica tion of the major metabolites of labetalol. A comparison of the 
HPLC retention times of labetalol and its metabolites is shown in Table 4.7. 
Solutions of metabolite II and metabolite III were stored at -40°C.
DISCUSSION
The prelim inary data described here confirm  the results of previous studies 
(M artin et al., 1976, and Oxford 1980). The TLC analysis of the organic and 
aqueous phases a fte r chloroform extraction of urine containing labetalol and its 
metabolites (Figures 4.5 and 4.15), combined w ith  the QAE Sephadex A25 column 
metabolite profiles of urine before and a fte r chloroform extraction 
(Figures 4.11-4.13), showed that only labetalol is extracted by chloroform . 
Although a urine pH/chloroform  extraction profile  was not carried out, i t  is
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TABLE 4.7
HPLC retention times of labetalol metabolites purified 
from dog urine
The urine was collected from  dogs given oral doses (20 mg/kg) o f ^ C -  
labetalol. The metabolites were separated and isolated by column 
chromatography. Samples o f various fractions collected from the fina l 
columns were subjected to HPLC analysis. The labetalol metabolites were 
detected in the HPLC eluate by radiochemical analysis and by 
measurement o f fluorescence (excitation wavelength = 334 nm, emission 
wavelength = 420 nm) and the retention times of the radioactive and 
fluorescent peaks were determined. Because there was no temperature 
controlled HPLC column jacket the analyses were carried out at room 
temperature so the retention times were subject to variation.
Compound Retention tim e 
(min)
Fluorescence
Labetalol 13a +
Metabolite I 35b +
Metabolite II 7a -
Metabolite III 10a +
M etabolite A 4b +
M etabolite A' 4b +
Metabolite B 6b +
a These retention times agree w ith published reports (Martin et al.
1978).
b These retention times have not been previously published.
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clearly more e ffic ien t to extract labetalol from  urine at pH 8.5 than at neutral 
pH. The HPLC retention times of labetalol and its metabolites (Figures 4.7-4.10) 
are in agreement w ith  previous data (Martin et al., 1978).
The percentage o f rad ioactiv ity  obtained in the methanol fraction a fte r the 
desalting procedures (Table 4.2) compared favourably w ith  previous data (Oxford, 
1980). However, to minimise any loss of metabolites, the urine or aqueous 
solution was washed through the resin four times before discarding the eluate, 
and four volumes of methanol were used to elute the metabolites from the resin, 
a fte r washing w ith  five  volumes o f d istilled water.
The chloroform extraction was very e ffic ie n t, and the b u ta n -l-o l 
extractions, though not highly e ffic ien t (Figure 4.15 and Table 4.2), were useful 
in reducing contamination by urinary pigments. The THAC extraction and the 
aqueous extraction of the THACMA solution reduced the amount of metabolites 
available fo r isolation, w ith  l i t t le  increase in purity (Figure 4.16 and Table 4.2); 
however, visually it  appeared that there was a reduction in urinary pigmentation. 
The effic iency of this last procedure was 45% compared w ith  67% o f previous 
studies (J. Oxford, personal communication). Higher yields of pure m etabolite 
might be achieved by separating the aqueous b u ta n -l-o l extract on a 40 x 2.5 cm 
QAE Sephadex A25 column. The separated metabolites could then be purified by 
elution through several 90 x 1.5 cm QAE Sephadex A25 columns. I f  labetalol 
contamination was increased by this method another chloroform extraction could 
be introduced to overcome the problem.
HPLC analysis of fractions from the fina l QAE Sephadex <425 columns 
showed that reasonable radioactive purity was achieved for metabolites II and III 
(Figures 4.22 and 4.25). There were some fluorescent contaminants, not of 
labetalol origin (i.e. they were non-radioactive).
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A number of unidentified labetalol metabolites were observed during this 
study which have previously been unreported. One metabolite (X, Figures 4.6 
and 4.11) is non-fluorescent and elutes from a 30 x 1 cm QAE Sephadex A25 
column before labetalol or its major glucuronide conjugates. Another two 
metabolites (A and B, Figures 4.22 and 4.25) were observed in the HPLC eluate 
having retention times o f 4 and 6 min, respectively, and are both fluorescent. I t  
seems like ly  that metabolite A (Figure 4.22) and A' (Figure 4.25) are the same 
m etabolite. These unidentified labetalol metabolites are discussed fu lly  in 
Chapter 7.
HPLC analysis o f solutions containing labetalol and metabolites I and III, by 
measuring the fluorescence in the eluate, was very sensitive. There was a linear 
correlation (r = > 0.9) between the amount o f labetalol, unlabelled or 
^ C -la b e lle d , injected on to the column and the fluorescent peak height eluted. 
However, recoveries were very poor and only circa 50% of the added 
rad ioactiv ity  o f ^ C - la b e ta lo l was detected in the HPLC eluate. Labetalol and 
metabolites I and III eluted from  the HPLC column can be detected in amounts 
> 1 ng by fluorescence. The 50% loss of rad ioactiv ity  of the amount injected on 
the column was, however, a major problem. As the quenching e ffe c t of the 
HPLC eluent was negligible, i t  may have been that ^ C - la b e ta lo l was being 
bound to the HPLC column. The fluorescent peak height eluted fo r the same 
quantity o f labetalol was the same fo r labelled or unlabelled drug. The poor 
recoveries of rad ioactiv ity  in the HPLC eluate a fte r injecting standards of 
labetalol and metabolite III indicated that the corresponding recoveries of 
metabolite II (non-fluorescent) and metabolite I (lost during purifica tion) may 
also be poor. Labetalol, metabolite I, and metabolite III could be d irectly  
quantified, because of the ir fluorescence, and metabolite II could be estimated 
by measuring the labetalol formed a fte r hydrolysis w ith 6 -glucuronidase. The
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la tte r procedure would have been a lengthy process and therefore unsuitable fo r 
routine analysis.
The results presented in this chapter have shown that although the yields of 
metabolites separated were low, separation and purification was achieved. The 
poor recovery of rad ioactiv ity  in the HPLC eluate did not allow fo r the d irect 
measurement o f metabolite II. However, i t  was possible to use the HPLC 
method of analysis fo r biological samples containing labetalol and its metabolites 
on a sem i-quantita tive basis.
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Chapter 5
Pharmacokinetics of labetalol 
in the rat, ferret, and dog
- 159 -
INTRODUCTION
Labetalol (2-hydroxy-5-(l-hydroxy-2-((l-methyl-3-phenylpropyl)amino)ethyl) 
-benzamide hydrochloride) is an antagonist fo r both a- and 8 -adrenoreceptors 
(Farmer et aL, 1972), and is e ffective  in the treatm ent o f hypertension in man 
(Pritchard et al., 1975). The labetalol metabolites, which have been isolated, 
have been shown to be pharmacologically inactive (Hopkins et al., 1976). Studies 
have shown that labetalol is absorbed well by a number of species (namely ra t, 
rabbit, dog, monkey, and man) when given orally, and tha t during absorption the 
labetalol is extensively metabolised (Hopkins et al., 1976; M artin  et al; 1976). 
Labetalol is rapidly taken up by the tissues of the ra t and cleared from  the body 
via the kidney and bile when given orally or intravenously (Hopkins et al; 1976; 
M artin et al., 1976).
Rat and dog metabolise more labetalol when administered orally than when 
given intravenously (Martin et al., 1976) It  was therefore proposed tha t, when 
the drug was given orally, f irs t pass metabolism in the gastrointestinal tra c t may 
decrease the concentration o f free drug in the systemic c ircula tion, compared to 
that observed when the drug was given intravenously.
The object o f this study was to evaluate the role of the gastrointestinal 
tra c t in the metabolism of labetalol by ra t, fe rre t and dog, by measuring the 
plasma concentration o f unchanged drug and its metabolism follow ing oral and 
intravenous administration. The fe rre t was included in this study to investigate 
its su itab ility  as an animal model fo r labetalol metabolism in man. F inally, the 
possibility that d iffe rent metabolites might be formed in the metabolism of 
labetalol by the liver and gastrointestinal tra c t o f fe rre t and dog was 
investigated.
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MATERIALS AND METHODS
Materials.
Labetalol HC1 and ^^C-labetalol HC1, specific a c tiv ity  25 mCi/g, 
(Amersham) were g ifts  from Dr. L. E. M artin, Glaxo Group Research, Ware, UK. 
Heparin, cetyltrim ethylam m onium  bromide (centrim ide), and ethylcarbamate 
(urethane) were from  BDH Chemicals L td ., Dorset, UK; sodium pentobarbitone 
(Sagatal) from  May and Baker L td ., Dagenham, UK; Spherisorb-ODS from Phase 
Separations L td ., Clwyd, UK; QAE Sephadex A25 from  Pharmacia Fine 
Chemicals AB, Uppsala, Sweden; interna lly polished stainless steel HPLC column 
shells (5 mm in t. diam. X 100 mm) from Shandon Southern Products L td ., 
Runcorn, UK; Dynagel liquid sc in tillan t from  J. T. Baker Company, Phillipsburg, 
N.J., USA; and Picocluor-30 sc in tillan t from  Packard, Instrument Co., Reading, 
U.K.
A ll solvents and other chemicals were Analar grade.
Animals and Experimental Procedure
Animal treatm ent
Two female beagle (6.7 and 7.0 kg) and three male beagle (8.2-8 .6  kg) dogs, 
bred and housed at Glaxo Group Research, Ware, three male ferre ts (1.0-2.0 kg), 
mustela putorius fu ro , from  Froxfie ld Rabbit Farm, Petersfield, Hants., and ten 
male Wistar albino rats (200-400 g) bred and housed at the University of Surrey, 
were used. A ll animals were given food and water ad lib itum .
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Experimental Procedures
Sf-yh \ Labetalol metabolic profiles in urine from  ra t, fe rre t and dog, a fte r oral 
adm inistration. (Oxford, 1980)
Oral doses of labetalol, were administered: 20 mg/kg in aqueous solution to
ra t 20  mg/kg in aqueous solution to fe rre t, and 20 mg/kg in a gelatin capsule to
1 àfemale dog, each dose also contained 0.4 to 7.0 mg C-labeta lo l-HC l. Each 
animal was placed in a metabolic cage and the urine was collected from  0-24 h in 
vessels containing 0 .2 - 1.0 ml chloroform , to inh ib it bacteria l a c tiv ity  and 
surrounded w ith  either solid carbon dioxide or a m ixture of ice and NaCl.
QAE Sephadex A25 resin was equilibrated overnight w ith 0.025 M sodium 
phosphate buffer pH 8.2 as eluent, and was packed in a column (30 x 1 cm) using 
an LKB peris ta ltic  pump to provide an eluent flow rate of 1.0 m l/m in. The eluent 
was pumped through the column fo r 6 h, before use, to allow the packing 
m ateria l to settle . The eluate was passed from  the column through a Perkin- 
Elmer 3000 spectrofluorim eter, attached to a V itation pen recorder, so tha t any 
fluorescence at 420 nm, using an excitation wavelength 334 nm, could be 
monitored. A known amount o f labetalol standard (111 ng or 86 pg in aqueous 
solution) was applied to the top of the column and eluted to measure the 
fluorescent peak retention tim e (mean = 47-7 min). A sample (0.5-1.0 ml) of 
urine was then applied to the top of the column and eluted; the eluate from  the 
spectrofluorim eter outle t was collected in serial fractions (5 .0  ml) w ith  a 
Redirac fraction collector. Samples (0.5 ml) from each eluate fraction  were 
added to 8 ml Dynagel liquid sc in tillant, and the rad ioactiv ity  measured w ith  an 
LKB Wallac 1210 U ltrobeta liquid sc in tilla tion  counter, which had a conversion 
programme to calculate d.p.m. values (see Chapter 4, ’Animals and Experimental 
Procedures’ section).
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Adm inistration o f labetalol to ra t, fe rre t and dog
Oral or intravenous (i.v.) doses of labetalol, as labetalol-HC l, were
administered to three male dogs and two male ferrets on separate occasions, 
w ith an intervening period o f at least one week. Two d iffe ren t groups of three
male rats were given either oral or intravenous doses of the drug. The doses
were:
Route Vehicle Total ^ C-labetalo l-HC l
labetalol 
(mg/kg)
oral gelatin 3 0 -^ c /.  20 mg
capsule
oral aqueous 23 ^ c - / .  1 -2  mg
solution
i.v. aqueous 1 the complete dose
solution
Oral adm inistration to ra t and fe rre t was via an intragastric tube; i t  was 
necessary to anaesthetise the ferrets s ligh tly w ith  ether. Intravenous doses to 
the dogs were given into a subcutaneous vein of a fron t paw, and those to the 
rats and ferrets were cannula into the le ft external jugular veins. Rats and
L
ferrets were anaesthetised w ith  ethylcarbamate (1-2 mg/kg) intrapertoneally as a 
25% (w/v) aqueous solution over a period o f 60 min, before exposure of the 
jugular vein and insertion of the cannula. Anaesthesia was maintained 
throughout the sampling period and the animals were killed at term ination of the 
experiment.
Blood sample collection
Blood samples (0.5 ml) were collected from  the tip  of the ra t ta il. A 
control ra t was anaesthetised by intraperitoneal injection of 0.25 ml sodium 
pentobarbitone (60 mg/ml) and term inally exsanguinated by cardiac puncture, the
Animal
Dog
Ferret 
and ra t
Dog, fe rre t 
and ra t
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blood being transferred to a; heparinised tube. This provided a volume of
14control ra t plasma fo r the measurement o f C-labetolol extraction from plasma
using chloroform . Ferret blood samples (0.5-1.0 ml) were taken from  the ta il
U
vein by syringe (Bleakey, 1980) a fte r oral administration and from  the cannlated
X
jugular vein a fte r giving the intravenous dose. Dog blood samples (3.0 ml) were 
taken, by syringe, from  a subcutaneous vein of the fron t paw.
Each blood sample was immediately transferred to a tube coated w ith  
heparin or to a tube containing 10 ul o f heparin solution (500 units/m l), and 
placed on ice. Each sample was then centrifuged at 1500g fo r 25 min, the 
plasma layer was transferred to a fresh tube and stored at -40°C.
Measurement o f the e ffic ien tcy  of labetalol extraction from  ra t plasma using 
chloroform
14A known amount of C -labetalol HC1 (0.3 ml of a 2 ug/m l solution) was 
added to a sample (2.55 ml) o f control ra t plasma. The plasma was extracted 
w ith  an equal volume of chloroform , using a ro tary extractor, fo r 15 min at room 
temperature. The plasma was separated from the chloroform by centrifuging at 
1500 g fo r 15 min at 10°C and the organic layer was removed by the use of a 
Pasteur pipette. This extraction procedure was repeated five times. Two 
samples (50 uO were taken from : (i) the plasma before and a fte r the addition of 
"^C -labeta lo l HC1, (ii) from  the "^C -labeta lo l HC1 solution, and ( iii)  from the 
plasma and chloroform a fte r each extraction. Each sample was added to 5 ml 
Dynagel liquid sc in tillan t, and the rad ioactiv ity  measured as previously 
described.
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Measurement o f the amount of unchanged and metabolised labetalol in plasma 
samples from ra t, fe rre t and dog, a fte r labetalol adm inistration
A portion (50 ul) o f each plasma sample was added to 5.0 m l P icofluor-30, 
liquid sc in tillan t, and the to ta l amount o f rad ioactiv ity  was measured as 
previously described, to determine the to ta l amount of labetalol and metabolites 
in the plasma.
A fu rther portion (0.2-0.5 ml) of each plasma sample was extracted w ith  an 
equal volume o f chloroform six times to remove labetalol, as previously 
described. A fte r extraction, a portion (50 pi) of each plasma sample was added 
to 5 ml P icofluor-30, liquid sc in tillan t, and the rad ioactiv ity  measured to 
determine the concentration of labetalol metabolites present in plasma.
The difference between the to ta l amount of labetalol in the plasma and the 
amount of labetalol metabolites was taken as the amount of" u nek tin q c tl
U b f c h t l o !  » -  . y - . . .
The effic iency o f the chloroform extraction of labetalol was estimated fo r 
each series o f plasma samples by adding a known amount o f ^C -la b e ta lo l-H C l (5 
pg) to a control plasma sample (0 .2-0.5 ml) which was then extracted, a t the 
same tim e in the same manner as the others.
Reverse-phase ion-pair HPLC analysis of dog plasma samples a fte r labetalol 
administration
The remainder of the plasma samples collected from two of the dogs given 
labetalol orally and intravenously were combined to give four pooled samples. 
These were freeze dried and the residues dissolved in distilled water (2.0 or 2.5 
ml). An equal volume of absolute ethanol was added to each solution to 
precip itate proteins, and the tubes were centrifuged at 1500g for 15 mins at 4° 
in a Beckman J6 centrifuge. Samples (100 or 250 uD of the supernatant were
- 165 -
injected on to an HPLC column and eluted w ith  a m ixture of 0.05 M sodium 
phosphate pH 7.0, methanol (3:2 v/v), and 1 mM w ith respect to Cetrim ate (for 
details see Experimental Procedures Section, Chapter 4). Serial fractions of 
eluate were collected, every 30 s for the firs t 15 min and every 60 s thereafter, 
from the spectrofluorim eter outle t. The rad ioactiv ity  in each fraction  was 
measured, a fte r the addition of 5 ml Picofluor-30, using a Denley 6882 Mark III 
liquid sc in tilla tion  counter which had a quench correction programme.
Pharmacokinetics of labetalol in the dog
The area under the curve (AUC) o f a dog plasma labetalol concentration 
plot against tim e was calculated by a computer programme (H Hassani and J A 
Bell, Glaxo Group Research L td ., Ware) which uses the trapezoidal method of 
œ IcuWHob (Nota ri, 1975). The AUC fo r labetalol metabolite concentrations in 
dog plasma were also calculation in the same way. The b ioava ilab ility  oral was 
calculated by the formula (Ritschel, 1976):
B ioava ilab ilityoraj
RESULTS
Rat, fe rre t, and dog excreted a large proportion of the oral labetalol, and 
the dog excreted a large proportion of the intravenous labetalol, in the urine 
during the f irs t 24 h (table 5.1). The order of excretion of "^C  into the urine in 
24 h was: female dog > male dog > male ra t > male fe rre t. The labetalol 
metabolite profile  of 0-24 h urine collected from  dog (figure 5.1), given an oral 
dose of the drug, showed the presence of the secondary amine glucuronide, the 
secondary alcohol glucuronide, the o-phenylglucuronide and labetalol, and a 
previously unidentified metabolite (X) which was non-fluorescent. A fte r an oral
AUC dose
oral x  i.v.
do$eoral AUCi.v.
i.v. = intravenous
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TABLE 5.1
T A
Urinary excretion of C-labetaloI by ra t, fe rre t and dog, 
a fte r oral or intravenous dosage of the drug"
Animals were given "^C -labeta lo l orally or i.v ., see 'Materials and 
Methods', and urine was collected between 0-24h. Total rad ioactiv ity  
in urine was measured and expressed as a percentage of dose.
Species Sex Dosageroute
Dose
(mg/kg)
Tota l14C in 0-24 h 
urine (% dose)
Dog female oral 20 56,79
female i.v. 1 72, 85
male oral 30 47 + 0.4a
male i.v. 1 46 + 1.5a
Rat male oral 25 38 + 7.2a
Ferret male oral 25 30 + 7.4a
a mean of three determinations + SEM.
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Figure 5.1
Chromatogram o f urine from dog dosed with labe ta lo l on a QAE Sephadex
A25 column
0-24 h dog urine (1.0 ml) a f te r  oral ^ C - la b e ta lo l  (20 mg/kg), was 
chromatographed on a QAE Sephadex A25 column (30 x 1 cm) with 0.025 ^  
sodium phosphate bu ffe r pH 8.0 using a flow rate o f 1 ml/min. Radio­
a c t iv i t y  added to the column was 4.68 x 10 d.p.m.
R ad ioactiv ity  in  each eluate f ra c t io n  (5 ml) is  given as (------) ,  and
fluorescence at 420 nm (exc ita t ion  wavelength = 334 nm) as (-------).
The e lu t ion  o f a labetalol-HCl standard (86 pg) so lu tion  is  indicated
( + ).
- 168 -
dose of labetalol the 0-24 h urine collected from fe rre t contained the secondary 
alcohol glucuronide, the O-phenylglucuronide and labetalol, and another 
previously unidentified metabolite (Y) which was fluorescent (figure 5.2). The 
Sephadex chromatogram of urine from ra t given an oral dose of labetalol showed 
only the presence of labetalol and its O-phenylglucuronide (figure 5.3).
Labetalol is known to be removed from  urine and plasma samples by 
chloroform extraction (Martin et al., 1976). I f  this extraction is at neutral pH 
there is l it t le  removal o f labetalol glucuronides (Chapter 4). The e ffic iency of 
extraction (figure 5.4) was 93% fo r six serial chloroform extractions o f control 
ra t plasma. This procedure was routinely adopted in order to measure the 
concentration o f the remaining metabolites by radioachemical analysis. The 
e ffic iency of extraction was measured for each series of plasma samples, and the 
mean value was 91% + 0.6.
In ra t (figure 5.5) and dog (figure 5.6) the oral plasma labetalol 
concentration (expressed as a percentage of the dose) was sim ilar to the 
intravenous labetalol concentration (expressed as a percentage of the dose) a fte r 
l i  h. In the fe rre t more of the labetalol dose appeared in the plasma a fte r 
intravenous administration than a fte r oral adm inistration (figure 5.7, table 5.2). 
However, because of the erra tic  results of the plasma analysis a fte r oral 
adm inistration of labetalol to the fe rre t i t  is d if f ic u lt to review these results. 
The concentration of labetalol metabolites in ra t and dog plasma (expressed as 
percentages of the doses given) appeared to be greater a fte r intravenous 
administration of the drug than a fte r oral adm inistration. The radioactive 
metabolites in ra t plasma a fte r intravenous dosage rises to a maximum at 1 h, 
fa lls o ff, and then begins to rise to a second maximum (figure 5.5). This may be 
explained by enterohepatic recirculation, but this has not been previously 
reported.
The results from the ra t and fe rre t were not suitable fo r calculating the
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Figure 5.2
Chromatogram o f  urine from fe r re t  dosed with la b e ta lo l ,  on a QAE
Sephadex A25 column
0-24h fe r re t  urine (1.0 ml) a f te r  oral ^ C - la b e ta lo l  (20 mg/kg), 
was chromatographed on a QAE Sephadex A25 column (30 x 1 cm) with
0.025 M sodium phosphate bu ffe r pH 8.2 using a flow rate o f 1 ml/min. 
R ad ioactiv ity  added to the column was 4.18 x 10^ d.p.m.
R ad ioactiv ity  in each eluate f ra c t io n  (5ml) is  given as ( --------- ),
and fluorescence at 420 nm (exc ita t ion  wavelength = 334 nm) as 
( ).
The e lu t ion  o f a labeta lo l HC1 standard (86 pg) so lu tion  is  
indicated (+).
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Figure 5.3
Chromatogram of urine from ra t  dosed with labe ta lo l on a QAE
Sephadex A25 column 
140-24h ra t  urine (0.5 ml) a f te r  oral C -labeta lo l (20 mg/kg), was
chromatographed on a QAE' Sephadex A25 column (30 x 1 cm) with 0.025 M
sodium phosphate bu ffe r pH 8.2 using a flow  rate o f 1 ml/min.
5
R ad ioactiv ity  added to the column was 4.22 x 10 d.p.m. R ad ioactiv ity
in each eluate f ra c t io n  (5 ml) is  given as (-------- ), and fluorescence
at 420 nm (exc ita t ion  wavelength = 334 nm) as (---------).
The e lu t ion  o f a labeta lo l HC1 standard (111 ug) so lu tion is  
indicated (+).
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Chloroform extractions
Figure 5.4
E ff ic iency  o f  the chloroform ex trac t ion  o f labe ta lo l from
ra t  plasma
^ C - la b e ta lo l  HC1 (0.6 pg or 8.59 x 10^ d .p .m .) added to 
2.55 ml ra t  plasma was extracted with an equal volume o f 
chloroform s ix  times. A fte r  each e x tra c t io n , the amount o f 
ra d io a c t iv i ty  in plasma and chloroform (50 p i)  was determined. 
The amount o f ra d io a c t iv i ty  in the plasma (o) and the 
cumulative amount o f ra d io a c t iv i ty  in the chloroform (o) is  
expressed as a percentage o f the i n i t i a l  amount o f rad io ­
a c t iv i t y  in the plasma.
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Figure 5 .5 . Semi-log p lo t of the concentrations of labetalo l and its  metabolites 
in the plasma of rats given an oral or intravenous dose of la b e ta lo l.
Male Wistar albino rats were given an oral (25mg/kg) or an intravenous dose (1 mg/kg) 
of ^ C -la b e ta lo l. Blood samples were taken at various time points and the concentrations
of unchanged drug (o o, A-------A ,fo r  oral and intravenous dosage, respectively) and its
metabolites ( * — #, i  -— a , oral and intravenous) were determined from the amount of C 
in  the plasma before and a fte r chloroform extraction . Results are expressed as 
percentage of the dose per ml of plasma and are from three animals; where time points 
coincided means were calculated, the bars represent the S.E.M.
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Figure 5 .6 . Semi-log p lot of the concentrations of labetalo l and its  metabolites 
in the plasma of dogs given an oral or intravenous dose of la b e ta lo l.
Male beagles were given an oral (30 mg/kg) or an intravenous dose (0 .9  mg/kg) of 
C -lab eta lo l. Blood samples were taken at various time points and the concentrations
of unchanged drug (o o, a------ A, fo r oral and intravenous dosage respectively) and
its^m etabolites ( * — ■•, i ------ 4 , oral and intravenous) were determined from the amount
of C in the plasma before and a fte r chloroform extraction . Results are expressed 
as percentage of the dose per ml of plasma and are from three animals; the bars 
represent the S.E.M.
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TABLE 5.2
The concentrations o f labetalol and labetaloLryetabolites 
in the plasma of ferre ts given an oral dose of C -labetalol
Male ferre ts were given an oral dose (25 mg/kg) ^C -la b e ta lo l. Blood samples were 
taken at various tim e points and the concentrations of labetalol and its metabolites 
were determined from  the amount o f "^C  in the plasma before and a fte r 
chloroform extraction. The results are expressed as ug/m l and as percentage of 
the dose/ml.
Ferre t 1 Ferret 2
Time
(h)
Labetalol 
concentration 
in plasma
Labetalol metabolite 
concentration in 
plasma
Labetalol 
concentration 
in plasma
Labetalol 
m etabolite 
concentration 
in plasma
ug/ml % doge 
x 10^
ug labetalol 
equivalent/m l
%dose ug/ml % doge 
x 1 0 ^ x KT
ug labetalol % 
equivalent/m l x
doge 
; 10
0.5 0.9 1.9 0.7 1.5 6.4 17.0 3.0 8 .1
1 .0 0.3 0 .6 2 .8 5.9
1.5 4.3 11.3 3.1 8 .1
2 .0 2 .8 5.8 1 .0 2.1 3.2 8.4 3.0 7.8
3.5 1.8 3.7 1 .2 2.5
4.0 0 .6 1.2 2 .6 5.4
4.5 2 .2 5.7 1.5 3.9
5.0 1 .6 3.4 1.3 2 .6
5.5 2 .0 5.3 1.1 2.9
6 .0 2 .8 6 .0 0.5 1.0
6.5 2.0 5.3 1.1 2.9
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Figure 5 .7 . Semi-log p lo t of the concentrations of labeta lo l and its  metabolites 
in the plasma of fe rre ts  given an intravenous dose of la b e ta lo l.
Male fe rre ts  were given an intravenous dose (1 mg/kg) of ^ C -la b e ta lo l. Blood samples
were taken a t various time points and the concentrations of unchanged drug ( a a )
and its  metabolites (i i) were determined from the amount o f 14C in the plasma before
and a fte r  chloroform extraction . Results are expressed as percentage of the dose per 
ml of plasma and are from two animals ; where time points coincided means were calculated,
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area under the curve (AUC) fo r labetalol and its metabolites so i t  was not 
possible to  estimate the b io a v a il ib il i ty ^ ^  for these animals. The 
b ioava ilab ilityora| fo r plasma labetalol in dog was 0.82 (table 5.3), which being 
less than one, indicates that first-pass metabolism of labetalol by the live r and 
gastrointestinal tra c t may have occurred in dog. The b io a v a il ib il i ty ^ ^  fo r 
plasma labetalol metabolites in dog was 0.87 (table 5.3). This does not 
necessarily indicate that there was less metabolism of labetalol a fte r an oral 
dose than a fte r an intravenous dose of the drug because the concentration of 
labetalol metabolites in the plasma does not take into account o f metabolites 
which are excreted via the bile.
I t  was necessary to  concentrate the rad ioactiv ity  in dog plasma samples for 
detection of labetalol metabolites by reverse-phase ion-pair HPLC. The HPLC 
chromatograms of plasma samples collected a fte r oral adm inistration to dog 
(figures 5.8 and 5.9) and of those collected a fte r intravenous adm inistration of 
the drug (figures 5.10 and 5.11) show the presence of the same metabolites. 
These are the O-phenylglucuronide, the secondary alcohol glucuronide, the 
secondary amine glucuronide, labetalol, and two previously unidentified 
metabolites (C and D). Metabolite C and D have retention times of 3 and 19 min, 
respectively, and both metabolites are non-fluorescent. Insuffic ien t blood was 
collected from ra t and fe rre t to carry out HPLC analysis.
DISCUSSION
The metabolism of labetalol by ra t, fe rre t, and dog was shown to d iffe r 
because of the d iffe ren t labetalol metabolites detected in the ir respective urines 
(table 5.4). Sim ilar observations have been previously reported on the major 
labetalol glucuronides detected in the urine from ra t and dog (Hopkins et al., 
1976; Martin et al., 1976; Oxford, 1980). The present study showed that labetalol 
metabolism by the fe rre t d iffers from that by the dog because no secondary
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Figure 5.8. Chromatogram of combined plasma samples from dog 1, dosed with 
labeta lo l o ra l ly ,  on an HPLC colurnnT
The remainder o f the plasma samples a f te r  oral ^ C - la b e ta lo l  (30 mg/kg) were 
combined, freeze dr ied , and the residue dissolved in 2.0 ml d i s t i l l e d  water 
followed by the addition of an equal volume o f absolute ethanol. The super­
natant (lOOyl) was chromatographed on an HPLC column (see 'M ateria ls  and 
Methods', Chapter 4). R ad ioactiv ity  added to the column was 1.04 x 10 d.p.m. 
Rad ioactiv ity  in each eluate f ra c t io n  (0._5ml fo r  0-15 min, 1.0ml fo r  15-60 min)
is  given as ( ------) ,  and fluorescence at 420 nm (exc ita t ion  wavelength = 334 nm)
as (-------).
The e lu tion  of 14,: ^C-labetalol (100 ng, 5.55 x 10 d .p .m .), 0-phenyl-glucuronide-
(87 ng, 4.8 x 10 d.p .m .), and secondary alcohol g lucuron ide ,(130 ng, 7.3 x 10 
d.p.m.) standards are given as (> ) labe lled with L, M2 or M3, respective ly
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Figure 5 .9 . Chromatogram o f combined plasma samples from dog 2, dosed 
w ith  labe ta lo l o r a l ly ,  on an HPLC column.
The remainder o f the plasma samples a f te r  oral ^ C - la b e ta lo l  (30 mg/kg) 
were combined, freeze d r ied , and the residue dissolved in 2.5 ml d i s t i l l e d  
water followed by the addition of an equal volume o f absolute ethanol. The 
supernatant (lOOwl) was chromatographed on an HPLC column (see "M ateria ls^ 
and Methods', Chapter 4). R ad ioac tiv ity  added to the column was 9.8 x 10 
d.p.m. R ad ioactiv ity  in each eluate f ra c t io n  (0.5 ml fo r  0-15 min, 1.0 ml
fo r  15-60 min) is given as (------ ) ,  and fluorescence at 420 nm (e xc ita t io n
wavelength =\334 nm) as (-------).
The e lu t ion  o f^ îc - la b e ta lo l  (100 ng, 5.55 x 10^ d .p .m .), O-phenylglucuronide 
873ng, 4.8 x 10 d .p .m .), and secondary alcohol glucuronide (130 ng, 7.3 x 
10 d.p.m.) standards are given as (* ) labe lled  with L, M2 or M3, respective ly
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Figure 5.10. Chromatogram of combined plasma samples from dog 1, dosed 
with labe ta lo l in travenous ly , on an HPLC column.
The remainder o f the plasma samples a f te r  intravenous ^ C - la b e ta lo l  (30 mg/kg) 
were combined, freeze dr ied , and the residue dissolved in 2.0 ml d i s t i l l e d  
water followed by the addition o f an equal volume o f absolute ethanol. The 
supernatant (250yl) was chromatographed on an HPLC column (see 'M a teria ls  and 
Methods', Chapter 4). R ad ioac tiv ity  added to the column was 1.5 x 10 d.p.m. 
R ad ioac tiv ity  in each eluate f ra c t io n  (0.5 ml fo r  0-15 min, 1.0 ml fo r  15-60
min) is given as ( ------) ,  and fluorescence at 420 nm (E xc ita tion  wavelength =
334 nm) as (-------).
The e lu t ion  o f l^C - labe ta lo l (100 ng, 5.55 x 10^ d .p .m .), O-phenylglucuronide^ 
87 ng, 4.8 x 10 d.p .m .), and secondary alcohol glucuronide (130 ng, 7.3 x 10 
d.p.m.) standards are given as (4-) labe lled w ith L, M2 or M3, respec tive ly .
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Figure 5.11. Chromatogram of combined plasma samples from dog 2, dosed with 
labe ta lo l in travenously, on an HPLC column.
The remainder o f  the plasma samples a f te r  intravenous ^ C - la b e ta lo l  (30 mg/kg) 
were combined, freeze dr ied , and the residue dissolved in  2.0 ml d i s t i l l e d  water 
followed by the addition o f  an equal volume o f absolute e thanol. The supernatant 
250yl) was chromatographed on an HPLC column (see 'Materia ls  and Methods',
Chapter 4). R ad ioactiv ity  added to the column was 1.4 x 104 d.p.m. R ad ioac tiv ity  
in each eluate f ra c t io n  (0.5 ml fo r  0-15 min, 1.0 ml fo r  15-60 min) is  given 
as ( ------- ) ,  and fluorescence at 420 nm (e xc ita t io n  wavelength = 334 nm) as (------ ).
The e lu t ion  o f ^C - la b e ta lo l  (100 ng, 5.55 x 103 d .p .m .), O-phenylglucuronide
3 ?(87 ng, 4.8 x 10 d .p .m .), and secondary alcohol glucuronide (130 ng, 7.3 x 10
d .p .m .) standards are given as (f ) labe lled  with L, M2 or M3, respective ly .
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amine glucuronide was observed in the urine of the form er. Two previously 
unidentified labetalol metabolites were detected; metabolite X (non-fluorescent) 
is present in dog urine and metabolite Y (fluorescent) is observed in fe rre t urine. 
This difference in metabolism of labetalol by the fe rre t and the dog indicates 
that the fe rre t is unlikely to be a suitable animal model fo r labetalol metabolism 
in man.
Labetalol metabolites appeared in ra t and fe rre t plasma at a faster rate 
a fte r intravenous administration of labetalol than a fte r oral adm inistration 
(figures 5.5, 5.7; table 5.3). This could have been the result o f more rapid drug 
metabolism or o f more rapid release of metabolites from the tissues. The la tte r 
is more like ly because these animals were anaethetised during the collection of 
blood samples a fte r intravenous administration of labetalol. Ethylcarbamate 
(the anaesthetic) could have altered cell permeability. The ra t plasma labetalol 
metabolite concentration/tim e curve a fte r intravenous adm inistration (figure 
5.5) indicated that enterohepatic recircu lation of labetalol or its metabolites 
may have occurred. As this has not been previously reported fu rthe r 
investigations would be necessary to confirm  this. The small volumes of blood 
which were collected from the ra t and fe rre t may have been a cause of the error 
in the estimation of the concentration of labetalol and its metabolites in the 
plasma of these animals. This was the most like ly reason fo r the e rra tic  results, 
especially from  the fe rre t a fte r the oral administration of labetalol. The e rra tic  
ra t and fe rre t plasma labetalol concentration values were therefore unsuitable 
fo r detailed pharmacokinetics analysis.
In the dog, the b i o a v a i l a b i l i t y o f  labetalol (0.82, table 5.3) being less 
than 1 .0  indicated that first-pass metabolism by the live r and gastointestinal 
tra c t may have occurred. The b ioavailability org| of labetalol metabolites (0.87, 
table 5.3) indicated that there was more metabolism of the drug a fte r 
intravenous administration than a fte r oral adm inistration of the drug. The la tte r
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bioavailab ility  may be low for two reasons. The intravenous dose (1 mg/kg) 
was much lower than the oral dose (30 mg/kg) causing differences in metabolism 
because drug metabolism has been shown to vary w ith  dose (Mehta et al., 1978). 
Furthermore, the b ioavilab ility  Qraj fo r metabolites does not take into account 
any b ilia ry  excreted metabolites which may be proportionately greater a fte r the 
oral dose than a fte r the intravenous dose of the drug.
The same labetalol metabolites were dectected by HPLC analysis in plasma 
samples collected from dogs given oral and intravenous doses of the drug (figures 
5.8 - 5.11, table 5.4). Although the secondary amine glucuronide was observed in 
the urine from  dogs (figure 5.1) i t  was not detected in the plasma. This could be 
explained i f  the secondary amine glucuronide was formed in the kidney. In 
addition to the previously identified metabolites of labetalol, four unidentified 
metabolites were detected in the present study: metabolite X (non-fluorescent) 
found in the urine of dogs (figure 5.1), metabolite Y (fluorescent) found in the 
urine o f the fe rre t (figure 5.2), metabolite A (fluorescent) and metabolite C 
(non-fluorescent) both of which were found in the plasma from dogs (table 5.4). 
The possible identities of these previously unidentified metabolites is discussed 
in Chapter 7.
In summary, the results from this study indicated that the fe rre t may not 
be a suitable animal model fo r the metabolism of labetalol in man because its 
metabolite profile  is d iffe rent in dog and man. First-pass metabolism by the 
gastrointestinal tra c t and liver in dog may occur. F inally, four previously 
unidentified labetalol metabolites were detected.
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TABLE 5.4 .
Summary of the metabolites o f C -labetalol detected in the 
urine and plasma from  dog, fe rre t, and ra t given an oral 
dose of labetalol
The animals were given an oral or an intravenous dose of C-labetalol, and urine 
and plasma samples were collected. The samples were chromatographed on either 
a QAE Sephadex A25 Column (SC) or on an HPLC column. Labetalol and its 
metabolites were detected by radiochemical analysis o f the eluate and 
fluorescence in the eluate. For details o f procedure see Materials and Methods 
section.
Sample Routedose
Method of 
separation Labetalol I II
Metabolites 
III X Y A C
ra t
urine
oral SC + +
fe rre t
urine
oral SC + + + +
dog
urine
oral SC + + + + +
dog
plasma
oral HPLC + + + + +
dog
plasma
i.v. HPLC + _L + + +
Metabolite I = secondary amine glucuronide
Metabolite II = O-phenylglucuronide
Metabolite III = secondary alcohol glucuronide
Metabolites X, Y, A, and C have not been previously identified
i.v. = intravenous.
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Chapter 6
Glucuronide conjugation of labetalol in the liver and gastrointestinal 
tract using perfused organ preparations from the rat, ferret, and dog
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INTRODUCTION
Previous studies have shown that labetalol was well absorbed from the 
intestine in the ra t and dog (Martin et al. 1976) and fe rre t (Chapter 5). Although 
the metabolism of labetalol by these species is d iffe ren t there is evidence that 
this drug undergoes first-pass metabolism by the intestine and/or live r in the ra t, 
dog, and fe rre t.
The isolated ra t live r perfusion has been used as a model fo r in vivo drug 
metabolism. A liver perfusion preparation from  the Sprague-Dawley ra t was 
shown to metabolise 35 pmoles of 1-naphthol in a period of 30 min, the major 
metabolite being the glucuronide, 30% of the dose was present in the perfusate, 
23% of the dose was in the bile, and 13% in the live r, w ith  23% of the dose in the 
perfusate as the sulphate conjugate (Bock, 1974). A Wistar ra t live r preparation 
perfused w ith  2-aminophenol, in the presence of pentan-3-one, fo r 60 min, 
metabolised 16% of the dose present in the perfusate as the glucuronide, and a 
sim ilar Gunn ra t live r preparation resulted in 13% of the dose being detected as 
glucuronide in the perfusate (Burchell and Bock, 1980).
The vascularly perfused intestine, in s itu , or isolated intestine loop, in s itu , 
preparations have been used to assess the contribution o f the intestine to f irs t-  
pass drug metabolism. The concept tha t the liver was the major organ of phenol 
detoxication was questioned when 72% of a dose o f phenol, injected into the 
lumen of a ra t intestine, was observed in the hepatic portal venous blood as the 
sulphate conjugate and 28% was present as the glucuronide conjugate a fte r 
vascularly perfusing the intestine fo r 120 min (Powell et al. 1974). Using a 
sim ilar preparation, 44% of a dose of salicylamide injected into the lumen of the 
intestine was metabolised to the glucuronide and sulphate conjugates a fte r 60 
min (Sakai et al. 1980). Isolated ra t and guinea pig intestinal loop preparations, iri 
s itu , metabolised between 50-91% of a dose of naphthol, introduced into the 
lumens, to the glucuronide a fte r 15 min (Turner et al. 1980). Also, the major part 
of the first-pass metabolism of isoprenaline and isoentharine was observed to be
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carried out by an isolated intestine loop preparation in the dog (George et al. 
1974; George, 1981).
The object of this study was to investigate the first-pass metabolism of 
labetalol and assess the contributions made by the liver and intestine in the 
formation of labetalol glucuronides. The isolated live r perfusion preparation, and 
the vascuiarly-perfused intestine preparation, in s itu , were suitable fo r use w ith  
the ra t and fe rre t. However, the only technique available fo r the dog was the 
isolated intestine loop, in s itu .
MATERIALS AND METHODS
Materials
Labetalo l-HC l and ^C -la b e ta lo l-H C l, specific ac tiv ity  25 mCi/g 
(Amersham), were g ifts  from  Dr. L.E. M artin, Glaxo Group Research, Ware, UK;. 
Heparin and cetyltrim ethylam m onium  bromide (cetrim ide) were purchased from  
BDH Chemicals L td ., Poole, Dorset, UK; sodium pentobarbitone (Sagatal) from  
May and Baker L td ., Dagenham, UK; bovine serum albumin from  Sigma Chemical 
Co., Poole, Dorset, UK; Picofluor-30 from  Packard Instrument Co., Reading, 
U.K., Dynagel from  J.T. Baker Co., Phillipsburg, N.J., USA; internally polished 
stainless steel HPLC column shells (5 mm in t. diam. x 100 mm) from Shandon 
Southern Products L td ., Runcorn, UK; Soluene from Packard Instrument Co., 
Reading, U.K., and Sherisorb-ODS from Phase Separations Ltd ., Clwyd, UK.
A ll solvents and the rest of the chemicals used were of Analar grade. 
Animals and Experimental Procedures
Animal treatm ent
Five male Wistar albino rats (30O-40Og) and one male beagle dog (9.6 kg) 
bred and housed at Glaxo Group Research, Ware, three male ferrets (1.5 - 2.0 
kg), mustela putorius furo , from Froxfie ld Rabbit Farm, Petersfield, Hants., and 
sixteen male MRC hooded rats (20O~4OOg) bred and housed at University College,
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C ard iff, Wales, were used in this study. A ll the animals were given food and 
water ad lib itu m .
Experimental Procedures 
Rat and fe rre t live r perfusions (Bell, 1981)
e
Four male Wistar albino rats, anaesthetised w ith  halothane, were 
term inally bled from  the dorsal aorta using a syringe, the blood being mixed w ith  
2 ml 0.9% saline (w/v) containing 10 mg heparin. A male fe rre t, anaesthetised 
w ith  ether, was term ina lly exsanguinated by cardiac puncture, the blood being 
immediately mixed w ith  30 mg heparin. The blood thus collected was then 
diluted w ith Krebs Ringer solution in the ra tio  o f 1:2 (v/v) giving to ta l perfusate 
volumes of 123 ml fo r the ra t live r and 138 ml fo r the fe rre t live r. The perfusion 
medium was poured into the reservoir o f the live r apparatus, in a cabinet 
maintained at 37°C, and allowed to circulate so that a stable temperature and 
level o f oxygenation could be reached.
Anaesthesia was induced in the Wistar ra t and the fe rre t using halothane 
and 1.4 ml Sagatal, 60 mg sodium phénobarbital per m l, given intra-peritonea lly 
over a period of 40 min, respectively. The hair on the abdomen was removed 
using an e lectric animal hair clipper and the skin was swabbed w ith  an 80% 
alcohol solution. A midline incision, made to expose the live r, was followed by 
cannulation of the hepatic portal vein, the in fe rio r vena cava, and the bile duct 
w ith  portex tubing. A fte r all the other blood vessels surrounding the live r were 
ligated, the heparinised perfusion medium (10 ml) was flushed through the live r 
via the hepatic portal vein. The liver was quickly and carefu lly excised and 
placed on a damp gauze on the liver p latform  in the perfusion cabinet. The 
hepatic portal vein was connected to the tube conveying perfusion medium from 
the a rtif ic ia l lung, ensuring that air bubbles were not introduced into the 
medium, and the inferio r vena cava cannula was connected to the perfusion 
medium reservoir. The perfusate was allowed to circulate fo r 15-25 min and the
- 189 -
flow rate measured (8.5 m l/m  in fo r the ra t live r perfusion and 25.7 m l/m in fo r 
the fe rre t live r perfusion). The ^C -la b e ta lo l-H C l, 7 mg fo r the ra t live r and 7.5 
mg fo r the fe rre t live r preparation, was dissolved in 10 ml 0.9% saline and 
transferred to the perfusion medium reservoir. Samples of perfusate was taken 
from the reservoir at various tim e points during the perfusion period, 120 min. 
The perfusate was centrifuged at 1500g fo r 25 min at 4°C to yield the perfusate 
supernatant, which along w ith the bile exudate, was collected over various tim e 
points, and then stored at -40°C.
Rat intestinal perfusion (Wishart, 1982)
€.
Fifteen male MRC hooded rats, anaesthetised w ith  ether, were term ina lly 
exsanguinated by inserting a portex tubing cannula into the dorsal aorta, the 
blood being collected in a flask containing 25 mg heparin. The to ta l volume of 
blood, 138 m l, was transferred to the perfusion medium reservoir, in a cabinet 
maintained at 37°C, and allowed to circulate the perfusion apparatus so that it  
could equilibrate at a stable termperature and oxygenation level.
A tracheotomy and le f t external jugular vein cannulation were performed 
on a MRC hooded ra t, anaesthetised w ith ether. A syringe containing Sagatal, 60 
mg sodium pentobarbitone per ml, diluted w ith  0.9% saline in the ra tio  1:1 (v/v) 
was connected to the cannulated jugular vein and the mode of anaesthesia 
carefu lly transferred from  ether to Sagatal. The stomach, duodenum, and the
5
large intestine were removed a fte r ligating the oesophagus, intestine, at the
duodenal flexure and rectum, together w ith the relevant blood vessels supplying
and draining these tissues. A fte r cannulae were inserted into the hepatic portal
vein and dorsal aorta, 10 ml of blood from the perfusion reservoir was flushed
into the dorsal aorta as soon as it  was ligated. The animal was quickly
transferred to a platform  in the perfusion carbinet and the dorsal aorta was
connected to the tube conveying blood from the ' a rtif ic ia l lung (figure 6.1),
ensuring that no air bubbles were introduced into the blood. A 25 mg/kg dose of 
^  Q .  Z / > v l  &-> < 5 ^ 2 A e u ry Q . ü n i  âr> Z & O fric t A dXJiS '
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Veins draining 
small intestine
HEPATIC PORTAL VEIN
Ligature iso lâ t 
hepatic portal 
from liv e r
Ligature securing 
catheter
Portex tubing 
from hepatic 
portal 
vein to 
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The stomach and duodenum were 
removed leaving the rest of the 
small in testine in s itu .
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the hepatic portal 
vein was collected  
in fractions a t 5 min 
in terva ls
Ligature at 
.duodenal flexure
The drug dose was 
injected into  the 
in te s tin a l lumen
Ligature iso la ting  
the dorsal aorta 
from the heart
Blood supply 
d irec t from 
a r t i f ic ia l  lung
Portex tubing
Ligature securing 
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Figure 6 .1 . A schematic representation of the small in testine  preparation 
of ra t and fe rre t which was perfused jn  s itu .
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1 A
labetalol-HC l, 11.5 mg including 1.2 mg C-labeta lo l-HC l, in aqueous solution,
was injected into the upper jejunal lumen and a damp gauze was placed over the
of l&iYvptWC;Hvfe
open abdomen to minimise any fluid^loss from the exposed tissues. A ll the blood 
draining from  the hepatic portal vein was collected in serial fractions of 5 min 
intervals; that is, the blood was not recirculated. The tim e taken from in itia lly  
anaesthetising the animal to the start o f the perfusion was 50 min. The average 
blood flow through the preparation during the firs t hour was 0.9 m l/m in and over 
the last hour was 0.3 m l/m in. A haematocrit was performed on each blood 
sample, the mean ratio  o f packed cells to to ta l blood volume was 0.4 + 0.03. Gut 
m o tility  was observed throughout the perfusion period which was term inated by 
k illing  the animal. A  portion of whole blood (50 pi) was taken from each fraction  
prior to weighing the fractions of blood in tared tubes to measure the volume, 1 
m l ra t blood = Ig . The blood fractions were centrifuged at 1500g fo r 25 min at 
4 °G and the plasma was separated from  the red blood cells. A t the end of the 
perfusion period, 135 min, the intestine was excised and the contents flushed out 
w ith  water into a container. The intestine, intestinal contents, whole blood, red 
blood cells and plasma, were stored at -40°C.
Ferret intestinal perfusion
The method used was essentially the same as that fo r the ra t intestine 
perfusion, as detailed above; however, there were certain modifications.
A litre  of outdated human blood, ABO Rhesus4", from C ard iff transfusion 
unit, was centrifuged at 1500g fo r 15 min at 4°C and the plasma was discarded. 
The red blood cells were resuspended in 600ml Tyrode solution:
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made up to 5L w ith 
distilled water
NaCl 40g
KC1 Ig
C aC ^ Ig
MgCl^ 0.5g
NaH2PO4.H20 0.25g
Glucose 5g
NaHCO^ 5g
The resuspended blood cells were then centrifuged, using the same conditions,
and the supernatant discarded; this procedure was repeated tw ice. F inally the
400 ml red blood cells were resuspended in 600 ml Tyrode solution, containing
I
3.9% (w/v) bovine serum albumen, which was then used as the perfusion medium.
The fe rre t was in itia lly  anaesthetised w ith  1.2 ml Sagatal given in tra -
peritoneally over a period o f 15 min. The syringe connected to the external
jugular cannula contained 50% Sagatal and 50% Tyrode solution (v/v). Tyrode
solution (50 ml), containing 1000 units o f heparin, was flushed through the dorsal
e
aorta to wash out the fe rre t blood. This was to reduce the likl^hood of any
precip itation of the human red blood cells (of the perfusion flu id) by the fe rre t
blood when the cannula from the a rtif ic ia l lung was connected to the dorsal
aorta o f the fe rre t. The animal remained on a table outside the perfusion
cabinet, two lamps being used to help maintain the animal's body temperature. A
1422 mg/kg dose o f labetalol, 48.8 including 4.3 mg C -labeta lo l-HC l, was 
dissolved in 5 ml water and injected into the upper jejunal lumen. The tim e taken 
from the in itia l anaethesia to starting the perfusion was 137 min. The average 
perfusion medium flow rate over the f irs t hour was 3.67 m l/m in, and over the 
last hour was 2.43 m l/m in. Gut m o tility  was observed throughout the whole 
perfusion period; perfusion was term inated by k illing  the animal. Three random 
samples o f perfusate were taken to perform haemotocrits, the ra tio  o f packed 
red blood cells to whole perfusate was 0.33 + 0.008.
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Isolated dog intestinal loop, in situ (George et al. 1974)
The beagle was anaesthetised w ith  thiopentone sodium (25 mg/kg, i.v.), 
anaesthesia was maintained w ith  pentobarbitone (25 mg/kg), and phenoxy- 
benzamine (50 mg i.v.) was administered just before surgery to maintain 
intestinal m o tility .
A loop of intestine, term inal duodenum anlproximal jejunum approximately
12 cm in length, was isolated between two balloon catheters and a polythene
cannula was inserted into the vein draining the loop (figure 6.2). A fte r flushing
14the loop w ith  0.9% saline, a 4.7 mg/kg dose of labetalol (including 2.9 mg C- 
labetalol-HCl), in aqueous solution was injected into the lumen of the intestine. 
Samples of abdominal aorta blood and serial fractions of venous blood draining 
the intestine loop were taken at 3 min intervals. The blood samples were 
centrifuged at 1500g fo r 25 min at 4°C, the plasma was separated from  the red 
blood cells and stored at -40°C.
Measurements of rad ioactiv ity  in the whole blood, whole perfusate, plasma, and 
perfusate supernatant samples
Samples (50-100 pi) o f dog and ra t plasma were added to 5 ml Picofluor-30, 
and the levels o f rad ioactiv ity  were measured in an LKB Walac 1210 U ltrabeta 
liquid sc in tilla tion  counter. The rad ioactiv ity  was expressed in disintegrations 
per minute (d.p.m) (see Materials and Methods, Chapter 4).
Samples (50 pi) o f whole blood or whole perfusate, and perfusate 
supernatant from the ra t intestine and fe rre t intestine, and liver perfusions were 
decolourised by adding 0.3 ml H^O^, drop by drop from a Pasteur pipette, and 
incubated in a water bath fo r 1 h. A fte r the addition of 8 ml Picofluor-30, the 
level of rad ioactiv ity  was measured using the liquid sc in tilla tion  counter, as 
above.
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Figure
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Catheter for collection 
of venous effluent
.2 . A diagram of the isolated dog in te s t in a l  
loop in s i tu .  
( I l l e t  and Davies, 1982)
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Measurement of labetalol and metabolites
Samples (0.2 - 0.5 ml) of plasma or perfusate supernatant were added to an 
equal volume o f chloroform and extracted fo r 15 min on a ro tary extractor at 
room temperature followed by centrifugation at 1500g fo r 15 min at 10°C. The 
chloroform was removed using a Pasteur pipette and the extraction was repeated 
five  times. A known quan titity  o f ^C -la b e ta lo l-H C l (0.5 pg) was added to a 
control sample o f plasma or perfusate supernatant, and extracted in the same 
manner, at the same tim e as the other samples in order that the extraction 
e ffic iency of labetalol could be measured; e ffic iency was found to be between 93 
- 98%. A sample (50 pi) o f the extracted plasma or perfusate supernatant was 
then added to 5 ml Picofluor-30 and the level of rad ioactiv ity  was measured 
using the sc in tilla tion  counter, as above.
HPLC analysis o f plasma or perfusate supernatant samples
The concentration of rad ioactiv ity  in the individual plasma was too low fo r 
identifica tion  o f metabolites by HPLC analysis and consequently i t  was 
necessary to concentrate the blood samples. The samples of plasma or perfusion 
flu id  supernatant remaining a fte r measuring the to ta l rad ioactiv ity  and 
metabolite content were combined together and freeze dried. The residues thus 
obtained were dissolved in smaller volumes of d istilled water:
Perfusate supernatant Volume of water (ml)
ra t: liver 2
intestine 3
fe rre t: liver 2
intestine 15
dog: intestine 6
Equal volumes of absolute alcohol were added, to precip itate the proteins in 
solution, and the tubes were centrifuged at 1500g for 15 min at 4°C. Samples 
(25, 100, or 250 pi) o f the supernatants were then injected on to an HPLC column 
(see 'Materials and Methods', Chapter 4, fo r details of procedure) and
” 1 9 6 -
rad ioactiv ity  levels in serial eluate fractions collected every 30s from 0-15 min 
and every 60s from  15-40 min, were measured as before.
Measurement o f rad ioactiv ity  in intestine and intestinal contents a fte r perfusion 
The ra t and fe rre t intestines were weighed and homogenised, as were the 
intestinal contents, in water using a polytron homogeniser; the volumes of the 
homogenates were measured. Four samples (0.1 - 0.5 ml) o f each homogenate, 
approximately 50 ug protein, were added to 0.25 - 0.5 ml soluene and incubated 
at 37°C overnight to digest the protein. Picofluor-30 (10 ml) was added to each 
vial and the amount of rad ioactiv ity  measured in the liquid sc in tilla tion  counter, 
as above.
RESULTS
Perfusion of the ra t live r w ith  labetalol
The to ta l labetalol, labetalol plus metabolites in the perfusate supernatant 
decreased w ith  tim e (figure 6.3) and the concentration of labetalol per m l of 
perfusate supernatant decreased in an exponential manner w ith  tim e. The 
appearance of labetalol metabolites in the perfusate supernatant rapidly 
increased during the period 0-45 min and then decreased slightly (figure 6.3, 
table 6.1). The amount o f labetalol excreted into the bile was 0.97% of the dose 
(table 6.1); the average rate of bile flow from  0-75 min was 8 p l/m in, but the 
flow  ceased at 75 min. A fte r perfusing the liver fo r 120 min, 16.8% of the 
radioactive labetalol dose was detected in the perfusate supernatant, 4.4% being 
labetalol and 12.4% being metabolised labetalol (table 6.2). HPLC analysis of the 
combined perfusate supernatant samples was a sem i-quantitative determ ination 
to detect which metabolites were present (figure 6.4). Three radioactive 
components were observed in the HPLC eluate; a previously unidentified 
metabolite (A), the O-phenylglucuronide (M2), and labetalol (L).
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14Figure 6.3 Metabolism o f C-labetalo l by a perfused iso la ted 
ra t  l i v e r  preparation
An iso la ted ra t l i v e r  perfused with 6.3 mg ^C - la b e ta lo l  in a 
perfusion medium, one part ra t  blood and two parts Krebs Ringer. 
A fte r removing the red blood c e l ls ,  the amount o f ra d io a c t iv i ty  
in various samples o f perfusate supernatant were used to ca lcu la te  
the amounts o f ^ C - la b e ta lo l plus i t s  metabolites (a ). The 
ra d io a c t iv i ty  remaining in the perfusate supernatants a f te r  
chloroform ex trac t ion , to remove the la b e ta lo l ,  was used to 
ca lcu la te  the amount of metabolised 11+C-labeta lo l ( • )  and hence 
unmetabolised14C-labeta lo l (o).
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TABLE 6.1
Labetalol concentrations in the ra t bile and ra t and fe rre t 
perfusate supernatant3 during liver perfusion
Animal
Bile (B) or 
perfusate 
supernatant (P)
Sample 
Collection 
Time (min)
Total mg 
Labetalol 
equivalent
% 'dose'b
Rat B 0-45 0.04 0.68
B 45-75 0.02 0.29
P 45 1.47 23
P 75 1.15 18
P 120 1.06 17
Ferret P 120 1.24 18
See 'Materials and Methods' fo r the details about procedure.
a As the ra t and fe rre t live r perfusate consisted of one part blood to two
parts Krebs Ringer, the perfusion medium minus red blood cells was the 
perfusate supernatant.
b The amount of ^C -la b e ta lo l-H C l injected into the perfusion medium
reservoir at tim e = 0 (7.0 mg for the ra t live r and 7.5 mg fo r the fe rre t 
liver) was regarded as the 'dose'.
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TABLE 6.2
Concentrations of labetalol and its metabolites in the perfusate supernatant 
of the ra t and fe rre t live r and intestine perfusions and 
isolated dog loop preparation
Animal
Tissue
preparation
Sample
period
(min)
Concentration of labetalol in 
perfusate supernatant expressed as 
percentage of the ’dose'3
Total Labetalol Metabolites
Rat Liver*3 0-120 16.8 4.4 12.4
Intestine0 0-160 10.2 7.6 2.6
Ferret Liver*3 0-120 18.3 9.5 8.8
Intestine^ 0-130 10.0 8.1 1.9
Dog Intestine0 0-30 10.3 8.7 1.6
See ’Materials and Methods’ fo r details o f procedure.
The amount of labetalol injected into the perfusion medium reservoir or 
intestine lumen was regarded as th e ’dose’.
The blood was diluted w ith  Krebs Ringer in the ra tio  o f 1:2 (v/v) so the 
perfusion medium minus red blood cells was referred to as perfusate 
supernatant.
The ra t and dog intestine preparations were vascularly perfused w ith 
ra t and dog blood, respectively, therefore the perfusate supernatant 
was plasma.
The perfusion was carried out w ith human red blood cells suspended in 
Tyrode solution, including 3.9% Bovine serum albumen, instead of 
plasma, therefore the Tyrode solution was referred to as perfusate 
supernatant.
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14Figure 6 .4 . HPLC detection o f C -labeta lo l and i t s  metabolites
in  the combined perfusate supernatants from an iso la ted  
ra t  l i v e r  perfusion preparation
A fte r  measuring the ra d io a c t iv i ty  in the 'plasma', before and a f te r  
chloroform ex tra c t io n , the various samples were combined, freeze d r ied , 
and the residue dissolved in 2 ml d i s t i l l e d  water followed by the 
addition o f an equal volume o f absolute ethanol. The supernatant 
(100 y1, co n ta in in g .1.4 x 10  ^ d .p .m .) was chromatographed on an HPLC 
column (see ‘Materia ls and Methods', Chapter 4). R ad ioac tiv ity  in 
each eluate f ra c t io n ,  co llected every 30 sec. from 0-15 min and 60 sec
from 15-45 min, is  given as ( ------). The e lu t ion  o f ^ C - la b e ta lo l  (100 ng,
5.55 x 103 d .p .m .), O-phenylglucuronide (87 ng, 4.8 x 10? d.p.m.) and
secondary alcohol glucuronide (130 ng, 7.3 x 103 d.p.m.) standards are 
given as ( t )  labe lled  with L, M2 or M3, respective ly .
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Perfusion of the fe rre t live r w ith  labetalol
The to ta l labetalol in the perfusate supernatant decreased over the firs t 45 
min and then levelled o ff  (figure 6.5). The concentration of labetalol in the 
perfusate supernatant decreased, and the concentration of labetalol metabolites 
in the perfusate supernatant increased w ith tim e (figure 6.5). A fte r 120 min, 
18.3% o f the radioactive labetalol dose was present in the perfusate supernatant, 
9.5% being metabolised labetalol (table 6.2). HPLC analysis o f the combined 
perfusate supernatant samples showed the presence of phenolic and alcoholic 
glucuronides (Metabolite II and Metabolite III, respectively), labetalol (L), and a 
previously unidentified metabolite (A) (figure 6.6).
Rat intestine perfusion
The to ta l recovery of labetalol a fte r the perfusion was 91% of the dose, 
14% in the hepatic portal blood, 23% in the intestine tissue, and 53% in the 
intestinal contents (table 6.3). As the labetalol was absorbed, 50% was associated 
w ith the red blood cells and 50% remained in the plasma (figure 6.7). The 
maximum rate of absorption was observed in the firs t 30 min a fte r which the 
rate slowly declined (figure 6.7). The intestine metabolised 2.6% of the labetalol 
dose detected in the portal vein plasma and 7.6% was present as parent 
compound (figure 6.8, table 6.2). The O-phenylglucuronide (Metabolite II), two 
previously unidentified metabolites (A and C), and labetalol (L) were detected in 
the combined plasma samples by HPLC analysis (figure 6.9).
Ferret intestine perfusion
The to ta l recovery of labetalol from  the various parts of the preparation 
was 81% of the dose, 19% in the blood collected from the hepatic porta l vein, 
29% in the intestine tissue, and 33% in the intestinal contents (table 6.3). H alf of 
the to ta l labetalol in the perfusate was associated w ith the red blood cells and 
the other half was present in the perfusate supernatant (figure 6.10). A fte r the
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Figure 6.5. Metabolism o f labe ta lo l by an iso la ted perfused fe r re t  
l i v e r  preparation
An iso la ted  fe r re t  l i v e r  was perfused w ith 6.8 mg14C-labeta lo l in 
the perfusion medium, one part fe r re t  blood and two parts Krebs 
Ringer. A f te r  removing the red blood c e l ls ,  the amount o f rad io­
a c t iv i t y  in various samples o f plasma, taken at d i f fe re n t  time po in ts , 
was used to ca lcu la te  the amounts o f labe ta lo l plus metabolites per 
ml ( a ). The amount o f ra d io a c t iv i ty  remaining in the perfusate 
supernatant samples a f te r  chloroform e x tra c t io n , to remove the 
la b e ta lo l ,  was used to ca lcu la te  the amount o f metabolised labe ta lo l 
( • )  and hence the unmetabolised labe ta lo l (o-)
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14Figure 6.6. HPLC detection o f C -labeta lo l and i t s  metabolites
in the combined perfusate supernatants from an iso la ted  
fe r re t  l i v e r  perfusion preparation.
A fte r  measuring the ra d io a c t iv i ty  in the 'plasma', before and a f te r  
chloroform e x tra c t io n , the various samples were combined, freeze 
d r ied , and the residue dissolved in 2 ml d i s t i l l e d  water followed 
by the add it ion  o f an equal volume o f absolute ethanol. The super­
natant (100 y l ,  containing 1.34 x 10s d.p.m.) was chromatographed 
on an HPLC column (see 'M ateria ls  and Methods', Chapter 4). Radio­
a c t iv i t y  in each eluate f r a c t io n , collected, every 30 sec from 0-15 min
and 60 sec from 15-45 min, is  given as ( ------). The e lu t ion  o f 14C-
labe ta lo l (100 ng, 5.55 x 103 d .p .m .), O-phenylglucuronide (87 ng,
4.8 x 103 d .p .m .), and secondary alcohol glucuronide (130 ng, 7.3 x 103 
d.p.m.) standards are given as ( i )  labe lled  w ith L, M2 or M3, respec tive ly .
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TABLE 6.3
Percentage recovery of C-labetalol in the d iffe rent
tissues a fte r ra t and fe rre t intestine perfusions
Animal Tissue
Total Radioactiv ity 
(d.p.m.)
% Recovery
o f a R adioactiv ity
Rat Intestinal
contents
3.58 x 107 54
Intestine 1.53 x 107 23
Hepatic portal 
venous blood 0.90 x 107
14
Total 6.01 x 107 91
Ferret Intestinal
contents
7.91 x 107 33
Intestine 6.90 x 107 29
Hepatic portal 
venous perfusion 
flu id
4.59 x 107 19
Total 19.41 x 107 81
See ’Materials and Methods' fo r details of procedure.
a The percentage of the ^C -la b e ta lo l injected into the lumen of the intestine
at tim e = 0.
b The fe rre t intestine was perfused w ith human blood cells which were
suspended in the same volume of Tyrode solution, including 3.9% bovine 
serum albumin, as plasma.
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Figure 6.7. Absorption o f C-labeta lo l from the lumen o f the 
ra t  in te s t in e  perfused in s i t u .
1410.4 mg labe ta lo l ( inc lud ing 1.2 mg C-labeta lo l ) in aqueous 
so lu tion  was in jected in to  the lumen o f a ra t  in te s t in e  which was 
perfused, in s i tu ,  w ith ra t  blood from an external source. A ll the 
blood emerging from the hepatic porta l vein was co llec ted in se r ia l  
f ra c t ions  q t  5 min in te rv a ls .  The ra d io a c t iv i ty  measured in each 
blood f ra c t io n  was used to ca lcu la te  the cumulative amount o f 
labe ta lo l absorbed in to  the hepatic porta l venous blood during 
perfusion.
The cumulative amount o f labe ta lo l in the whole blood, a f te r
decolouris ing w ith H909 , is  given as ( ------) ,  and tha t in plasma
as (-----)
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14Figure 6.8. Metabolism o f C-labeta lo l by a ra t  in te s t in e  perfused 
in s i tu  w ith blood from an external source.
1410.4 mg labe ta lo l ( inc lud ing 1.1 mg C - la b e ta lo l) in aqueous 
so lu tion was in jected in to  the lumen o f a ra t  in te s t in e  which 
was perfused with ra t  blood from an external source. The se r ia l 
f ra c t ions  o f blood emerging from the hepatic porta l vein were 
combined in to  f ra c t io n s  of 15 min in te rv a ls .  The to ta l  ra d io a c t iv i t y  
o f each fra c t io n  was used to ca lcu la te  the amount o f labe ta lo l plus
i t s  metabolites in the plasma (----- ). A fte r  ex trac t ing  the plasma
with chloroform, to remove the la b e ta lo l ,  the ra d io a c t iv i ty  remaining was 
used to ca lcu la te  the cumulative amount o f metabolised labe ta lo l ( —  )
and hence the cumulative amount o f unchanged labe ta lo l ( -------- ] absorbed
in to  the plasma from the in te s t in e .
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Figure 6.9 HPLC de tec tion  o f  la b e ta lo l and i t s  m etabo lites  in  the 
combined plasma fra c t io n s  from the in  s i tu  perfused ra t  
in te s t in e .
A fte r  measuring the ra d io a c t iv ity  in  the 'p lasm a1, before and a f te r  
ch loro form  e x tra c tio n , the various samples were combined, freeze  d r ie d , 
and the residue d isso lved  in  3 ml d is t i l le d  water fo llow ed  by the 
a d d itio n  o f an equal volume o f absolute e thano l. The supernatant (100 p i ,  
con ta in ing  2.3 x 10 d .p .m .) was chromatographed on to  an HPLC column 
(see 'M a te r ia ls  and M ethods', Chapter 4 ). R a d io a c tiv ity  in  each e lua te  
f r a c t io n ,  co lle c te d  every 30 sec fro m .0-15 min and 60 sec from 15-40.m in,
is  given as (-------) . The e lu t io n  o f C -la b e ta lo l (100 ng, 5.55 x 10
d .p .m .), O -phenylglucuronide (220 n g ,-1 .2  x 10 d .p .m .) , and secondary 
a lcohol g lucuronide (130 ng, 7.3 x 10 ) standards are given as ( 4 ) 
la b e lle d  w ith  L, M2 o r M3, re s p e c tiv e ly .
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Figure 6.10. D is tr ib u t io n  o f ra d io a c t iv i ty  in the perfusate from the in s i tu  
fe r re t  in te s t in e  perfusion preparation? ~  ~
in ip r t iH bfn tn 0lh ^ 1* iCludinf  ^ C - la b e ta lo l^  in aqueous so lu t io n , wasin jected in to  the lumen o f a fe r re t  in te s t in e  which was perfused in s i tu
with human red blood c e l ls  suspended in Tyrode so lu tion . A ll the~perfïïsate 
emerging from the hepatic portal vein was collected in se r ia l f ra c t io n s  of 
^rva ls . The to ta l amount of ra d io a c t iv i ty  in the whole perfusate
^ 1 a ' t e r  decolourising with H?CL, and perfusate supernatant (---------) ,
perfusate with red blood ce l ls  removed, was measured and the resu lts  expressed 
as cumulative amounts o f labeta lo l plus metabolites absorbed in to  the hepatic 
m  .cVenous d during perfusion. The 'plasma1 was extracted with 
chloroform, to remove the la b e ta lo l,  and the remaining ra d io a c t iv i ty  was used
to ca lcu la te the cumulative amount o f metabolised labe ta lo l ( ------ ) and hence
the cumulative amount o f unmetabolised labe ta lo l ( -------- ) absorbed by the
intestine.
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perfusion period, the intestine had metabolised 1.9% of the labetalol dose 
present in the perfusate supernatant and 8% of the dose in the perfusate 
supernatant was labetalol (figure 6.10, table 6.2). HPLC analysis o f the combined 
perfusate supernatant fractions showed the presence of the alcoholic glucuronide 
(Metabolite III), labetalol, and two previously unidentified metabolites (A and C) 
which are also observed in the plasma collected from  the hepatic portal vein of 
the ra t intestine (figures 6.11 and 6.9).
Isolated dog intestine loop preparation
The difference in concentrations of rad ioactiv ity  in the venous and a rte ria l 
blood samples indicates e ffec tive  isolation of the dog intestine loop (figure 6.12). 
The rate of labetalol absorption from  the lumen of the intestine loop, as 
measured by the rad ioactiv ity  in the venous plasma samples, increased to a peak 
level at 12-15 min a fte r which i t  declined (figure 6.12). A small but detectable 
concentration of labetalol metabolites was observed in the venous plasma. These 
were identified by HPLC analysis as the phenolic glucuronide (Metabolite II), and 
small amounts of the previously unidentified metabolites A and C (figure 6.13). 
The m ajority of the drug in the venous plasma was found to be labetalol.
DISCUSSION
The vascularly perfused ra t and fe rre t intestine preparations measured 
first-pass metabolism, whereas in the liver perfusion preparation fu rthe r 
metabolism was possible because the drug was recycled. In the live r perfusion 
preparation, excretion of unchanged labetalol and its metabolites into the bile 
and extraction of the drug and its metabolites from the circulating perfusate by 
the liver tissue were possible, but there was no excretion of the drug and its 
metabolites from the perfusate as per the kidney. The vascularly perfused 
intestine preparations in situ were much closer models for these tissues in vivo 
than the isolated perfused liver preparations.
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Figure 6,11. HPLC.detection o f labe ta lo l and i t s  metabolites in  the
combined perfusate supernatant f ra c t ions  from the in s i tu  
perfused fe r re t  in te s t in e
A fte r measuring the ra d io a c t iv i ty  in the ' p l a s m a b e f o r e  and a f te r  chloroform 
e x trac t ion , the various samples were combined, freeze d r ied , and the residue 
dissolved in  15 ml d is t i l l e d  water, 5 ml o f which was added to  an.equal volume 
o f absolute ethanol. The supernatant (25 p i ,  containing 3.7 x 10 d .p .m .) was 
chromatographed on to an HPLC column (see 'M ateria ls  and Methods', Chapter 4 ). 
R ad ioactiv ity  in each eluate f ra c t io n ,  co llec ted every 30 sec from 0-15 min
and 60 sec from 15=40 min, is  given as ( ------). The e lu t ion  o f C -labeta lo l
(100 ng, 5.55 x 10 d .p .m .), O-phenylglucuronide (220 ng, 1.2.x 10 d.p.m.)
and secondary alcohol glucuronide (130 ng, 7.3 x 10 d.p.m.) standards are
given as (+) labe lled  with L, M2 or M3, respective ly .
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Figure 6.12. Absorption and metabolism o f labe ta lo l by an iso la ted
dog loop in s i tu .
14,45 mg labe ta lo l ( inc lud ing  2.9 mg C - la b e ta lo l) ,  in aqueous s o lu t io n ,  
was in jec ted  in to  the lumen o f an iso la ted  dog loop lumen in s i t u . Samples 
o f blood were taken over three minute periods from the vein dra in ing the 
in te s t in a l  loop. The amount o f  ra d io a c t iv i ty  measured in the plasma was 
used to ca lcu la te  the concentration o f  labe ta lo l plus metabolites absorbed
from the in te s t in e  (------- ). The plasma was extracted w ith chloroform, to
remove the la b e ta lo l ,  and the amount o f ra d io a c t iv i ty  remaining was used
to ca lcu la te  the concentration o f labe ta lo l metabolites ( ------) and hence
the concentration o f labe ta lo l ( ------- ). Samples o f blood were taken from
the abdominal aorta to measure the amount o f ra d io a c t iv i ty  in the plasma 
(---------) to estimate the e f fe c t iv e  is o la t io n  o f the in te s t in e  loop.
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Figure 6.13. HPLC detection o f labe ta lo l and i t s  metabolites in  the 
combined plasma samples from the in s i tu  iso la ted  dog 
loop preparation.
A fte r  measuring the ra d io a c t iv i ty  in the 'plasma1, before and a f te r  
chloroform ex trac t ion , the various samples were combined, freeze dr ied , 
and the residue dissolved in 6 ml d is t i l l e d  water followed by the addition 
o f an equal volume o f absolute ethanol. The supernatant (100 p i ,  containing 
1.05 x 10 d.p .m .) was chromatographed on an HPLC column (see 'M ateria ls  
and Methods', Chapter 4). R ad ioactiv ity  in each eluate f ra c t io n ,  co llec ted 
every 30 sec from 0-15 min and 60 sec from 15-40 min, is  given as ( —  ).
The e lu t ion  o f C-labeta lo l (100 ng, 5.55 x 10 d.p .m .). O-phenyl­
glucuronide (220 ng, 1.2 x 10 d .p .m .), and secondary alcohol glucuronide
(130 ng, 7.3 x 10 d.p.m.) standards are given as (+) labe lled  w ith L, M2 
or M3 respective ly.
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Metabolism of labetalol by the live r
The rapid uptake of labetalol by the ra t and fe rre t livers from the 
perfusate (figures 6.3 and 6.5), concentrations of labetalol at t=0 were 51 ug and 
43 ug per ml perfusate, respectively, indicates that these tissues extract a large 
portion of the drug dosage from the blood. However, the appearance of labetalol 
metabolites in the perfusate supernatant occurred at a slower rate than the 
uptake of the drug by the livers. This observation has previously been reported in 
the lite ra tu re  fo r isolated ra t live r preparations perfused w ith 1-naphthol (Bock, 
1974) and w ith  4-nitrophenol (Minck, 1973). During the ra t live r perfusion, the 
concentration of labetalol in the perfusate supernatant decreased w ith  tim e and 
the appearance of metabolised labetalol in the perfusate supernatant reached a 
peak at 45 min (figure 6.3, table 6.1). The fa ll in labetalol m etabolite 
concentration in the perfusate supernatant a fte r 45 min could be the result of 
product inhibition of metabolism or 3-glucuronidase hydrolysis o f metabolites 
becoming operative factors. The perfusion of the fe rre t live r contrasted w ith  
that o f the ra t live r; as the concentration of labetalol in the perfusate 
supernatant decreased w ith  tim e the concentration o f labetalol metabolites 
increased (figure 6.3).
The perfused ra t live r had metabolised 2.4 pmoles of the labetalol dosage 
(19 pmoles) a fte r 120 min. I t  has been shown that 35 pmoles of 1-naphthol were 
completely metabolised by an isolated ra t live r preparation a fte r 30 min (Bock, 
1974); the perfusate contained both the glucuronide conjugate (30% of the 
dosage, 10 pmoles) and the sulphate conjugate (26% of the dosage, 9 pmoles). 
Even i f  the sulphation of 1-naphthol is not taken into consideration, the rate of 
labetalol metabolism by the ra t live r is less than the rate of 1-naphthol 
metabolism. Sim ilarly, the rate of 2-aminophenol glucuronylation by perfused ra t 
livers (6 pmoles per 60 min; Burchell and Bock, 1980) is greater than the rate of 
labetalol metabolism by ra t live r. These results indicate that the metabolism of 
labetalol by ra t liver may be greater than that of fe rre t live r, 12.4% and 8.8% of
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the dose was present as metabolites in the respective perfusate supernatants at 
the end of the perfusion periods (table 6.2).
B ilia ry excretion of labetalol or its metabolites by the ra t live r was not of 
great importance in the present investigation because less than 1% of the dosage 
was measured in the bile (table 6.1). There was insuffic ient fe rre t bile for 
analysis.
The ra t liver metabolised labetalol to its O-phenylglucuronide and to a 
previously unidentified metabolite (A) as detected by HPLC analysis (figure 6.4). 
The fe rre t liver metabolised labetalol to its O-phenylglucuronide, secondary 
alcohol glucuronide, and to the previously unidentified metabolite (A) which is 
sim ilar to that observed in the ra t live r perfusate supernatant (figure 6.6).
Absorption and metabolism o f labetalol by the intestine
The recovery of rad ioactiv ity  from the vascularly perfused ra t and fe rre t 
intestines, in s itu , 91% and 81% of the doses respectively, accounted fo r the 
larger part o f the labetalol injected into the lumen of each intestine. The amount 
o f rad ioactiv ity  absorbed by the fe rre t intestine was 19% and tha t o f the ra t 
intestine was 14% of the ir respective doses. In each case the major part o f the 
rad ioactiv ity  remained in the intestinal tissue and intestinal contents, 62% and 
77% respectively (table 6.3). The fe rre t intestine absorbed a sim ilar proportion 
o f the labetalol dosage as the ra t intestine despite the greater surface area of 
the fe rre t intestinal lumen. Only 50% of the rad ioactiv ity  in the whole perfusion 
flu id  was detected in the perfusate supernatant (figures 6.7 and 6.9), therefore 
50% of the to ta l rad ioactiv ity  in the whole perfusion flu id must have been 
associated w ith  the red blood cells. A sim ilar observation has been reported in 
the lite ra tu re  (Martin et al. 1976).
The ra t intestine metabolised a sim ilar amount of labetalol, 2.6% of the 
dose in 160 min, to the fe rre t intestine, 1.9% of the dose in 130 min (table 6.2, 
figures 6.8 and 6.10). The rates of absorption and metabolism of labetalol by the
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ra t intestine were slower than those observed fo r phenol (Powell et al. 1974), 
salicylamide (Sakai et al. 1980), or 1-naphthol (Turner et a l. 1980) injected into 
the lumens of sim ilar intestinal preparations. These other xenobiotics were 
conjugated w ith  glucuronic acid and sulphate by the intestine; however, even if  
the sulphate conjugation is ignored the rate o f glucuronylation by the intestine is 
s t il l greater fo r these xenobiotics than that observed fo r labetalol in the present 
investigation. This may be explained by the access o f labetalol to the UDP- 
glucuronyltransf erase enzyme being restricted, or by the conjugation 
mechanisms of the enzyme being restricted by the structure of the molecule.
The ra t intestine forms the O-phenylglucuronide of labetalol whereas the 
fe rre t intestine forms the secondary alcohol glucuronide of labetalol (Figures 6.9 
and 6.11). This difference in metabolism may be an indication tha t the 
isoenzymes of UDP-glucuronyltransferase may d iffe r in the intestines of these 
two species. However, both intestines formed two metabolites (A and C) which 
have not been previously identified. Metabolite A is fluorescent and is also 
formed by the livers o f these two animals, whereas metabolite C is non- 
fluorescent and is not formed by the livers of these two animals. The possible 
identity of these metabolites is discussed in Chapter 7.
The rate of absorption, 15% of the dose in 30 min, and the rate of 
metabolism, 1.6% of the dose in 30 min, o f labetalol by the isolated dog intestine 
loop, were much faster than those observed for the ra t and fe rre t (table 6.2). The 
absorption rate of labetalol, by the dog intestine loop, was greater (3.5-fold) than 
that observed fo r isoprenaline (George et al. 1974). These same workers observed 
greater metabolism of isoprenaline in the ir dog intestine preparation than was 
observed fo r labetalol in this preparation. This may be because the metabolites 
of isoprenaline, O-sulphate ester and methyl ester, are d iffe ren t to those of 
labetalol. The metabolites of labetalol observed in the venous plasma draining 
the intestine loop of the dog were sim ilar to those observed in the hepatic portal 
venous plasma of ra t (table 6.4). That is the dog intestine forms the O-
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TABLE 6.4
Summary of the metabolites o f ^C -ia b e ta lo l detected 1n the 
perfusate supernatants of the isolate liver and in situ intestine 
preparations of ra t and fe rre t, and of the isolated dog 
intestine loop preparation
Perfusate supernatant samples from  the various preparations were 
concentrated by freeze drying. The residues were dissolved in smaller 
volumes o f d istilled water and absolute ethanol was added to precip itate the 
proteins. Samples of the resulting supernatants were then subjected to HPLC 
analysis. For details o f procedure see ’Materials and Methods'.
Animal Tissue
Preparation
Labetalol
I
Metabolites 
II III A C
Rat Liver + + +
Intestine + + + +
Ferret Liver + + + +
Intestine + + + +
Dog Intestine + + + +
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phenylglucuronide of labetalol and metabolites A and C as detected by HPLC 
analysis (figure 6.13).
In summary, the absorption rate and metabolism of labetalol was sim ilar 
fo r ra t and fe rre t intestines but greater fo r the dog intestine (table 6.2). The ra t 
and dog intestine both formed the O-phenylgucuronide whereas the fe rre t 
intestine formed the secondary alcohol glucuronide. A ll three intestine 
preparations formed two previously unidentified metabolites (A and C). The 
present investigation shows that some first-pass metabolism does occur in the 
intestines from  ra t, fe rre t, and dog. As the patterns of labetalol metabolism in 
the dog and in man are s im ilar this may indicate that first-pass metabolism by 
the human intestine may occur. However, the ra t and fe rre t livers were much 
more e ffective  at labetalol metabolism than the ir respective intestines (table 
6.2). The ra t live r and intestine have sim ilar plasma metabolite profiles, whereas 
those from the fe rre t d iffe r from each other (table 6.4). As urine from  dog, given 
labetalol ora lly, has been shown to contain three labetalol glucuronides, these 
results (table 6.4) suggest that the metabolism o f labetalol by the dog live r is 
probably d iffe rent to tha t of the intestine.
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DISCUSSION
Drug-Metabolising Enzyme Activities and Microsomal 
Preparations of Liver and Gastrointestinal Tract from 
Rat and Ferret
Comparative A c tiv ities  o f Enzymes in L iver and Gastrointestinal Tract
The livers o f both rats and ferrets have specific drug-metabolising enzyme 
activ ities  fa r greater than those of the gastrointestinal tra c t. However, there 
are certain enzymes, e.g. 2-aminophenol glucuronyltransferase in the foeta l 
stomach of mouse and guinea pig (Dutton, 1980), 1-naphthol 
glucuronyltransferase in the duodenum and jejunum of ra t (Chapter 3), and 
possibly 4-nitrophenol glucuronyltransferase in the small intestine o f ra t 
(Hietanen and Vainio, 1973), which may occur in the gastrointestinal tra c t at 
equal or greater a c tiv ity  than that occurring in the live r. This difference may 
vary from  species to species.
Comparison of the m ixed-function oxidase and UDP-glucuronyltransferase 
activ ities in the various microsomal preparations from both species used in the 
present studies showed that these enzymes were more active in the ra t than in 
the fe rre t. One exception was hydroxylation of biphenyl at the C-4 position 
which occurred at greater ac tiv ity  in the gastrointestinal tra c t preparations 
from  fe rre t than in the sim ilar preparations from the ra t. The difference in 
m ixed-function oxidation might be a ttributed to the lower body weight of rats, 
since oxidative metabolism varies inversely w ith log body weight (Walker, 1978), 
or may be due to the diet of ra t containing more natural enzyme-inducing agents 
(flavanoids, etc.) than the diet of fe rre t. Although UDP-glucuronyltransferase 
ac tiv ity  does not vary inversely w ith log body weight, glucuronylation by the 
intestines of carnivores occurs at lower ac tiv ity  than that occurring in intestines
-  2 2 0  -
of herbivores, and this has also been attributed to the difference in diet of the 
two species (Dutton, 1980).
The specific activ ities (nmol product/m in/mg protein) o f the enzyme 
systems studied indicated tha t UDP-glucuronyltransferases (Chapter 3) were 
more active than the m ixed-function oxidases (Chapter 2) in the preparations of 
livers and gastrointestinal tracts from  both species. These observations may be 
misleading because activated UDP-glucuronyltransferase a c tiv ity  was measured 
in this study and a d irect extrapolation to whole tissues is not possible because a 
certain proportion of this enzyme a c tiv ity  would be latent in vivo (Bock, 1974). 
Other workers using isolated hepatocytes (Bridges, 1980) and isolated intestinal 
cells (Dawson and Bridges, 1979; Shirkey et al., 1979b) have shown that products 
o f m ixed-function oxidases were rapidly conjugated and that the metabolism by 
phase II enzymes was not a ra te -lim iting  step. Therefore there is evidence tha t 
the rate o f glucuronylation in the liver and gastrointestinal tra c t may be greater 
than the rate of m ixed-function oxidation. However, i t  is necessary to know 
much more about the mechanisms of regulation of these enzymes before 
conclusions can be made concerning the re la tive  predominance of the various 
enzyme pathways o f drug metabolism in v ivo.
D istribution of Enzymes along the Gastrointestinal Tract
The d istribution of cytochrome P-450 concentration and various related 
enzyme activ ities (including: benzo(a)pyrene and aniline hydroxylases, 
ethylmorphine N-demethylase, and UDP-glucuronyltransferase w ith  4- 
nitrophenol and 2-aminophenol as substrates) along the small intestines from  a 
number of species has been studied (Hanninen et al., 1968; Hietanen and Vainio, 
1973; Chhabra, 1979). The greatest drug-metabolising enzyme ac tiv ity  occurred 
in the proximal section of the small intestine, and this ac tiv ity  progressively 
declined along the small intestine towards the aboral end. A sim ilar pattern of
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distribution of cytochrome c reductase, ethoxyresorufin Q-deethylase, and UDP- 
glucuronyltransferase (w ith 1-naphthol, 4-nitrophenol, and 4- 
methylumbelliferone as substrates) was observed along the small intestine of the 
ra t, in the present studies. The ac tiv ity  o f m ixed-function oxidase in the 
stomach and caecum/colon preparations tended to be lower than that observed in 
the ileum, but glucuronylation of some substrates by the caecum/colon 
preparation may be sim ilar to that occurring in the middle section of the small 
intestine (Chapter 3; Hanninen et al., 1968).
The m ixed-function oxidase activ ities  in the gastrointestinal tra c t 
preparations from  the fe rre t were distributed in a sim ilar pattern to that
observed in the tissue preparations from  ra t, but this was not so fo r UDP-
glucuronyltransferase. The greatest glucuronylation of the three substrates used 
in this investigation occurred in the ileum w ith  a progressive decline in enzyme 
a c tiv ity  along the tra c t towards both oral and aboral ends (Chapter 3).The 
significance of this result is not clear, but i t  may be an im portant consideration 
when using this species as an animal model fo r drug metabolism in man.
The distribution pattern of drug-metabolising enzyme a c tiv ity  along the 
gastrointestinal tra c t may be caused by the natural and xenobiotic inducing 
agents in the diet. M ixed-function oxidase ac tiv ity  of the gastrointestinal tra c t 
is dependent on the composition of the diet (Wattenberg, 1971; Pantuck et al., 
1976a and 1976b) and this indicates that there is l i t t le  constitu tive mixed-
function oxidation by this tissue. Therefore i f  the m ajority o f dietary
components which induce these enzymes are absorbed in the proximal small 
intestine, as is the case w ith the m ajority of drugs (Wagner, 1961),the enzyme 
activ ities in this part of the gastrointestinal tra c t would be induced to a greater 
extent than those on other parts of the trac t. However, UDP- 
glucuronyltransferase a c tiv ity  in the gastrointestinal tra c t is not so sensitive to 
the composition of the diet as m ixed-function oxidase a c tiv ity . Therefore the
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pattern of drug metabolising enzyme a c tiv ity  along the gastrointestinal tra c t 
may be d irectly  or ind irectly  affected by the composition of the diet.
M ixed-Function Oxidases
D iffe ren t isoenzymes of cytochrome P-450 are present in ra t live r and 
these carry out cytochrome P-450-related or cytochrome P-448-related mixed- 
function oxidation reactions (Ryan et al., 1982). These d iffe ren t isoenzymes 
have cross-over substrate specific ities except w ith  7-ethoxyresorufin as 
substrate which is metabolised specifica lly by cytochrome P-448 (Guengerich et 
al., 1982; Phillipson et al., 1984). Because cytochrome P-450 and cytochrome 
P-448 are pre ferentia lly  induced by phenobarbitone and 3-methlycholanthene 
respectively (Parke, 1979a), pretreatm ent o f animals w ith  these two mixed- 
function oxidase inducing agents can be used to detect the presence of the two 
d iffe ren t forms o f cytochrome P-450 in tissues. Aroclor 1254 is a potent inducer 
o f both cytochrome P-450 and cytochrome P-448 m ixed-function oxidation 
(Parkinson e t al., 1980). However, l it t le  is known about the presence o f d iffe ren t 
forms o f cytochrome P-450 in the gastrointestinal tra c t, but the evidence in 
published reports suggests that cytochrome P-448-related m ixed-function 
oxidase predominates in this tissue (Burke and Orrenius, 1979; McDanell and 
McClean, 1984).
A ll substrates used in this study were metabolised by the microsomal 
preparations of livers from  both ra t and fe rre t, indicating the presence o f both 
cytochrome P-450-related and cytochrome P-448-related m ixed-function oxidase 
activ ities  (Chapter 2). Treatment o f rats and ferrets w ith  3-methylcholanthene, 
and rats w ith Aroclor 1254, was observed to increase cytochrome P-448-related 
m ixed-function oxidations in the liver of these two species. Although treatm ent 
of rats w ith  phenobarbitone was observed to increase hydroxylation of biphenyl 
at the C-4 position, i t  was not observed to a ffec t ethylmorphine
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N-dem ethylation or cytochrome c reductase by the live r preparation (this is 
discussed below). These results are therefore consistent w ith  published reports 
that both cytochrome P-450-related and cytochrome P-448-related mixed- 
function oxidation occurs in the livers from  ra t and fe rre t (loannides et al., 1977; 
Miranda and Chhabra, 1980).
The gastrointestinal tra c t preparations from  ra t and fe rre t did not 
N-demethylate ethylmorphine, even in the preparations from  rats treated w ith  
phenobarbitone. I t  is known tha t hydroxylation of biphenyl at the C-4 position is 
associated w ith  both cytochrome P-450 and cytochrome P-448. Therefore, the 
increases in biphenyl 4-hydroxylase ac tiv ity  observed in the gastrointestinal 
tra c t preparations a fte r treatm ent o f rats w ith  phenobarbitone indicate tha t 
cytochrome P-450-related m ixed-function oxidation may be induced in the ra t 
gastrointestinal tra c t. As cytochrome P-448-related enzyme a c tiv ity  is observed 
in gastrointestinal tra c t preparations from  untreated rats and ferrets, i t  is like ly  
that the biphenyl 4-hydroxylase a c tiv ity  in these preparations is also associated 
w ith  cytochrome P-448.
The small intestine of ra t was observed to carry out O-deethylation of 
7-ethoxyresorufin; this enzyme ac tiv ity  in the duodenum and jejunum from  
untreated rats was approximately 50% o f that in the live r. Although the 
stomach from  untreated ra t and small intestine from  untreated fe rre t lacked this 
enzyme ac tiv ity , i t  was observed in these tissues a fte r treating the animals w ith  
3-methylcholanthene. The rat small intestine 7-ethoxyresorufin O-deethylase 
was also very sensitive to induction by 3-methylcholanthene. These results 
indicate that cytochrome P-448-related m ixed-function oxidase occurs in the 
small intestine from  rats, given a normal laboratory diet, and this enzyme is very 
sensitive to inducing agents. However, the stomach from rats and small 
intestine from ferrets require an inducing agent to produce cytochrome P-448- 
related enzyme a c tiv ity , but despite treating both these species w ith
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3-methylcholanthrene this type o f m ixed-function oxidase a c tiv ity  was not 
observed in the caecum/colon preparations.
The results of the present investigation therefore provided equivocal 
evidence fo r the predominance o f m ixed-function oxidation by either form of 
cytochrome P-450 in the gastrointestinal tra c t from  ra t or fe rre t. However, 
there were indications that cytochrome P-448-related m ixed-function oxidations 
may predominate in the small intestine of ra t.
UDP-Glucuronyltransf erases 
Classification o f UDP-glucuronyltransferase activ ities
Classification o f UDP-glucuronyltransferases has been on the basis of the ir 
inducib ility  by classical xenobiotic inducing agents (Bock et al., 1979), o f the ir 
perinatal development (Wishart, 1978; Dutton and Leakey, 1981), and of the co- 
purifica tion  of enzyme a c tiv ity  towards various substrates during the ir isolation 
(Bock et al., 1979; Burchell, 1981). The major groups of ra t live r UDP- 
glucuronyltransferases have been distinguished according to substrate 
specific ity : (i) glucuronylation o f group-1 substrates (e.g. 1-naphthol, 4-
nitrophenol, 4-methylumbelliferone, etc.) occurs in the perinatal ra t live r and is 
greatly increased (three- to six-fo ld) in adult live r by treating rats w ith  3- 
methylcholanthrene, and (ii) glucuronylation o f group-2 substrates 
(e.g. morphine, 4-hydroxybiphenyl, etc.) occurs in neonatal ra t live r and is
greatly increased (two-to five -fo ld ) by treating rats w ith  phenobarbitone. 
Group-1 substrates are mostly planar phenols whereas group-2 substrates are not 
(Bock et al., 1983). Although two major groups of ra t live r UDP-
glucuronyltransferases have been classified according to the ir substrate 
specific ities, other smaller groups of substrates have also been distinguished 
(Table 7.1). Similar groups of substrates for the rabbit live r UDP-
glucuronyltransferases have been reported (Burchell, 1981).
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This classification o f the UDP-glucuronyltransferases has d istinct 
s im ila rities to the classification of the cytochromes P-450. For example, 3- 
methylcholanthrene and phenobarbitone pre ferentia lly  induce d iffe ren t forms of 
cytochrome P-450 in ra t live r (Ryan et al., 1982). Also, Aroclor 1254, which 
induces both these forms o f cytochrome P-450 (Parkinson et al., 1980), has 
recently been shown to induce UDP-glucuronyltransferase ac tiv ity  both towards 
group-1 substrates and towards group-2 (Lilienblum et al., 1982). These 
observations indicate that the genetic regulation of these two enzyme systems 
may be linked.
Tissue d istribution of UDP-glucuronyltransferases
The ubiquity o f UDP-glucuronyltransferase, sim ilar to that o f mixed- 
function oxidase, has been demonstrated using group-1 substrates. 
Glucuronylation occurs in numerous tissues including brain, diaphragm, heart, 
intestine, kidney, live r, lung, skin, and spleen (A itio , 1974). G lucuronylation of 
group-2 substrates occurs only in the live r and intestine from ra t, but this may 
not be so in other species because high UDP-glucuronyltransferase a c tiv ity  
towards 4-hydroxybiphenyl and morphine has been observed in the human kidney 
(Bock et al., 1979). However, a fte r a detailed tissue survey of UDP- 
glucuronyltransferase a c tiv ity  in the ra t i t  was concluded that the live r of this 
species was the most important organ fo r the synthesis of glucuronides (A itio , 
1974; Dutton and Burchell, 1975). The results of the present study are in 
agreement w ith  this thesis. Although the specific a c tiv ity  of UDP- 
glucuronyltransferase towards individual substrates of the group-1 classification 
may vary in the tissues studied, particu larly  w ith 1-naphthol as substrate, the 
overall capacity fo r glucuronylation in the liver is much greater than that in the 
gastrointestinal tra c t from both ra t and fe rre t.
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Two of the activated UDP-glucuronyltransferase activ ities observed in this 
study are o f particu lar interest because they contrast w ith  observations reported 
in the lite ra tu re . In untreated rats, glucuronylation of 1-naphthol was greater in 
the duodenal microsomal preparation than in the live r preparation. Other 
workers have reported tha t glucuronylation of this substrate by intestinal 
microsomal preparations is lower than in live r preparations (Bock et al., 1980). 
This difference in enzyme a c tiv ity  may be attributed to d iffe ren t methods of 
preparing the intestinal microsomal fraction . Glucuronylation o f 4-nitrophenol 
by the live r enzyme is less than glucuronylation of this substrate by the small 
intestine enzyme (Hietanen and Vainio, 1973; Koivusaari et al., 1980). However, 
the ac tiv ity  of the hepatic enzyme reported by these workers is much lower than 
that reported by other workers (Bock et al., 1979). The small intestine 
microsomal a c tiv ity  fo r 4-nitrophenol glucuronylation observed in this study 
agrees w ith the form er reports, and the enzyme a c tiv ity  in the live r preparations 
o f this study agrees w ith  the la tte r report. But this study showed that the 
glucuronylation o f 4-nitrophenol by the live r microsomal preparations was 
greater than that in the intestinal preparations. I t  is not possible to o ffe r an 
explanation fo r this difference in observation because precise details of 
experimental protocol adopted by the other workers were not reported.
Induction of Mixed-Function Oxidase and UDP-Glucuronyltransf erase by 
Phenobarbitone, 3-Methylcholanthrene, and Aroclor 1254
A sim ilar pattern of induction of cytochrome P-448-mediated mixed- 
function oxidation (Figure 7.1) and UDP-glucuronyltransferase a c tiv ity  towards 
group-1 substrates (Figure 7.2) was observed in liver microsomal preparations 
from  rats treated w ith  the three inducing agents. Glucuronylation was less 
sensitive than m ixed-function oxidation in the liver to the inductive effects o f 
these agents. These results are consistent w ith other reports that ra t
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f ig u re  7.1 Induction o f mixed- 
function oxidation in the l i v e r  
and ga s tro in tes t ina l t ra c t  from rats
The enzyme a c t iv i t y  in microsomal 
preparations o f l i v e r  (L ) ,  stomach 
(S), duodenum (D), jejunum (J ) ,  
ileum ( I ) ,  caecum/colon (C/C), from 
rats treated with phenobarbitone (P),
3-methylcholanthrene (M), or Aroclor 
1254 (A) was expresssed as a percentage 
of tha t in s im ila r  microsomal 
preparations from untreated ra ts  (— ). 
ND means no enzyme a c t iv i t y  was detectec 
For de ta i ls  o f procedure see 'M ateria ls  
and Methods', Chapter 2.
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Figure 7 .2 . Induction o f UDP-glucuronyltransferase in the l i v e r  and
gas tro in tes t in a l t ra c t  from r a ts .
The enzyme a c t iv i t y  in microsomal preparations o f l i v e r  (L ), stomach (S), 
duodenum (D), jejunum (J ) ,  ileum ( I ) ,  and caecum/colon (C/C) from ra ts  
treated with phenobarbitone (P), 3-methylcholanthrene (M), or Aroclor 1254 
(A) was expressed as a percentage of tha t in s im ila r  microsomal preparations 
from untreated rats (— ). For de ta ils  o f  procedure see 'M ateria ls  and 
Methods1, Chapter 3.
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UDP-glucuronyltransferase may be regulated by the gene which controls 
cytochrome P-448-mediated m ixed-function oxidation, the so-called Ah locus 
(Owens, 1977; Nebert and Jensen, 1979). However, not only did these inducing 
agents produce d iffe ren t effects on the gastrointestinal tra c t and hepatic 
enzymes, but they also produced d iffe ren t effects on the enzymes in d iffe ren t 
parts of the gastrointestinal tra c t. This indicates that the mechanism of 
regulating drug metabolism enzymes in the gastrointestinal tra c t d iffe rs from 
tha t in the live r.
Aroclor 1254 was more e ffective  than 3-methylcholanthrene in inducing 
cytochrome P-448-mediated m ixed-function oxidation in ra t live r (Figure 7.1), 
however both agents produced marked increases in enzyme a c tiv ity . In the 
intestine 3-methylcholanthrene was the best inducer, o f the three used, fo r 
m ixed-function oxidation, and only biphenyl 2-hydroxylase a c tiv ity  in the 
duodenum and 7-ethoxyresorufin O-deethylase a c tiv ity  in the ileum were greatly 
increased. In the upper intestine 3-methylcholanthrene was a good inducer of 
biphenyl 2- and 4-hydroxylase and 7-ethoxyresorufin O-deethylase activ ities, 
whereas phenobarbitone was a poor inducer except fo r biphenyl 4-hydroxylase 
a c tiv ity . In addition hydroxylation o f biphenyl at the C -4 position was better 
induced by 3-methylcholanthrene in the upper small intestine than in the live r. 
This may indicate that the substrate specific ities of the forms of cytochrome 
P-450 induced in the small intestine and liver may d iffe r. Poor induction of 
m ixed-function oxidation was observed in the stomach and caecum/colon of the 
ra t. This may indicate that the m ixed-function oxidase ac tiv ity  in the small 
intestine may be more important than that in the stomach or large intestine in 
drug metabolism because its ac tiv ity  is related to the concentrations of inducing 
agents in the diet (Wattenberg, 1972).
Treatment of rats w ith the d iffe ren t inducing agents affected 
glucuronylation of the three group-1 substrates in d iffe ren t ways (Figure 7.2).
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Phenobarbitone was a poor inducer o f UDP-glucuronyltransferase and only 
effected increases in enzyme a c tiv ity  in the live r w ith  1-naphthol as substrate, 
and in the liver, stomach, duodenum and caecum/colon w ith  4-nitrophenol as 
substrate. With 1-naphthol as substrate glucuronylation was markedly increased 
in the live r by Aroclor 1254, and in the stomach by Aroclor 1254 and 
3-methylcholanthrene. S im ilarly, Aroclor 1254 was a good inducer of 1-naphthol 
glucuronylation in the duodenum, but only moderately induced this enzyme 
a c tiv ity  in the lower small intestine and caecum/colon, as did 
3-methylcholanthrene. However, no clear pattern of UDP-glucuronyltransferase 
a c tiv ity  emerged other than the glucuronylation of 1-naphthol in a ll the tissues 
was most sensitive to stim ulation by polycyclic aromatic hydrocarbons. The 
enzyme a c tiv ity  towards 4-nitrophenol was only affected in the live r by 
Aroclor 1254, in the ileum by 3-methylcholanthrene, and in the large intestine by 
phenobarbitone. S im ilarly, glucuronylation of 4-m ethylum belliferone in the 
stomach was sensitive to induction by 3-methylcholanthrene and A roclor 1254. 
These results indicate tha t the mechanisms of regulation of 
UDP-glucuronyltransferase in the live r, stomach, and d iffe ren t sections of the 
intestine may d iffe r. I t  is like ly  tha t the differences in enzyme induction by 
these three agents observed in the gastrointestinal trac t may also be affected by 
the composition of the diet.
First-Pass Metabolism by the Gastrointestinal Tract and L iver
The results of this study therefore indicate that the gastrointestinal tra c t 
is capable of metabolising drugs s im ila rly  to the live r. The characteristics of the 
drug metabolising enzymes of both tissues are sim ilar, although the ir mechanism 
of regulation in the two tissues appear to be d iffe ren t. Also the enzyme 
capacity fo r drug metabolism in the liver is much greater than the capacity in 
the mucosal epithelia l cells o f the gastrointestinal tra c t from  both ra t
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(Table 7.2) and fe rre t (Table 7.3). This indicates that the gastrointestinal tra c t 
would metabolise a small proportion of a drug during its passage through the gut 
wall.
Evidence to the contrary has been reported, indicating tha t the small
intestine from  ra t metabolises large proportions o f a number of orally
administered compounds including: phenol (Powell et al., 1974), salicylamide
(Sakai et al., 1980), clonazepam (Colburn et al., 1980), and ethinylestradiol
(Schwenk et al., 1982). This suggests that i t  is not only the specific a c tiv ity  of
an enzyme which determines the amount of drug metabolism by the small
intestine, but also the dose of the drug, its rate of absorption of the drug from
the gastrointestinal lumen (hence the rate of flow  of drug through the epithelia l
cells), and the a ffin ity  (K ^ )  o f the enzyme fo r that drug. This means that:
rate of
extent o f metabolism = rate of absorption x enzymic x time
reaction
I f  the follow ing assumptions are made:
(i) the specific activ ities o f the enzymes measured in v itro  in the present 
studies re fle c t the enzyme activ ities  in vivo,
(ii) most o f a particu lar drug is absorbed from  the gastrointestinal tra c t in 
30 min,
( iii)  the drug is metabolised by m ixed-function oxidase or UDP- 
glucuronyltransferase,
then the metabolism of the drug by the liver and gastrointestinal tra c t from  ra t 
and fe rre t would be as shown in Table 7.4.
Sim ilarly i f  the drug had a molecular weight of 300, and a 100 mg dose was 
given orally, the proportions of drug metabolised by the ra t and fe rre t would be 
as shown in Table 7.5. This indicates that m ixed-function oxidase in the small 
intestine of ra t and fe rre t may not metabolise large proportions of a drug but 
glucuronylation of group-1 substrates in the small intestine of these species,
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TABLE 7.4
The Capacity of Various Tissues from  Rat and Ferret fo r 
Mixed-Function Oxidation and Glucuronylation over a 
Period of 30 min.
The lowest and highest m ixed-function oxidase (Chapter 2) and UDP- 
glucuronyltransferase (Chapter 3) activ ities in various tissue microsomal 
preparations from ra t and fe rre t were used to calculate the range o f ac tiv ities  of 
these enzymes for first-pass metabolism in a period of 30 min.
Rat Ferret
M ixed-function M ixed-function
oxidation 
Mmol/30 min
Glucuronylation 
mmol/30 min
oxidation 
Mmol/30 min
Glucuronylation 
mmol/30 min
Liver 0 .4 - 30 0.2 - 1.3 0.05 - 15 0.14 - 1.0
Stomach 0.003 - 0.03 0.0006 - 0.002 0.2 0.0003 - 0.0009
Duodenum 0.003 - 0.03 0.009 - 0.04 0.009 - 0.3 0.001 - 0.005
Jejunum 0.02-0 .10 0.009 - 0.06 0.6 0.004 - 0.012
Ileum 0.006 - 1.33 0.006 - 0.04 0.02 - 0.6 0.005 - 0.013
Caecum/ 0.003 - 0.009 0.001 - 0.003 0.003 - 0.06 0.006 - 0.002
colon
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TABLE 7.5
Estimated First-Pass Metabolism in the L iver 
and Small Intestine
The lowest and highest drug metabolising enzyme activ ities of the to ta l live r and 
to ta l small intestine epithelium (Table 7.4) were used to estimate the possible 
range of first-pass metabolism in these tissues from ra t and fe rre t of a drug w ith 
a molecular weight of 300 which was given as a 100 mg dose, orally.
M ixed-function
oxidation Glucuronylation
Rat: liver
small intestine
epithelium
Ferret: liver
small intestine
epithelium
0.10 - 9% 
0.10 - 0.95%
0.02 - 4.5% 
0.01 - 0.45%
60 - > 100% 
7 - 42%
42 - > 100% 
3 - 9%
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particu la rly  the ra t, may result in a significant proportion of the drug dose being 
conjugated. Drug metabolism in the livers o f both species is greater than tha t of 
the small intestine and therefore the major part o f first-pass metabolism w ill 
occur in this tissue. However, these results indicate tha t the specific ac tiv ities  
of UDP-glucuronyltransferase towards group-1 substrates in the small intestine 
of rats, and to a certain extent o f fe rre ts, are su ffic ien t to account fo r 
significant first-pass metabolism of drugs by this tissue.
Labetalol Metabolism
Rate of Metabolism by Rat, Ferret, and Dog
The perfused live r preparation from  the fe rre t metabolised labetalol at a 
slower rate than the sim ilar preparation from the ra t (Chapter 6). This is 
consistent w ith  the observation that the activated UDP-glucuronyltransferase 
specific activ ities  were lower in the hepatic microsomal preparations from  the 
fe rre t than those in the hepatic microsomal preparations from  the ra t 
(Chapter 3). Although the size of the live r is greater in the fe rre t than ra t, the 
enzyme capacity of fe rre t live r to glucuronate group-1 substrates was less than 
that o f ra t live r. In contrast the perfused small intestine preparations from  
fe rre t and ra t were found to have sim ilar rates of labetalol metabolism 
(Chapter 6). This is despite the observation that UDP-glucuronyltransferase 
ac tiv ity  towards group-1 substrates was lower in the gastrointestinal tra c t 
microsomal preparations from the fe rre t than those in the sim ilar preparations 
from the ra t (Chapter 3). This may be because the intestine from  the fe rre t 
metabolises labetalol to its secondary alcohol glucuronide, the intestine from ra t 
metabolises labetalol to its O-phenylglucuronide, and intestines from  both 
species form the unidentified metabolites A and C (Chapter 6, see below). The 
rate of labetalol metabolism in the isolated dog intestine loop, however, was
-  238
found to be faster than that observed in the perfused intestines from ra t and 
fe rre t. This may be because the rate of labetalol metabolism is not governed by 
the size of the species but by the a c tiv ity  o f the relevant enzymes in the ir 
tissues. A lte rna tive ly , i t  may be a dose related phenomenon. The doses injected 
into the ra t and fe rre t intestines were sim ilar to the oral doses (25 mg/kg) given 
to these animals fo r the pharmacokinetic study (Chapter 5), but the dose injected 
into the isolated dog intestine loop was lower (5 mg/kg) because of the low 
so lub ility o f labeta lo l-H C l in water.
First-Pass Metabolism by Liver and Gastrointestinal Tract from Rat, Ferret, and 
Dog
First-pass metabolism of labetalol by the gastrointestinal tra c t was 
observed to occur in the ra t, fe rre t, and dog (Table 7.6). This was not as great as 
tha t observed fo r other drugs such as isoprenaline (George, 1981) and may be due 
to the lower metabolism o f labetalol. A lte rna tive ly , the drug dosage used in this 
study was higher than that used by other workers to ensure su ffic ien t plasma 
concentrations o f labetalol metabolites were present fo r HPLC analysis. The 
first-pass metabolism of labetalol by the livers o f the ra t and fe rre t was seen to 
be much greater than tha t by the ir respective intestines. This suggests that the 
major site o f labetalol metabolism in these species is the live r. Also, the 
isolated livers from  ra t and fe rre t were observed to extract a large proportion of 
the labetalol in the perfusing medium, as is observed w ith  propranolol (Evans et 
al., 1973). This was taken to indicate that live r extraction of labetalol from the 
blood may influence how much unchanged drug is available in the c ircu la tory 
system of these species when the drug is given orally. The first-pass metabolism 
of labetalol by the dog intestine may be of much greater significance than that 
observed in the ra t and fe rre t (Table 7.6). The dog may be a more suitable 
animal model fo r metabolism of labetalol in man, not only because of its general
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TABLE 7.6
Levels of labetalol and its metabolites in the plasma from 
intestine and liver preparations from  ra t and fe rre t and 
from an isolated dog loop preparation
The amount of labetalol injected into the live r perfusates at t=0 and the 
amount o f labetalol injected into the gut lumens of the intestine preparations 
was regarded as the dose, the figures in parentheses are the amounts of ^ C -  
labetalol included in the doses given. The concentrations of labetalol and its 
metabolites in the plasma samples was determined by measuring the to ta l 
amount o f rad ioactiv ity  in the plasma samples and the amount of 
rad ioactiv ity  remaining a fte r the free labetalol had been extracted from the 
plasma samples w ith  chloroform. These concentrations were then expressed 
as percentages o f the to ta l amount o f labetalol in the plasma.
Animal Perfused tissue 
preparation
Labetalol
dose
(mg)
Sample
time
(min)
Percentage of to ta l 
labetalol in plasma
labetalol metabolites
Rat isolated liver 7.0 (7.0) 0-120 26 74
small intestine 
in situ
11.5 (1.2) 0-160 75 25
Ferret isolated live r 7.5 (7.5) 0-120 52 48
small intestine 
in situ
48.8 (4.3) 0-130 81 19
Dog small intestine 
in situ
50.0 (2.9) 0-30 84 16
For details of procedure see 'Materials and Methods' section, Chapter 6.
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s im ila rity  in metabolism of the drug but also because o f a specific pattern of 
metabolism by the intestines and livers of these species. Another fac to r which 
may a ffec t the first-pass metabolism of labetalol in vivo, as opposed to the In 
situ intestine preparations, is the pharmacological ac tiv ity  o f the drug. The 
resultant reduction in blood flow a fte r adm inistration of labetalol may be a great 
influence on the metabolism of the drug by the gastrointestinal tra c t and live r, 
especially when high doses, such as those used in this study, are given.
Pattern o f Metabolism by Rat, Ferret, and Dog
The major labetalol metabolites detected in the urine of these animals 
were observed to be one or more of the previously identified glucuronides. 
Despite evidence that there are several forms o f UDP-glucuronyltransferase 
present in ra t live r (Bock et al., 1979; Burchell, 1981) the O-phenylglucuronide 
(Figure 7.3) is the only major urinary metabolite produced by the ra t (Table 7.7). 
This metabolite is produced by the intestine and live r from  the ra t (Table 7.7). 
Labetalol metabolism by the intestine from  dog is sim ilar to that from  ra t and 
only the phenyl hydroxyl group is glucuronylated. This indicates that although 
the liver from  dog is responsible fo r producing the secondary alcohol and 
secondary amine glucuronides observed in its urine, the production o f the 
O-phenylglucuronide by dog liver cannot be discounted. The intestine from 
fe rre t contrasts w ith  those from  ra t and dog because i t  produces the secondary 
alcohol glucuronide whilst the liver from fe rre t forms both secondary alcohol and 
O-phenyl-glucuronides. This pattern of metabolism could be explained by there 
being sim ilar forms of UDP-glucuronyltransferase present in the live r from ra t 
and small intestines from ra t and dog, but d iffe ren t forms of enzyme present in 
the small intestine from fe rre t. Also there may be other forms of the enzyme 
present in the livers from fe rre t and dog which are not present in the live r from 
ra t and the small intestines from ra t, fe rre t, and dog.
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Figure 7.3. The structures o f the major metabolites o f labe ta lo l in  urine 
from r a t ,  dog, monkey, and man.
(Oxford, 1980)
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TABLE 7.7
Labetalol metabolites detected in various biological samples taken 
from ra t, fe rre t, and dog which had been treated w ith  labetalol
The samples of 0-24h urine were passed through a QAE Sephadex A25 column 
and the labetalol metabolites were detected by measuring the fluorescence 
and rad ioactiv ity  in the eluate. The fractions containing labetalol metabolites 
formed in the dog were then analysed by HPLC. The plasma samples were 
mixed w ith ethanol to precip itate the protein and an aliquot o f the 
supernatant was injected onto the HPLC column and chromatographed in the 
ion-pair mode. The labetalol metabolites were detected in the HPLC eluate 
by measuring fluorescence and rad ioactiv ity  in collected fractions. For 
details of procedure see Materials and Methods sections of Chapter 5 (urine 
samples and the ir analysis) and Chapter 6 (plasma samples and the ir analysis).
Animal Sample Method of 
Separation
Labetalol
ia IIb
Metabolites 
IIIa Xb Ya A a Ba Cb
Rat urine SCc + +
plasma from
perfused
intestine
HPLCd + + + +
plasma from
perfused
liver
HPLC + + +
Ferret urine SC + + + +
plasma from
perfused
intestine
HPLC + + + +
plasma from
perfused
liver
HPLC + + + + +
Dog urine SC + + + + +
urine HPLC + + + + + + +
plasma from 
isolated 
intestine 
loop
HPLC + + + +
a These metabolites have a sim ilar fluorescence spectra to that of labetalol
b These metabolites are not fluorescent
c Sephadex column
d High pressure liquid chromatography
Metabolite I = Secondary amine glucuronide
Metabolite II = O-phenylglucuronide
Metabolite III = Secondary alcohol glucuronide
Metabolites X, Y, A, B and C are as yet unidentified.
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In addition to the major labetalol glucuronide metabolites, five possible 
metabolites of labetalol which have not been previously identified were detected 
in various urine and plasma samples (Table 7.7). Metabolite X (non-fluorescent) 
and metabolite Y (fluorescent) were detected in the urine collected from the dog 
and fe rre t, respectively (Chapter 5). Labetalol was metabolised to metabolite A 
(fluorescent) by the intestines from  the ra t, fe rre t, and dog and by the livers 
from  the ra t and fe rre t (Chapter 6). Metabolite C (non-fluorescent) was 
produced by the intestines from  ra t, fe rre t, and dog and the live r from  fe rre t. 
Small amounts of metabolites A and B (fluorescent) were detected in 
concentrated urine, collected from  dogs, and were associated w ith  the known 
labetalol glucuronides during the ir purifica tion (Chapter 4). The pattern of 
minor metabolite form ation by the intestines from  ra t, fe rre t, and dog and the 
liver from fe rre t indicates that the minor pathways of labetalol metabolism by 
these species may be sim ilar.
Insuffic ient concentrations of these unidentified metabolites were present 
in the urine or plasma or perfusate supernatant samples fo r isolation and 
characterisation. The presence of rad ioactiv ity  ( ^ C - )  and the presence or 
absence of a fluorescent spectrum sim ilar to that o f labetalol enables a number 
of candidate molecules to be proposed for these metabolites. The labetalol 
metabolite which is conspicuous by its absence is the sulphate ester. As other 
workers (Hopkins et al., 1976; M artin et al., 1976) did not detect any sulphate 
esters in the urine collected from  dogs, metabolite X (non-fluorescent) is 
unlikely to be the O-phenylsulphate ester, which would be non-fluorescent.
Metabolite Y found in fe rre t urine and fluorescent may be a secondary 
alcohol sulphate ester because this metabolite would be fluorescent. 
Metabolite C (non-fluorescent) was not observed in any urine sample but was 
found in plasma samples. This metabolite could be the O-phenylsulphate ester 
which could be excreted in the bile, an im portant route of excretion fo r the
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e lim ination of sulphate esters originating in the live r (Powell, 1982). Such a 
metabolite would not have been previously observed because b ilia ry  metabolites 
o f labetalol have not been extensively studied.
Further work w ith  sulphatase hydrolysis o f labetalol metabolites excreted 
in the urine and bile of ra t, fe rre t, and dog would be necessary to confirm  these 
hypotheses. I t  is possible that N-dealkylation o f labetalol could occur, i f  so the 
rad ioactiv ity  would be associated w ith compounds 3,4,6 and 7 in Figure 7.4, or 
w ith any conjugates of these compounds.
Metabolism of Labetalol compared to Chemically Related Compounds
Labetalol has a phenyl hydroxyl group and also can be considered as a 
substituted salicylamide. Whereas phenol (Powell et al., 1974), 1-naphthol 
(Turner e t al., 1980), and salicylamide (Sakai et al., 1980) are substrates for both 
sulphotransferase and UDP-glucuronyltransferase in the intestine from  ra t, 
labetalol only appears to be a substrate for UDP-glucuronyltransferase. 
Dopamine is metabolised to a glucuronide conjugate by the ra t (Wang et al., 
1983a and 1983b) and to both sulphate and glucuronide conjugates in man (Rein 
et al., 1981; Wang et al., 1983). Also adrenaline (Wang et ai., 1983a and 1983b), 
isoprenaline (George et al., 1974), and terbutaline (Nilssen et al., 1972) are ail 
substrates for sulphotransferase and are all catechols which are substituted w ith 
a lkyl groups (R) of increasing size at the secondary amine position (Figure 7.3). 
Consequently, i t  would appear that the bulky side chain (u, Figure 7.5) of 
labetalol interferes w ith the access of this molecule to the sulphotransferase 
enzyme. Further work is necessary to provide evidence fo r this hypothesis.
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Figure 7.4 Candidate metabolites fo r the unidentified  labetalol
metabolites observed in the urine and plasma from ra t ,  
fe r r e t ,  and dog.
I t  is possible fo r any of the a lcoholic hydroxyl, phenolic hydroxyl, carboxylic, 
or N-groups to be conjugated with glucuronic acid, sulphate, g lu tath ione, amino 
acids, etc.
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Figure 7 .5 . Comparison o f the s truc tu re  o f labe ta lo l with the 
structures o f s im i la r  compounds.
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Evaluation of Results Presented in this Study
Prelim inary investigations of the methods of assay used in this study 
indicated that the errors were w ith in  the bounds of acceptability (i.e. less than 
10%). However, biphenyl 2-hydroxylase a c tiv ity  in the gastrointestinal tra c t 
microsomal preparations from untreated ra t, and 4-nitrophenol 
UDP-glucuronyltransferase a c tiv ity  in caecum/colon microsomal preparations 
from  the same rats, did have large variations between determinations. This 
indicated that these enzyme activ ities  may be so low as to be on the borders of 
sensitiv ity o f the assays.
The treatm ent of rats w ith  phenobarbitone did not cause increases in the 
activ ities  o f ethylmorphine N-demethylase and cytochrome c reductase in live r 
microsomal preparations from these animals. These results contrast w ith  reports 
published by other workers (Parkinson et 'al., 1980). There are a varie ty of 
possible reasons fo r this difference in observation, the most important of which 
are:
(i) the route of administration (intraperitoneal injection) of phenobarbitone 
d iffered from that used by other workers (addition o f phenobarbitone to the 
drinking water of the animals). The la tte r method of adm inistration does 
not guarantee an equal dose o f phenobarbitone to each animal and this may 
cause variations of enzyme induction between animals.
(ii) The dose of phenobarbitone used in this investigation was sim ilar to that of 
some other workers. I t  could be that the particular animals used in this
t
study required a longer dosing period to e lic it the effects on mixed- 
function oxidase enzymes which other workers have reported (e.g. 
Hietanen, 1980 used a dosing regime of 80 mg/kg fo r five  consecutive days 
in the ir study).
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(iii) Genetic variation in the animals used in this study may have been 
responsible fo r this difference in observation in rats treated w ith  
phenobarbitone.
The dosage in the oral adm inistration and intestinal perfusion of labetalol 
(20-30 mg/kg) in the present studies was 2-5 times the therapeutic dose 
(2-15 mg/kg). Also this dose of labetalol was the middle dose used in the
tox ic ity  test. Although the pattern of drug metabolism can vary w ith  dose 
(Mehta et bL, 1978), i t  was thought tha t the doses used in this study would be 
relevant to doses o f labetalol used in the c lin ica l situation.
The main critic ism  of this study is that s ta tis tica l methods of analysing the 
results could not be applied because insuffic ient numbers o f animals were used in 
these studies. As a consequence the difference of drug metabolism observed 
between the various tissues of the animals used in each investigation cannot be 
examined in detail. I t  has been possible to survey the results and point out 
trends in drug metabolism of the livers and gastrointestinal tracts of the 
animals.
Concluding Remarks
The results of this study therefore indicated that the gastrointestinal tra c t 
from  ra t and fe rre t is capable of metabolising drugs by m ixed-function oxidation 
and glucuronylation. The characterisation of these drug metabolising enzymes in 
live r and gastrointestinal tra c t are sim ilar, but the mechanisms of regulating 
these enzymes in the various tissues appear to be d iffe ren t. Although the 
capacity of the liver to metabolise drugs is greater than that of the 
gastrointestinal trac t, the specific a c tiv ity  of drug metabolising enzymes, 
particu larly  UDP-glucuronyltransferase, in the small intestine, is su ffic ien t to 
account fo r significant first-pass metabolism.
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First-pass metabolism of labetalol occurred in the small intestine of ra t, 
fe rre t, and dog, but the results indicate that the main site o f this process is the 
live r. However, the concentration of labetalol in the systemic circula tion, a fte r 
an oral dose o f the drug, may not only be a function of the first-pass metabolism 
by the liver and gastrointestinal tra c t, but may also be related to the amount of 
drug extracted from the plasma by the liver. This needs to be confirmed by 
repeating the study and looking at live r protein binding o f labetalol. The species 
and tissue differences in metabolism o f labetalol by ra t, fe rre t, and dog, indicate 
tha t the forms of UDP-glucuronyltransferase present in the live r and 
gastrointestinal tra c t o f these species vary. Investigation of the kinetics of 
labetalol conjugation by isolated forms of UDP-glucuronyltransferase from  the 
tissues of these species may resolve whether the gastrointestinal tra c t has a fu ll 
complement o f the forms of this enzyme. Also fu rther studies are required to 
identify  the unknown metabolites of labetalol which were observed in this study. 
Further studies in v itro  and in vivo are necessary to establish whether 
sulphotransferase is involved w ith  labetalol metabolism.
Current research is providing evidence for the gastrointestinal tra c t being 
an im portant site o f drug metabolism and that the biosynthetic enzyme pathways 
o f this tissue seem to be more active than the biotransformation pathways. In 
order that the role of the gastrointestinal trac t in drug metabolism can be be tte r 
defined, biochemical characterisation of the drug-metabolising enzymes in this 
tissue needs to be achieved so that a more rigorous comparison of the live r and 
gastrointestinal tra c t enzymes can be made. Isolation of cytochrome P-450 
from  rabbit small intestine has already been reported (Ichihara at al., 1981), 
therefore the isolation of other enzymes such as UDP-glucuronyltransferase and 
sulphotransferase might also be accomplished. Furthermore, the mechanisms of 
regulation of the drug-metabolising enzymes in the liver and gastrointestinal 
trac t appear to d iffe r. However, these mechanisms of regulation may be sim ilar
but the effects of environmental factors, such as hormones and/or xenobiotic 
chemicals, on the regulatory genes of the two tissues may d iffe r. The 
mechanisms of regulation of the drug-metabolising enzymes in the live r and 
gastrointestinal tra c t need to be rigorously investigated. An understanding of 
first-pass metabolism in the live r and gastrointestinal tra c t would be beneficial 
to the design and evaluation o f new candidate drugs and pro-drugs.
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